{
    "drugSuccessPredictions": [
      {
        "drugId": "72133",
        "displayName": "nogapendekin alfa",
        "drugPrograms": [
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "158",
              "name": "HIV infection"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "26-Jun-2016",
            "endDate": "",
            "statusDate": "01-Aug-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "26-Jun-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "307",
              "name": "Squamous cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-May-2014",
            "endDate": "",
            "statusDate": "11-Dec-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "31-May-2014",
                "endDate": "11-Dec-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "11-Dec-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "319",
              "name": "Non-Hodgkin lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Mar-2015",
            "endDate": "",
            "statusDate": "01-Aug-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "09-Mar-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "427",
              "name": "Uterine cervix tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Dec-2018",
            "endDate": "",
            "statusDate": "11-Dec-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-Dec-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "623",
              "name": "Head and neck tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Dec-2018",
            "endDate": "",
            "statusDate": "11-Dec-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-Dec-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "651",
              "name": "Cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Apr-2014",
            "endDate": "",
            "statusDate": "01-Aug-2017",
            "phaseHighestStatus": "Repositioned",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "18-Apr-2014",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "989",
              "name": "Colorectal tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Dec-2018",
            "endDate": "05-Nov-2027",
            "statusDate": "11-Dec-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "15%",
            "timeToRegistration": "3.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-Dec-2018",
                "endDate": "23-Aug-2024",
                "successPercentage": "46%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "23-Aug-2024",
                "endDate": "21-Dec-2026",
                "successPercentage": "34%",
                "predictedDateL50": "10-Feb-2024",
                "predictedDateU50": "09-Feb-2025",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "21-Dec-2026",
                "endDate": "06-Oct-2027",
                "successPercentage": "95%",
                "predictedDateL50": "23-Dec-2025",
                "predictedDateU50": "12-May-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "06-Oct-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-Jun-2027",
                "predictedDateU50": "05-Nov-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "1261",
              "name": "Small-cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Dec-2018",
            "endDate": "",
            "statusDate": "11-Dec-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-Dec-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "1262",
              "name": "Non-small-cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Jan-2016",
            "endDate": "",
            "statusDate": "01-Aug-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "21-Jan-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Dec-2018",
            "endDate": "14-Sep-2027",
            "statusDate": "11-Dec-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "10%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-Dec-2018",
                "endDate": "01-Aug-2024",
                "successPercentage": "49%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "01-Aug-2024",
                "endDate": "28-Oct-2026",
                "successPercentage": "22%",
                "predictedDateL50": "01-Feb-2024",
                "predictedDateU50": "03-Jan-2025",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "28-Oct-2026",
                "endDate": "15-Aug-2027",
                "successPercentage": "94%",
                "predictedDateL50": "04-Nov-2025",
                "predictedDateU50": "18-Mar-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "15-Aug-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-May-2027",
                "predictedDateU50": "14-Sep-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "1828",
              "name": "Multiple myeloma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Sep-2014",
            "endDate": "",
            "statusDate": "10-Sep-2014",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "10-Sep-2014",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "2054",
              "name": "Hematological neoplasm"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Nov-2013",
            "endDate": "",
            "statusDate": "01-Aug-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Nov-2013",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "2380",
              "name": "Bladder cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Breakthrough Therapy",
            "startDate": "25-Jul-2014",
            "endDate": "09-May-2024",
            "statusDate": "11-May-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "25-Jul-2014",
                "endDate": "02-Jun-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "02-Jun-2017",
                "endDate": "11-May-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "11-May-2023",
                "endDate": "09-Apr-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "09-Apr-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Feb-2024",
                "predictedDateU50": "09-May-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Breakthrough Therapy",
                "status": "Granted",
                "milestoneDate": "04-Dec-2019",
                "milestoneExtendedDate": "",
                "notes": "In December 2019, the company had received Breakthrough Therapy Designation (BTD) for N-803, in combination with Bacillus Calmette-Guerin (BCG), for the treatment of patients with BCG-unresponsive non-muscle invasive bladder carcinoma in situ (CIS) [ <ulink linkID=\"2224046\" linkType=\"Reference\"> 2224046 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "30-Nov-2021",
                "milestoneExtendedDate": "",
                "notes": "In November 2021, cut off data from phase II/III trial (NCT03022825) demonstrated 72% complete response rate in the CIS cohort and 100% bladder cancer-specific overall survival at 24 months [ <ulink linkID=\"2586770\" linkType=\"Reference\">  2586770 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Jan-2022",
                "notes": "In December 2021, further data from phase II/III trial (NCT03022825) were expected in January 2022 [ <ulink linkID=\"2586770\" linkType=\"Reference\">  2586770 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Mar-2022",
                "notes": "In December 2021, Biologics License Application (BLA) filing to the US FDA for Anktiva plus BCG for BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ was expected in first quarter of 2022 [ <ulink linkID=\"2586770\" linkType=\"Reference\">  2586770 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Feb-2022",
                "milestoneExtendedDate": "28-Feb-2022",
                "notes": "In December 2021, further data from phase II/III trial (NCT03022825) were expected in January 2022 and data update from papillary cohort were expected to be presented as a part of an oral presentation at the ASCO Genitourinary Cancers Symposium in February 2022 [ <ulink linkID=\"2586770\" linkType=\"Reference\">  2586770 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Month)",
                "milestoneDate": "01-Apr-2022",
                "milestoneExtendedDate": "30-Apr-2022",
                "notes": "In April 2022, the BLA had been compiled, and will be submitted to the USFDA later this month after final quality review [ <ulink linkID=\"2643782\" linkType=\"Reference\">  2643782 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "23-May-2022",
                "milestoneExtendedDate": "",
                "notes": "In May 2022, the company had submitted BLA to the US FDA for NL-803 plus BCG for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) with or without Ta or T1 disease [ <ulink linkID=\"2674600\" linkType=\"Reference\">  2674600 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "10-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, further data from a phase II/III study (NCT03022825; QUILT-3.032) of ALT-803 in combination with BCG in patients with BCG unresponsive high-grade non-muscle invasive bladder cancer were published [ <ulink linkID=\"2769973\" linkType=\"Reference\">  2769973 </ulink>], [ <ulink linkID=\"2799710\" linkType=\"Reference\">  2799710 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Complete Response Letter",
                "status": "Negative Outcome",
                "milestoneDate": "09-May-2023",
                "milestoneExtendedDate": "",
                "notes": "By May 2023, the USFDA delivered a complete response letter to us regarding the BLA [ <ulink linkID=\"3006686\" linkType=\"Reference\"> 3006686 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "23-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2022, the PDUFA target action date was May 23, 2023 [ <ulink linkID=\"2710858\" linkType=\"Reference\"> 2710858 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "23-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, Biologics License Application (BLA) for N-803 plus Bacillus Calmette-Gu√©rin (BCG) was resubmitted high-risk non-muscle-invasive bladder cancer and the resubmission was accepted for review by the US FDA [ <ulink linkID=\"3481864\" linkType=\"Reference\"> 3481864 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "23-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, long-term follow up data from phase Ib trial (NCT02138734) were reported [ <ulink linkID=\"3477398\" linkType=\"Reference\"> 3477398 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "23-Apr-2024",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, the PDUFA date was set on April 23, 2024 [ <ulink linkID=\"3481864\" linkType=\"Reference\"> 3481864 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "3235",
              "name": "Merkel cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Dec-2018",
            "endDate": "",
            "statusDate": "11-Dec-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-Dec-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "3246",
              "name": "Hormone refractory prostate cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-May-2018",
            "endDate": "29-Aug-2027",
            "statusDate": "01-May-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "18%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-May-2018",
                "endDate": "07-Aug-2024",
                "successPercentage": "54%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "07-Aug-2024",
                "endDate": "03-Nov-2026",
                "successPercentage": "35%",
                "predictedDateL50": "23-Jan-2024",
                "predictedDateU50": "06-Nov-2024",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-Nov-2026",
                "endDate": "25-Jul-2027",
                "successPercentage": "94%",
                "predictedDateL50": "10-Nov-2025",
                "predictedDateU50": "24-Mar-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-Jul-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "27-Apr-2027",
                "predictedDateU50": "29-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Dec-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, the phase I/II study ( NCT03493945) <ulink linkID=\"62577\" linkType=\"Drug\"> </ulink>in patients with metastatic castration resistant prostate cancer was expected to complete in December 2023 [ <ulink linkID=\"2025086\" linkType=\"Reference\"> 2025086 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "3257",
              "name": "Stage IV melanoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-May-2014",
            "endDate": "",
            "statusDate": "11-Dec-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "31-May-2014",
                "endDate": "11-Dec-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "11-Dec-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "US",
              "name": "US, US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Dec-2021",
            "endDate": "04-Aug-2027",
            "statusDate": "20-Dec-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "19%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "20-Dec-2021",
                "endDate": "16-Jun-2024",
                "successPercentage": "52%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Jun-2024",
                "endDate": "12-Sep-2026",
                "successPercentage": "38%",
                "predictedDateL50": "20-Jan-2024",
                "predictedDateU50": "22-Aug-2024",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "12-Sep-2026",
                "endDate": "05-Jul-2027",
                "successPercentage": "94%",
                "predictedDateL50": "19-Sep-2025",
                "predictedDateU50": "31-Jan-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Jul-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Mar-2027",
                "predictedDateU50": "04-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US",
              " US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "3658",
              "name": "Metastatic colorectal cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "22-Sep-2020",
            "endDate": "15-Mar-2029",
            "statusDate": "22-Sep-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "12%",
            "timeToRegistration": "5.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "22-Sep-2020",
                "endDate": "31-Jan-2026",
                "successPercentage": "46%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "31-Jan-2026",
                "endDate": "28-Apr-2028",
                "successPercentage": "28%",
                "predictedDateL50": "21-Sep-2025",
                "predictedDateU50": "08-May-2026",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "28-Apr-2028",
                "endDate": "13-Feb-2029",
                "successPercentage": "93%",
                "predictedDateL50": "06-May-2027",
                "predictedDateU50": "16-Sep-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Feb-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "31-Oct-2028",
                "predictedDateU50": "15-Mar-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Jan-2026",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, phase II trial (NCT04491955) was expected to complete in January 2026 [ <ulink linkID=\"2306033\" linkType=\"Reference\"> 2306033 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-May-2014",
            "endDate": "",
            "statusDate": "18-May-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "31-May-2014",
                "endDate": "18-May-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "18-May-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Dec-2018",
            "endDate": "",
            "statusDate": "11-Dec-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-Dec-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "3669",
              "name": "Metastatic pancreas cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Aug-2016",
            "endDate": "",
            "statusDate": "01-Aug-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "21-Aug-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "3673",
              "name": "Metastatic head and neck cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-May-2014",
            "endDate": "28-Aug-2027",
            "statusDate": "20-Dec-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "19%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "31-May-2014",
                "endDate": "20-Dec-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "20-Dec-2021",
                "endDate": "23-Jun-2024",
                "successPercentage": "48%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "23-Jun-2024",
                "endDate": "26-Oct-2026",
                "successPercentage": "43%",
                "predictedDateL50": "23-Jan-2024",
                "predictedDateU50": "05-Sep-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-Oct-2026",
                "endDate": "26-Jul-2027",
                "successPercentage": "94%",
                "predictedDateL50": "21-Oct-2025",
                "predictedDateU50": "19-Mar-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-Jul-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Apr-2027",
                "predictedDateU50": "28-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "4166",
              "name": "Small intestine cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "22-Sep-2020",
            "endDate": "07-May-2029",
            "statusDate": "22-Sep-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "17%",
            "timeToRegistration": "5.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "22-Sep-2020",
                "endDate": "31-Jan-2026",
                "successPercentage": "46%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "31-Jan-2026",
                "endDate": "27-Jun-2028",
                "successPercentage": "40%",
                "predictedDateL50": "29-Aug-2025",
                "predictedDateU50": "23-May-2026",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Jun-2028",
                "endDate": "07-Apr-2029",
                "successPercentage": "95%",
                "predictedDateL50": "12-Jun-2027",
                "predictedDateU50": "15-Nov-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-Apr-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "29-Dec-2028",
                "predictedDateU50": "07-May-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Jan-2026",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, phase II trial (NCT04491955) was expected to complete in January 2026 [ <ulink linkID=\"2306033\" linkType=\"Reference\"> 2306033 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1015036",
              "name": "ImmunityBio Inc"
            },
            "indication": {
              "id": "4250",
              "name": "Metastatic renal cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Dec-2018",
            "endDate": "",
            "statusDate": "11-Dec-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-Dec-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "81193",
        "displayName": "durvalumab",
        "drugPrograms": [
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Nov-2022",
            "endDate": "11-Jul-2031",
            "statusDate": "28-Nov-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "58%",
            "timeToRegistration": "7.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "28-Nov-2022",
                "endDate": "27-Mar-2030",
                "successPercentage": "61%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Mar-2030",
                "endDate": "10-May-2031",
                "successPercentage": "95%",
                "predictedDateL50": "12-May-2029",
                "predictedDateU50": "04-Aug-2030",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-May-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "26-Dec-2030",
                "predictedDateU50": "11-Jul-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "15-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, phase III trial (NCT06112379) for breast tumor was planned to initiate in later that month [ <ulink linkID=\"3487124\" linkType=\"Reference\"> 3487124 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "27-Mar-2030",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, phase III trial (TROPION-Breast03) for Dato-DXd with or without durvalumab in patients with stage I to III triple negative breast cancer with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy was expected to complete in March 2030 [ <ulink linkID=\"2787089\" linkType=\"Reference\"> 2787089 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "15-Aug-2030",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, phase III trial (NCT06112379) for breast tumor was expected to complete in August 20230 { <ulink linkID=\"3487124\" linkType=\"Reference\"> 3487124 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Nov-2022",
            "endDate": "14-Feb-2031",
            "statusDate": "28-Nov-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "58%",
            "timeToRegistration": "7.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "28-Nov-2022",
                "endDate": "27-Mar-2030",
                "successPercentage": "61%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Mar-2030",
                "endDate": "15-Jan-2031",
                "successPercentage": "95%",
                "predictedDateL50": "14-May-2029",
                "predictedDateU50": "03-Aug-2030",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "15-Jan-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Sep-2030",
                "predictedDateU50": "14-Feb-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "27-Mar-2030",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, phase III trial (TROPION-Breast03) for Dato-DXd with or without durvalumab in patients with stage I to III triple negative breast cancer with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy was expected to complete in March 2030 [ <ulink linkID=\"2787089\" linkType=\"Reference\"> 2787089 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Nov-2022",
            "endDate": "12-Feb-2031",
            "statusDate": "28-Nov-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "58%",
            "timeToRegistration": "7.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "28-Nov-2022",
                "endDate": "27-Mar-2030",
                "successPercentage": "61%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Mar-2030",
                "endDate": "13-Jan-2031",
                "successPercentage": "95%",
                "predictedDateL50": "16-Jun-2029",
                "predictedDateU50": "17-Jul-2030",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Jan-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Sep-2030",
                "predictedDateU50": "12-Feb-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "15-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, phase III trial (NCT06112379) for breast tumor was planned to initiate in later that month [ <ulink linkID=\"3487124\" linkType=\"Reference\"> 3487124 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "27-Mar-2030",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, phase III trial (TROPION-Breast03) for Dato-DXd with or without durvalumab in patients with stage I to III triple negative breast cancer with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy was expected to complete in March 2030 [ <ulink linkID=\"2787089\" linkType=\"Reference\"> 2787089 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "15-Aug-2030",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, phase III trial (NCT06112379) for breast tumor was expected to complete in August 20230 { <ulink linkID=\"3487124\" linkType=\"Reference\"> 3487124 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Aug-2016",
            "endDate": "10-Feb-2031",
            "statusDate": "28-Nov-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "56%",
            "timeToRegistration": "7.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "31-Aug-2016",
                "endDate": "28-Nov-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "28-Nov-2022",
                "endDate": "27-Mar-2030",
                "successPercentage": "59%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Mar-2030",
                "endDate": "11-Jan-2031",
                "successPercentage": "95%",
                "predictedDateL50": "11-Apr-2029",
                "predictedDateU50": "01-Aug-2030",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Jan-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "29-Sep-2030",
                "predictedDateU50": "10-Feb-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "15-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, phase III trial (NCT06112379) for breast tumor was planned to initiate in later that month [ <ulink linkID=\"3487124\" linkType=\"Reference\"> 3487124 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Nov-2026",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, phase II trial (NCT05498155; OlympiaN) for HER2-negative metastatic breast cancer was expected to complete in November 2026 [ <ulink linkID=\"2753062\" linkType=\"Reference\"> 2753062 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "27-Mar-2030",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, phase III trial (TROPION-Breast03) for Dato-DXd with or without durvalumab in patients with stage I to III triple negative breast cancer with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy was expected to complete in March 2030 [ <ulink linkID=\"2787089\" linkType=\"Reference\"> 2787089 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "15-Aug-2030",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, phase III trial (NCT06112379) for breast tumor was expected to complete in August 20230 { <ulink linkID=\"3487124\" linkType=\"Reference\"> 3487124 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Jun-2016",
            "endDate": "10-May-2031",
            "statusDate": "28-Nov-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "57%",
            "timeToRegistration": "7.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Jun-2016",
                "endDate": "28-Nov-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "28-Nov-2022",
                "endDate": "27-Mar-2030",
                "successPercentage": "60%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Mar-2030",
                "endDate": "25-Mar-2031",
                "successPercentage": "95%",
                "predictedDateL50": "10-Apr-2029",
                "predictedDateU50": "30-Jul-2030",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-Mar-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Nov-2030",
                "predictedDateU50": "10-May-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Nov-2026",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, phase II trial (NCT05498155; OlympiaN) for HER2-negative metastatic breast cancer was expected to complete in November 2026 [ <ulink linkID=\"2753062\" linkType=\"Reference\"> 2753062 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "27-Mar-2030",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, phase III trial (TROPION-Breast03) for Dato-DXd with or without durvalumab in patients with stage I to III triple negative breast cancer with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy was expected to complete in March 2030 [ <ulink linkID=\"2787089\" linkType=\"Reference\"> 2787089 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "15-Aug-2030",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, phase III trial (NCT06112379) for breast tumor was expected to complete in August 20230 { <ulink linkID=\"3487124\" linkType=\"Reference\"> 3487124 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "127",
              "name": "Stomach tumor"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Nov-2020",
            "endDate": "07-May-2025",
            "statusDate": "17-Nov-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "10%",
            "timeToRegistration": "1.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "17-Nov-2020",
                "endDate": "19-Jun-2024",
                "successPercentage": "11%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "19-Jun-2024",
                "endDate": "07-Apr-2025",
                "successPercentage": "95%",
                "predictedDateL50": "16-Jan-2024",
                "predictedDateU50": "30-Sep-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-Apr-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Dec-2024",
                "predictedDateU50": "07-May-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In February 2021, first data from the phase III MATTERHORN trial (NCT04592913) for neoadjuvant-adjuvant durvalumab for resectable gastric and gastroesophageal cancer were expected in 2022 or later [ <ulink linkID=\"2405453\" linkType=\"Reference\">  2405453 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2025",
                "milestoneExtendedDate": "14-Feb-2025",
                "notes": "In November 2020, the phase III MATTERHORN trial (NCT04592913) for neoadjuvant-adjuvant durvalumab for resectable gastric and gastroesophageal cancer was expected to complete in February 2025 [ <ulink linkID=\"2402876\" linkType=\"Reference\">  2402876 </ulink>]</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "127",
              "name": "Stomach tumor"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Nov-2020",
            "endDate": "20-Mar-2025",
            "statusDate": "17-Nov-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "12%",
            "timeToRegistration": "1.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "17-Nov-2020",
                "endDate": "04-May-2024",
                "successPercentage": "13%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "04-May-2024",
                "endDate": "18-Feb-2025",
                "successPercentage": "95%",
                "predictedDateL50": "07-Jan-2024",
                "predictedDateU50": "27-Jul-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "18-Feb-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "06-Nov-2024",
                "predictedDateU50": "20-Mar-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In February 2021, first data from the phase III MATTERHORN trial (NCT04592913) for neoadjuvant-adjuvant durvalumab for resectable gastric and gastroesophageal cancer were expected in 2022 or later [ <ulink linkID=\"2405453\" linkType=\"Reference\">  2405453 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2025",
                "milestoneExtendedDate": "14-Feb-2025",
                "notes": "In November 2020, the phase III MATTERHORN trial (NCT04592913) for neoadjuvant-adjuvant durvalumab for resectable gastric and gastroesophageal cancer was expected to complete in February 2025 [ <ulink linkID=\"2402876\" linkType=\"Reference\">  2402876 </ulink>]</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "127",
              "name": "Stomach tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "17-Nov-2020",
            "endDate": "04-Jul-2025",
            "statusDate": "17-Nov-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "19%",
            "timeToRegistration": "1.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "17-Nov-2020",
                "endDate": "31-Aug-2024",
                "successPercentage": "20%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Aug-2024",
                "endDate": "02-Jun-2025",
                "successPercentage": "95%",
                "predictedDateL50": "07-Feb-2024",
                "predictedDateU50": "14-Jan-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Jun-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Feb-2025",
                "predictedDateU50": "04-Jul-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In February 2021, first data from the phase III MATTERHORN trial (NCT04592913) for neoadjuvant-adjuvant durvalumab for resectable gastric and gastroesophageal cancer were expected in 2022 or later [ <ulink linkID=\"2405453\" linkType=\"Reference\">  2405453 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "07-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, a phase I trial (NCT04504669) in adult patients with select advanced solid tumors including HNSCC, TNBC, NSCLC, ccRCC, gastric cancer, melanoma, cervical cancer and small-cell lung cancer was expected to complete in September 2023 [ <ulink linkID=\"2308081\" linkType=\"Reference\"> 2308081 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "12-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, US FDA granted Orphan Drug Designation for the treatment of gastric cancer, including gastroesophageal junction cancer [ <ulink linkID=\"3477312\" linkType=\"Reference\"> 3477312 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2025",
                "milestoneExtendedDate": "14-Feb-2025",
                "notes": "In November 2020, the phase III MATTERHORN trial (NCT04592913) for neoadjuvant-adjuvant durvalumab for resectable gastric and gastroesophageal cancer was expected to complete in February 2025 [ <ulink linkID=\"2402876\" linkType=\"Reference\">  2402876 </ulink>]</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "127",
              "name": "Stomach tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Nov-2020",
            "endDate": "04-Sep-2025",
            "statusDate": "17-Nov-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "12%",
            "timeToRegistration": "1.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "17-Nov-2020",
                "endDate": "27-Aug-2024",
                "successPercentage": "13%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Aug-2024",
                "endDate": "28-Jul-2025",
                "successPercentage": "95%",
                "predictedDateL50": "07-Feb-2024",
                "predictedDateU50": "06-Jan-2025",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "28-Jul-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Apr-2025",
                "predictedDateU50": "04-Sep-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In February 2021, first data from the phase III MATTERHORN trial (NCT04592913) for neoadjuvant-adjuvant durvalumab for resectable gastric and gastroesophageal cancer were expected in 2022 or later [ <ulink linkID=\"2405453\" linkType=\"Reference\">  2405453 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "07-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, a phase I trial (NCT04504669) in adult patients with select advanced solid tumors including HNSCC, TNBC, NSCLC, ccRCC, gastric cancer, melanoma, cervical cancer and small-cell lung cancer was expected to complete in September 2023 [ <ulink linkID=\"2308081\" linkType=\"Reference\">  2308081 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2025",
                "milestoneExtendedDate": "14-Feb-2025",
                "notes": "In November 2020, the phase III MATTERHORN trial (NCT04592913) for neoadjuvant-adjuvant durvalumab for resectable gastric and gastroesophageal cancer was expected to complete in February 2025 [ <ulink linkID=\"2402876\" linkType=\"Reference\">  2402876 </ulink>]</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "131",
              "name": "Gastrointestinal tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Nov-2018",
            "endDate": "",
            "statusDate": "14-Nov-2018",
            "phaseHighestStatus": "Repositioned",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "14-Nov-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "203",
              "name": "Lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-May-2016",
            "endDate": "16-Aug-2028",
            "statusDate": "12-May-2015",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "16%",
            "timeToRegistration": "4.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-May-2016",
                "endDate": "27-Dec-2024",
                "successPercentage": "50%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "27-Dec-2024",
                "endDate": "03-Oct-2027",
                "successPercentage": "34%",
                "predictedDateL50": "09-Mar-2024",
                "predictedDateU50": "16-Jul-2025",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-Oct-2027",
                "endDate": "17-Jul-2028",
                "successPercentage": "95%",
                "predictedDateL50": "02-Aug-2026",
                "predictedDateU50": "25-Mar-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Jul-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "06-Apr-2028",
                "predictedDateU50": "16-Aug-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "230",
              "name": "Neoplasm"
            },
            "country": {
              "id": "EU",
              "name": "EU (IT)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Feb-2017",
            "endDate": "",
            "statusDate": "01-Feb-2017",
            "phaseHighestStatus": "Repositioned",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-Feb-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "IT"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "249",
              "name": "Pancreas tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Mar-2017",
            "endDate": "14-Aug-2028",
            "statusDate": "02-Mar-2017",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "02-Mar-2017",
                "endDate": "11-Feb-2025",
                "successPercentage": "20%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "11-Feb-2025",
                "endDate": "13-Oct-2027",
                "successPercentage": "15%",
                "predictedDateL50": "21-Mar-2024",
                "predictedDateU50": "29-Jun-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Oct-2027",
                "endDate": "13-Jul-2028",
                "successPercentage": "95%",
                "predictedDateL50": "25-Aug-2026",
                "predictedDateU50": "15-Mar-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Jul-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Apr-2028",
                "predictedDateU50": "14-Aug-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "307",
              "name": "Squamous cell carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Dec-2022",
            "endDate": "25-Jul-2028",
            "statusDate": "29-Dec-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "62%",
            "timeToRegistration": "4.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "29-Dec-2022",
                "endDate": "20-May-2027",
                "successPercentage": "65%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-May-2027",
                "endDate": "03-Jun-2028",
                "successPercentage": "95%",
                "predictedDateL50": "14-Jun-2026",
                "predictedDateU50": "28-Sep-2027",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "03-Jun-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Jan-2028",
                "predictedDateU50": "25-Jul-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-May-2027",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, a phase III trial (NCT05687266) was expected to complete in May 2027 [ <ulink linkID=\"2811470\" linkType=\"Reference\"> 2811470 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "307",
              "name": "Squamous cell carcinoma"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Sep-2013",
            "endDate": "18-Mar-2028",
            "statusDate": "29-Dec-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "57%",
            "timeToRegistration": "4.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "12-Sep-2013",
                "endDate": "09-Sep-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.11",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "09-Sep-2015",
                "endDate": "20-May-2027",
                "successPercentage": "60%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "11.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-May-2027",
                "endDate": "15-Feb-2028",
                "successPercentage": "95%",
                "predictedDateL50": "15-Mar-2026",
                "predictedDateU50": "31-Oct-2028",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "15-Feb-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Nov-2027",
                "predictedDateU50": "18-Mar-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected sNDA/sBLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2019",
                "milestoneExtendedDate": "30-Jun-2019",
                "notes": "In February 2019, further regulatory submissions for durvalumab with or without tremelimumab for the first-line treatment of squamous cell carcinoma were expected in 1H19 [ <ulink linkID=\"2119607\" linkType=\"Reference\">  2119607 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-May-2027",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, a phase III trial (NCT05687266) was expected to complete in May 2027 [ <ulink linkID=\"2811470\" linkType=\"Reference\"> 2811470 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "307",
              "name": "Squamous cell carcinoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "17-Mar-2028",
            "statusDate": "29-Dec-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "57%",
            "timeToRegistration": "4.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "09-Sep-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "09-Sep-2015",
                "endDate": "20-May-2027",
                "successPercentage": "60%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "11.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-May-2027",
                "endDate": "14-Feb-2028",
                "successPercentage": "95%",
                "predictedDateL50": "27-Jun-2026",
                "predictedDateU50": "25-Feb-2028",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Feb-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "12-Nov-2027",
                "predictedDateU50": "17-Mar-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-May-2027",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, a phase III trial (NCT05687266) was expected to complete in May 2027 [ <ulink linkID=\"2811470\" linkType=\"Reference\"> 2811470 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "307",
              "name": "Squamous cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "16-Mar-2028",
            "statusDate": "29-Dec-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "53%",
            "timeToRegistration": "4.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "09-Sep-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "09-Sep-2015",
                "endDate": "20-May-2027",
                "successPercentage": "56%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "11.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-May-2027",
                "endDate": "11-Feb-2028",
                "successPercentage": "95%",
                "predictedDateL50": "22-Mar-2026",
                "predictedDateU50": "12-Jan-2029",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Feb-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "12-Nov-2027",
                "predictedDateU50": "16-Mar-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected sNDA/sBLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2019",
                "milestoneExtendedDate": "30-Jun-2019",
                "notes": "In February 2019, further regulatory submissions for durvalumab with or without tremelimumab for the first-line treatment of squamous cell carcinoma were expected in 1H19 [ <ulink linkID=\"2119607\" linkType=\"Reference\"> 2119607 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "31-Jul-2019",
                "milestoneExtendedDate": "",
                "notes": "In June 2019, a phase II trial was planned to initiate in July 2019 in high-risk HPV 16 positive oropharynx cancer patients with durvalumab and Medi-0457 [ <ulink linkID=\"2171112\" linkType=\"Reference\"> 2171112 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "29-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, positive data were reported for the phase II trial (NCT03373760) in patients with with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer which showed that the trial met its co-primary endpoints. The objective response rate in ARC versus PRC was 0 versus 7.1%, respectively [ <ulink linkID=\"2283990\" linkType=\"Reference\"> 2283990 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "29-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, interim data of a phase II trial (NCT03373760) in patients with with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer were presented [ <ulink linkID=\"2283990\" linkType=\"Reference\"> 2283990 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "07-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, a phase I trial (NCT04504669) in adult patients with select advanced solid tumors including HNSCC, TNBC, NSCLC, ccRCC, gastric cancer, melanoma, cervical cancer and small-cell lung cancer was expected to complete in September 2023 [ <ulink linkID=\"2308081\" linkType=\"Reference\"> 2308081 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-May-2027",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, a phase III trial (NCT05687266) was expected to complete in May 2027 [ <ulink linkID=\"2811470\" linkType=\"Reference\"> 2811470 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2027",
                "milestoneExtendedDate": "01-Jul-2027",
                "notes": "In June 2019, a phase II trial was expected to complete in July 2027 in high-risk HPV 16 positive oropharynx cancer patients with durvalumab and Medi-0457 [ <ulink linkID=\"2171112\" linkType=\"Reference\"> 2171112 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Sep-2027",
                "milestoneExtendedDate": "30-Sep-2027",
                "notes": "In December 2019, a phase II trial (NCT04001413) in patients with high-risk HPV 16-positive oropharynx cancer was expected to complete in September 2027 [ <ulink linkID=\"2171112\" linkType=\"Reference\"> 2171112 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "307",
              "name": "Squamous cell carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "05-Jun-2028",
            "statusDate": "29-Dec-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "21%",
            "timeToRegistration": "4.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "29-Dec-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "10.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "29-Dec-2022",
                "endDate": "20-May-2027",
                "successPercentage": "22%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-May-2027",
                "endDate": "24-Apr-2028",
                "successPercentage": "95%",
                "predictedDateL50": "18-Apr-2026",
                "predictedDateU50": "27-Nov-2027",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "24-Apr-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-Jan-2028",
                "predictedDateU50": "05-Jun-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected sNDA/sBLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2019",
                "milestoneExtendedDate": "30-Jun-2019",
                "notes": "In February 2019, further regulatory submissions for durvalumab with or without tremelimumab for the first-line treatment of squamous cell carcinoma were expected in 1H19 [ <ulink linkID=\"2119607\" linkType=\"Reference\"> 2119607 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "07-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, a phase I trial (NCT04504669) in adult patients with select advanced solid tumors including HNSCC, TNBC, NSCLC, ccRCC, gastric cancer, melanoma, cervical cancer and small-cell lung cancer was expected to complete in September 2023 [ <ulink linkID=\"2308081\" linkType=\"Reference\">  2308081 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-May-2027",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, a phase III trial (NCT05687266) was expected to complete in May 2027 [ <ulink linkID=\"2811470\" linkType=\"Reference\"> 2811470 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "319",
              "name": "Non-Hodgkin lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Nov-2016",
            "endDate": "24-Apr-2028",
            "statusDate": "15-Nov-2016",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "15-Nov-2016",
                "endDate": "07-Mar-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "07-Mar-2019",
                "endDate": "27-Nov-2024",
                "successPercentage": "34%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "27-Nov-2024",
                "endDate": "20-Jun-2027",
                "successPercentage": "16%",
                "predictedDateL50": "29-Feb-2024",
                "predictedDateU50": "26-Jun-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-Jun-2027",
                "endDate": "25-Mar-2028",
                "successPercentage": "92%",
                "predictedDateL50": "11-May-2026",
                "predictedDateU50": "03-Nov-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-Mar-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "20-Dec-2027",
                "predictedDateU50": "24-Apr-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "606",
              "name": "Female genital tract tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Nov-2018",
            "endDate": "01-Aug-2028",
            "statusDate": "14-Nov-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "14-Nov-2018",
                "endDate": "30-Dec-2024",
                "successPercentage": "27%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "30-Dec-2024",
                "endDate": "29-Sep-2027",
                "successPercentage": "16%",
                "predictedDateL50": "10-Mar-2024",
                "predictedDateU50": "30-May-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Sep-2027",
                "endDate": "01-Jul-2028",
                "successPercentage": "95%",
                "predictedDateL50": "03-Aug-2026",
                "predictedDateU50": "13-Mar-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Jul-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Mar-2028",
                "predictedDateU50": "01-Aug-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "650",
              "name": "Male genital tract tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Nov-2018",
            "endDate": "04-Jul-2028",
            "statusDate": "14-Nov-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "6%",
            "timeToRegistration": "4.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "14-Nov-2018",
                "endDate": "30-Dec-2024",
                "successPercentage": "27%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "30-Dec-2024",
                "endDate": "29-Sep-2027",
                "successPercentage": "24%",
                "predictedDateL50": "10-Mar-2024",
                "predictedDateU50": "30-May-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Sep-2027",
                "endDate": "31-May-2028",
                "successPercentage": "95%",
                "predictedDateL50": "03-Aug-2026",
                "predictedDateU50": "13-Mar-2028",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "31-May-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "09-Mar-2028",
                "predictedDateU50": "04-Jul-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "725",
              "name": "Solid tumor"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Apr-2017",
            "endDate": "",
            "statusDate": "17-Apr-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "17-Apr-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "725",
              "name": "Solid tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Sep-2012",
            "endDate": "10-Aug-2025",
            "statusDate": "17-Apr-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "46%",
            "timeToRegistration": "1.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "14-Sep-2012",
                "endDate": "12-Nov-2014",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "12-Nov-2014",
                "endDate": "17-Apr-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "17-Apr-2017",
                "endDate": "11-Oct-2024",
                "successPercentage": "48%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "11-Oct-2024",
                "endDate": "09-Jul-2025",
                "successPercentage": "95%",
                "predictedDateL50": "13-Feb-2024",
                "predictedDateU50": "02-Feb-2025",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "09-Jul-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "06-Apr-2025",
                "predictedDateU50": "10-Aug-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "17-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, safety data from (NCT03509012) in patients (n =105) with advanced solid tumors and the primary endpoint was to determine DLT.The study was expected to be completed in April 2022 [ <ulink linkID=\"2339855\" linkType=\"Reference\"> 2339855 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "725",
              "name": "Solid tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Dec-2013",
            "endDate": "03-Oct-2025",
            "statusDate": "17-Apr-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "46%",
            "timeToRegistration": "1.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "04-Dec-2013",
                "endDate": "17-Apr-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "17-Apr-2017",
                "endDate": "08-Oct-2024",
                "successPercentage": "48%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "08-Oct-2024",
                "endDate": "23-Aug-2025",
                "successPercentage": "95%",
                "predictedDateL50": "13-Feb-2024",
                "predictedDateU50": "30-Jan-2025",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Aug-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "14-May-2025",
                "predictedDateU50": "03-Oct-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "738",
              "name": "Urinary tract tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Jan-2018",
            "endDate": "27-Apr-2028",
            "statusDate": "31-Jan-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "6%",
            "timeToRegistration": "4.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Jan-2018",
                "endDate": "28-Sep-2024",
                "successPercentage": "26%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "28-Sep-2024",
                "endDate": "28-Jun-2027",
                "successPercentage": "24%",
                "predictedDateL50": "08-Mar-2024",
                "predictedDateU50": "07-Apr-2025",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "28-Jun-2027",
                "endDate": "27-Mar-2028",
                "successPercentage": "95%",
                "predictedDateL50": "02-May-2026",
                "predictedDateU50": "11-Dec-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Mar-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Dec-2027",
                "predictedDateU50": "27-Apr-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "793",
              "name": "Mouth tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Sep-2015",
            "endDate": "25-Jul-2026",
            "statusDate": "17-Sep-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "41%",
            "timeToRegistration": "2.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Sep-2015",
                "endDate": "17-Sep-2025",
                "successPercentage": "43%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "10.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "17-Sep-2025",
                "endDate": "25-Jun-2026",
                "successPercentage": "95%",
                "predictedDateL50": "31-Mar-2024",
                "predictedDateU50": "10-Jan-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-Jun-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Mar-2026",
                "predictedDateU50": "25-Jul-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "31-Jul-2019",
                "milestoneExtendedDate": "",
                "notes": "In June 2019, a phase II trial was planned to initiate in July 2019 in high-risk HPV 16 positive oropharynx cancer patients with durvalumab and Medi-0457 [ <ulink linkID=\"2171112\" linkType=\"Reference\"> 2171112 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "794",
              "name": "Pharynx tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Sep-2015",
            "endDate": "31-Jul-2026",
            "statusDate": "17-Sep-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "41%",
            "timeToRegistration": "2.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Sep-2015",
                "endDate": "17-Sep-2025",
                "successPercentage": "43%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "10.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "17-Sep-2025",
                "endDate": "01-Jul-2026",
                "successPercentage": "95%",
                "predictedDateL50": "31-Mar-2024",
                "predictedDateU50": "10-Jan-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Jul-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "21-Mar-2026",
                "predictedDateU50": "31-Jul-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "31-Jul-2019",
                "milestoneExtendedDate": "",
                "notes": "In June 2019, a phase II trial was planned to initiate in July 2019 in high-risk HPV 16 positive oropharynx cancer patients with durvalumab and Medi-0457 [ <ulink linkID=\"2171112\" linkType=\"Reference\"> 2171112 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "799",
              "name": "Ovary tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Jan-2019",
            "endDate": "25-Jul-2025",
            "statusDate": "04-Jan-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "77%",
            "timeToRegistration": "1.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "04-Jan-2019",
                "endDate": "04-Apr-2024",
                "successPercentage": "81%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "04-Apr-2024",
                "endDate": "21-May-2025",
                "successPercentage": "95%",
                "predictedDateL50": "21-Nov-2023",
                "predictedDateU50": "22-Jul-2024",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "21-May-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Jan-2025",
                "predictedDateU50": "25-Jul-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In April 2023, results from a planned interim analysis of the phase III trial NCT03737643 (DUO-O) in patients with ovarian cancer without BRCA mutations were reported. Data demonstrated a significant improvement in PFS in the durvalumab + olaparib + bevacizumab combination arm compared with the bevacizumab control arm [ <ulink linkID=\"2886368\" linkType=\"Reference\"> 2886368 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "799",
              "name": "Ovary tumor"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Jan-2019",
            "endDate": "25-Feb-2025",
            "statusDate": "04-Jan-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "77%",
            "timeToRegistration": "1.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "04-Jan-2019",
                "endDate": "04-Apr-2024",
                "successPercentage": "81%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "04-Apr-2024",
                "endDate": "25-Jan-2025",
                "successPercentage": "95%",
                "predictedDateL50": "25-Nov-2023",
                "predictedDateU50": "09-Jul-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-Jan-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "09-Oct-2024",
                "predictedDateU50": "25-Feb-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In April 2023, results from a planned interim analysis of the phase III trial NCT03737643 (DUO-O) in patients with ovarian cancer without BRCA mutations were reported. Data demonstrated a significant improvement in PFS in the durvalumab + olaparib + bevacizumab combination arm compared with the bevacizumab control arm [ <ulink linkID=\"2886368\" linkType=\"Reference\"> 2886368 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "799",
              "name": "Ovary tumor"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "23-Feb-2025",
            "statusDate": "04-Jan-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "77%",
            "timeToRegistration": "1.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "04-Jan-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "04-Jan-2019",
                "endDate": "04-Apr-2024",
                "successPercentage": "81%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "04-Apr-2024",
                "endDate": "24-Jan-2025",
                "successPercentage": "95%",
                "predictedDateL50": "16-Dec-2023",
                "predictedDateU50": "29-May-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "24-Jan-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "08-Oct-2024",
                "predictedDateU50": "23-Feb-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In April 2023, results from a planned interim analysis of the phase III trial NCT03737643 (DUO-O) in patients with ovarian cancer without BRCA mutations were reported. Data demonstrated a significant improvement in PFS in the durvalumab + olaparib + bevacizumab combination arm compared with the bevacizumab control arm [ <ulink linkID=\"2886368\" linkType=\"Reference\"> 2886368 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "799",
              "name": "Ovary tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "20-Feb-2025",
            "statusDate": "04-Jan-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "75%",
            "timeToRegistration": "1.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "04-Jan-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "04-Jan-2019",
                "endDate": "04-Apr-2024",
                "successPercentage": "79%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "04-Apr-2024",
                "endDate": "21-Jan-2025",
                "successPercentage": "95%",
                "predictedDateL50": "27-Oct-2023",
                "predictedDateU50": "14-Aug-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "21-Jan-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Oct-2024",
                "predictedDateU50": "20-Feb-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "31-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, topline data of a phase Ib study (NCT03430518) in patients (n = 9) with HER2-negative metastatic breast cancer and recurrent ovarian cancer were presented. The RP2D was determined (eribulin 1.4 mg/m2 in combination with durvalumab); no DLTs were experienced during the first two cycles of therapy. Fatigue, neutropenia, decreased WBC count, anemia, AST and alkaline phosphatase elevation, hyperglycemia and nausea were the most common treatment-related AEs (&gt; 50%) and mostly were of grade 1/2. Grade &gt;/= 3 hepatitis (immune-related AE) was reported by one patient [ <ulink linkID=\"2284855\" linkType=\"Reference\"> 2284855 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "31-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, positive data of a phase Ib study (NCT03430518) in patients with HER2-negative metastatic breast cancer and recurrent ovarian cancer were presented which showed that the trial met its primary endpoint (DLT). The RP2D was determined (eribulin 1.4 mg/m2 in combination with durvalumab); no DLTs were experienced during the first two cycles of therapy. Fatigue, neutropenia, decreased WBC count, anemia, AST and alkaline phosphatase elevation, hyperglycemia and nausea were the most common treatment-related AEs (&gt; 50%) and mostly were of grade 1/2. Grade &gt;/= 3 hepatitis (immune-related AE) was reported by one patient [ <ulink linkID=\"2284855\" linkType=\"Reference\"> 2284855 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "10-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, positive results of a phase I trial (NCT03277482) of durvalumab and tremelimumabin in 12 subjects were presented. No DLT was noted in cohort A and one DLT was noted in cohort B. A single patient in cohort B showed partial response after five months of durvalumab + tremelimumab + radiation therapy and after three months, there was 80% reduction in the size of lesions 1 and 2 [ <ulink linkID=\"2779008\" linkType=\"Reference\"> 2779008 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In April 2023, results from a planned interim analysis of the phase III trial NCT03737643 (DUO-O) in patients with ovarian cancer without BRCA mutations were reported. Data demonstrated a significant improvement in PFS in the durvalumab + olaparib + bevacizumab combination arm compared with the bevacizumab control arm [ <ulink linkID=\"2886368\" linkType=\"Reference\"> 2886368 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "799",
              "name": "Ovary tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "21-May-2025",
            "statusDate": "04-Jan-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "76%",
            "timeToRegistration": "1.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "04-Jan-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "04-Jan-2019",
                "endDate": "04-Apr-2024",
                "successPercentage": "80%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "04-Apr-2024",
                "endDate": "04-Apr-2025",
                "successPercentage": "95%",
                "predictedDateL50": "27-Oct-2023",
                "predictedDateU50": "14-Aug-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Apr-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Dec-2024",
                "predictedDateU50": "21-May-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In April 2023, results from a planned interim analysis of the phase III trial NCT03737643 (DUO-O) in patients with ovarian cancer without BRCA mutations were reported. Data demonstrated a significant improvement in PFS in the durvalumab + olaparib + bevacizumab combination arm compared with the bevacizumab control arm [ <ulink linkID=\"2886368\" linkType=\"Reference\"> 2886368 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "989",
              "name": "Colorectal tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Mar-2017",
            "endDate": "09-Aug-2028",
            "statusDate": "02-Mar-2017",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "02-Mar-2017",
                "endDate": "11-Feb-2025",
                "successPercentage": "20%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "11-Feb-2025",
                "endDate": "08-Oct-2027",
                "successPercentage": "15%",
                "predictedDateL50": "21-Mar-2024",
                "predictedDateU50": "29-Jun-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "08-Oct-2027",
                "endDate": "09-Jul-2028",
                "successPercentage": "94%",
                "predictedDateL50": "19-Aug-2026",
                "predictedDateU50": "04-Mar-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "09-Jul-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-Apr-2028",
                "predictedDateU50": "09-Aug-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1011",
              "name": "Esophagus tumor"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Nov-2020",
            "endDate": "23-May-2025",
            "statusDate": "17-Nov-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "36%",
            "timeToRegistration": "1.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "17-Nov-2020",
                "endDate": "06-Jul-2024",
                "successPercentage": "38%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "06-Jul-2024",
                "endDate": "23-Apr-2025",
                "successPercentage": "95%",
                "predictedDateL50": "18-Jan-2024",
                "predictedDateU50": "18-Oct-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Apr-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "08-Jan-2025",
                "predictedDateU50": "23-May-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In February 2021, first data from the phase III MATTERHORN trial (NCT04592913) for neoadjuvant-adjuvant durvalumab for resectable gastric and gastroesophageal cancer were expected in 2022 or later [ <ulink linkID=\"2405453\" linkType=\"Reference\">  2405453 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2025",
                "milestoneExtendedDate": "14-Feb-2025",
                "notes": "In November 2020, the phase III MATTERHORN trial (NCT04592913) for neoadjuvant-adjuvant durvalumab for resectable gastric and gastroesophageal cancer was expected to complete in February 2025 [ <ulink linkID=\"2402876\" linkType=\"Reference\">  2402876 </ulink>]</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1011",
              "name": "Esophagus tumor"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Nov-2020",
            "endDate": "30-Mar-2025",
            "statusDate": "17-Nov-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "40%",
            "timeToRegistration": "1.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "17-Nov-2020",
                "endDate": "17-May-2024",
                "successPercentage": "42%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "17-May-2024",
                "endDate": "28-Feb-2025",
                "successPercentage": "95%",
                "predictedDateL50": "12-Jan-2024",
                "predictedDateU50": "21-Aug-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "28-Feb-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "18-Nov-2024",
                "predictedDateU50": "30-Mar-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In February 2021, first data from the phase III MATTERHORN trial (NCT04592913) for neoadjuvant-adjuvant durvalumab for resectable gastric and gastroesophageal cancer were expected in 2022 or later [ <ulink linkID=\"2405453\" linkType=\"Reference\">  2405453 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2025",
                "milestoneExtendedDate": "14-Feb-2025",
                "notes": "In November 2020, the phase III MATTERHORN trial (NCT04592913) for neoadjuvant-adjuvant durvalumab for resectable gastric and gastroesophageal cancer was expected to complete in February 2025 [ <ulink linkID=\"2402876\" linkType=\"Reference\">  2402876 </ulink>]</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1011",
              "name": "Esophagus tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "14-Nov-2016",
            "endDate": "09-Jul-2025",
            "statusDate": "17-Nov-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "49%",
            "timeToRegistration": "1.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "14-Nov-2016",
                "endDate": "17-Nov-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "17-Nov-2020",
                "endDate": "05-Sep-2024",
                "successPercentage": "52%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Sep-2024",
                "endDate": "07-Jun-2025",
                "successPercentage": "95%",
                "predictedDateL50": "10-Feb-2024",
                "predictedDateU50": "20-Jan-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-Jun-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "04-Mar-2025",
                "predictedDateU50": "09-Jul-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In February 2021, first data from the phase III MATTERHORN trial (NCT04592913) for neoadjuvant-adjuvant durvalumab for resectable gastric and gastroesophageal cancer were expected in 2022 or later [ <ulink linkID=\"2405453\" linkType=\"Reference\">  2405453 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "12-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, US FDA granted Orphan Drug Designation for the treatment of gastric cancer, including gastroesophageal junction cancer [ <ulink linkID=\"3477312\" linkType=\"Reference\"> 3477312 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2025",
                "milestoneExtendedDate": "14-Feb-2025",
                "notes": "In November 2020, the phase III MATTERHORN trial (NCT04592913) for neoadjuvant-adjuvant durvalumab for resectable gastric and gastroesophageal cancer was expected to complete in February 2025 [ <ulink linkID=\"2402876\" linkType=\"Reference\">  2402876 </ulink>]</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1011",
              "name": "Esophagus tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "16-Jun-2016",
            "endDate": "07-Sep-2025",
            "statusDate": "17-Nov-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "38%",
            "timeToRegistration": "1.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "16-Jun-2016",
                "endDate": "17-Nov-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "17-Nov-2020",
                "endDate": "31-Aug-2024",
                "successPercentage": "40%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Aug-2024",
                "endDate": "31-Jul-2025",
                "successPercentage": "95%",
                "predictedDateL50": "07-Feb-2024",
                "predictedDateU50": "14-Jan-2025",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "31-Jul-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Apr-2025",
                "predictedDateU50": "07-Sep-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In February 2021, first data from the phase III MATTERHORN trial (NCT04592913) for neoadjuvant-adjuvant durvalumab for resectable gastric and gastroesophageal cancer were expected in 2022 or later [ <ulink linkID=\"2405453\" linkType=\"Reference\">  2405453 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2025",
                "milestoneExtendedDate": "14-Feb-2025",
                "notes": "In November 2020, the phase III MATTERHORN trial (NCT04592913) for neoadjuvant-adjuvant durvalumab for resectable gastric and gastroesophageal cancer was expected to complete in February 2025 [ <ulink linkID=\"2402876\" linkType=\"Reference\">  2402876 </ulink>]</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1055",
              "name": "Rectal tumor"
            },
            "country": {
              "id": "EU",
              "name": "EU (IT)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Jan-2020",
            "endDate": "19-Jun-2028",
            "statusDate": "01-Jan-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-Jan-2020",
                "endDate": "02-Oct-2024",
                "successPercentage": "21%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "02-Oct-2024",
                "endDate": "23-Jun-2027",
                "successPercentage": "19%",
                "predictedDateL50": "19-Feb-2024",
                "predictedDateU50": "30-Apr-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "23-Jun-2027",
                "endDate": "11-May-2028",
                "successPercentage": "95%",
                "predictedDateL50": "02-May-2026",
                "predictedDateU50": "01-Dec-2027",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-May-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Jan-2028",
                "predictedDateU50": "19-Jun-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "IT"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1240",
              "name": "Mesothelioma"
            },
            "country": {
              "id": "EU",
              "name": "EU (IT)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Oct-2015",
            "endDate": "14-Jun-2021",
            "statusDate": "31-Oct-2015",
            "phaseHighestStatus": "Reg",
            "probabilityOfSuccess": null,
            "timeToRegistration": "-2.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Oct-2015",
                "endDate": "14-Jun-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Jun-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "IT"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1240",
              "name": "Mesothelioma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Jun-2017",
            "endDate": "16-Apr-2025",
            "statusDate": "06-Apr-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "30%",
            "timeToRegistration": "1.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "13-Jun-2017",
                "endDate": "06-Apr-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "06-Apr-2020",
                "endDate": "22-Jun-2024",
                "successPercentage": "32%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Jun-2024",
                "endDate": "12-Mar-2025",
                "successPercentage": "95%",
                "predictedDateL50": "18-Jan-2024",
                "predictedDateU50": "28-Sep-2024",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Mar-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "14-Dec-2024",
                "predictedDateU50": "16-Apr-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "02-Jun-2019",
                "milestoneExtendedDate": "",
                "notes": "In June 2019, study did not meet its primary endpoint (overall response rate) [ <ulink linkID=\"2155780\" linkType=\"Reference\"> 2155780 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "06-Apr-2020",
                "milestoneExtendedDate": "",
                "notes": "In April 2020, a phase III trial was planned to be initiated in September 2020 [ <ulink linkID=\"2291717\" linkType=\"Reference\"> 2291717 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "29-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, topline results of phase II trial (NCT02899195) in patients with unresectable malignant pleural mesothelioma were presented which showed that the primary endpoint (OS) was met. The median OS was 20.4 months (p = 0.0014); OS rate at 6-months was 87.2%, OS rate at 12-months 70.4%, and OS rate at 24-months 44.2% [ <ulink linkID=\"2284218\" linkType=\"Reference\"> 2284218 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "29-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, primary endpoint (OS) of phase II trial (NCT02899195) in patients with unresectable malignant pleural mesothelioma was met. The median OS was 20.4 months (p = 0.0014); OS rate at 6-months was 87.2%, OS rate at 12-months 70.4%, and OS rate at 24-months 44.2% [ <ulink linkID=\"2284218\" linkType=\"Reference\"> 2284218 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "06-Apr-2025",
                "milestoneExtendedDate": "",
                "notes": "Source Date: 6/04/2020; Phase: C2;  In April 2020, a phase III trial was planned to be completed in May 2025 [ <ulink linkID=\"2291717\" linkType=\"Reference\"> 2291717 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1262",
              "name": "Non-small-cell lung cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe (DE, GB, GB, IT)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "24-Oct-2017",
            "statusDate": "12-Apr-2021",
            "phaseHighestStatus": "Reg",
            "probabilityOfSuccess": null,
            "timeToRegistration": "-6.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "08-May-2014",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "08-May-2014",
                "endDate": "10-Oct-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Oct-2017",
                "endDate": "24-Oct-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "24-Oct-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "DE",
              " GB",
              " GB",
              " IT"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1272",
              "name": "Myelodysplastic syndrome"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "20-May-2014",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1272",
              "name": "Myelodysplastic syndrome"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "20-May-2014",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1516",
              "name": "Biliary cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Aug-2020",
            "endDate": "22-Nov-2025",
            "statusDate": "19-Aug-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "60%",
            "timeToRegistration": "1.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "10-Aug-2020",
                "endDate": "27-Aug-2024",
                "successPercentage": "63%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Aug-2024",
                "endDate": "27-Sep-2025",
                "successPercentage": "95%",
                "predictedDateL50": "01-Feb-2024",
                "predictedDateU50": "09-Jan-2025",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Sep-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "21-May-2025",
                "predictedDateU50": "22-Nov-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN",
              " CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1516",
              "name": "Biliary cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Sep-2013",
            "endDate": "21-Dec-2022",
            "statusDate": "29-Jul-2022",
            "phaseHighestStatus": "Reg",
            "probabilityOfSuccess": null,
            "timeToRegistration": "-0.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "12-Sep-2013",
                "endDate": "09-Nov-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "09-Nov-2018",
                "endDate": "16-Apr-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Apr-2019",
                "endDate": "29-Jul-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Jul-2022",
                "endDate": "21-Dec-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "21-Dec-2022",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Oct-2018",
                "milestoneExtendedDate": "20-Oct-2018",
                "notes": "In October 2018, a phase II combination trial of durvalumab and tremelimumab with or without weekly paclitaxel in patients with advanced BTC after failure of platinum-based chemotherapy was planned to initiate later that month. At that time, the trial was expected to complete in October 2021 [ <ulink linkID=\"2082840\" linkType=\"Reference\">  2082840 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "25-Oct-2021",
                "milestoneExtendedDate": "",
                "notes": "In October 2021, positive data from an interim analysis of the TOPAZ-1 study were reported. The trial met its primary endpoint, with durvalumab plus chemotherapy showing improved OS versus chemotherapy alone. The trial also met key secondary endpoints, including improved PFS and ORR [ <ulink linkID=\"2554468\" linkType=\"Reference\">  2554468 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "25-Oct-2021",
                "milestoneExtendedDate": "",
                "notes": "In October 2021, positive data from an interim analysis of the TOPAZ-1 study were reported. The trial met its primary endpoint, with durvalumab plus chemotherapy showing improved OS versus chemotherapy alone. The trial also met key secondary endpoints, including improved PFS and ORR [ <ulink linkID=\"2554468\" linkType=\"Reference\">  2554468 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Oct-2021",
                "milestoneExtendedDate": "",
                "notes": "In October 2018, a phase II combination trial of durvalumab and tremelimumab with or without weekly paclitaxel in patients with advanced BTC after failure of platinum-based chemotherapy was planned to initiate later that month. At that time, the trial was expected to complete in October 2021 [ <ulink linkID=\"2082840\" linkType=\"Reference\">  2082840 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Expected sNDA/sBLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In November 2021, regulatory submissions for biliary tract cancer, presumably first-line treatment based on TOPAZ-1 data, were expected in 1H22 [ <ulink linkID=\"2565879\" linkType=\"Reference\">  2565879 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Half)",
                "milestoneDate": "01-Feb-2022",
                "milestoneExtendedDate": "29-Jul-2022",
                "notes": "By July 2022, a regulatory decision on the EU filing for biliary tract cancer, presumably first-line treatment based on TOPAZ-1 data; at that time, was expected in 2H22 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "15-Mar-2022",
                "milestoneExtendedDate": "",
                "notes": "In May 2019, a phase III trial of durvalumab with gemcitabine plus cisplatin for biliary tract cancer was expected to complete in March 2022 [ <ulink linkID=\"2150253\" linkType=\"Reference\">  2150253 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "By July 2022, a regulatory decision on the EU filing for biliary tract cancer, presumably first-line treatment based on TOPAZ-1 data; at that time, was expected in 2H22 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "sNDA/sBLA Filing",
                "status": "Filed",
                "milestoneDate": "29-Jul-2022",
                "milestoneExtendedDate": "",
                "notes": "By July 2022, EU filing for biliary tract cancer had been submitted, presumably first-line treatment based on TOPAZ-1 data; at that time [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "CHMP Opinion",
                "status": "Positive Opinion",
                "milestoneDate": "10-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, the EMA's CHMP recommended approval of durvalumab in combination with gemcitabine and cisplatin for the first‚Äëline treatment of unresectable or metastatic biliary tract cancer (BTC) in adult patients [ <ulink linkID=\"2770492\" linkType=\"Reference\"> 2770492 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Mar-2021",
            "endDate": "17-Aug-2025",
            "statusDate": "18-Mar-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "84%",
            "timeToRegistration": "1.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "18-Mar-2021",
                "endDate": "09-May-2024",
                "successPercentage": "88%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-May-2024",
                "endDate": "17-Jun-2025",
                "successPercentage": "95%",
                "predictedDateL50": "05-Oct-2023",
                "predictedDateU50": "30-Sep-2024",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Jun-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-Feb-2025",
                "predictedDateU50": "17-Aug-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In July 2021, first data from the DUO-E phase III trial (NCT04269200) assessing durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer were expected in 2022 or later [ <ulink linkID=\"2501429\" linkType=\"Reference\">  2501429 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "10-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, data from the phase III trial NCT04269200 (DUO-E) in patients with newly diagnosed advanced or recurrent endometrial cancer were reported. Patients treated with durvalumab plus chemotherapy, with durvalumab alone or in combination with olaparib maintenance therapy had statistically significant improvement of PFS compared with chemotherapy alone [ <ulink linkID=\"2955752\" linkType=\"Reference\"> 2955752 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In July 2022, data readout from phase III trial (NCT04269200; DUO-E) of durvalumab with or without olaparib for first-line treatment of advanced or recurrent endometrial neoplasms were expected in 2H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2025",
                "milestoneExtendedDate": "05-Mar-2025",
                "notes": "In February 2020, it was reported that the phase III trial (NCT04269200) in patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer was expected to complete in March 2025 [ <ulink linkID=\"2402913\" linkType=\"Reference\">  2402913 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Feb-2020",
            "endDate": "28-Mar-2025",
            "statusDate": "13-Feb-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "81%",
            "timeToRegistration": "1.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "13-Feb-2020",
                "endDate": "09-May-2024",
                "successPercentage": "85%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-May-2024",
                "endDate": "26-Feb-2025",
                "successPercentage": "95%",
                "predictedDateL50": "06-Nov-2023",
                "predictedDateU50": "26-Oct-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-Feb-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "12-Nov-2024",
                "predictedDateU50": "28-Mar-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In July 2021, first data from the DUO-E phase III trial (NCT04269200) assessing durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer were expected in 2022 or later [ <ulink linkID=\"2501429\" linkType=\"Reference\">  2501429 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "10-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, data from the phase III trial NCT04269200 (DUO-E) in patients with newly diagnosed advanced or recurrent endometrial cancer were reported. Patients treated with durvalumab plus chemotherapy, with durvalumab alone or in combination with olaparib maintenance therapy had statistically significant improvement of PFS compared with chemotherapy alone [ <ulink linkID=\"2955752\" linkType=\"Reference\"> 2955752 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In July 2022, data readout from phase III trial (NCT04269200; DUO-E) of durvalumab with or without olaparib for first-line treatment of advanced or recurrent endometrial neoplasms were expected in 2H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2025",
                "milestoneExtendedDate": "05-Mar-2025",
                "notes": "In February 2020, it was reported that the phase III trial (NCT04269200) in patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer was expected to complete in March 2025 [ <ulink linkID=\"2402913\" linkType=\"Reference\">  2402913 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Feb-2020",
            "endDate": "26-Mar-2025",
            "statusDate": "13-Feb-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "82%",
            "timeToRegistration": "1.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "13-Feb-2020",
                "endDate": "09-May-2024",
                "successPercentage": "86%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-May-2024",
                "endDate": "24-Feb-2025",
                "successPercentage": "95%",
                "predictedDateL50": "14-Dec-2023",
                "predictedDateU50": "31-Jul-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "24-Feb-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Nov-2024",
                "predictedDateU50": "26-Mar-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In July 2021, first data from the DUO-E phase III trial (NCT04269200) assessing durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer were expected in 2022 or later [ <ulink linkID=\"2501429\" linkType=\"Reference\">  2501429 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "10-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, data from the phase III trial NCT04269200 (DUO-E) in patients with newly diagnosed advanced or recurrent endometrial cancer were reported. Patients treated with durvalumab plus chemotherapy, with durvalumab alone or in combination with olaparib maintenance therapy had statistically significant improvement of PFS compared with chemotherapy alone [ <ulink linkID=\"2955752\" linkType=\"Reference\"> 2955752 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In July 2022, data readout from phase III trial (NCT04269200; DUO-E) of durvalumab with or without olaparib for first-line treatment of advanced or recurrent endometrial neoplasms were expected in 2H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2025",
                "milestoneExtendedDate": "05-Mar-2025",
                "notes": "In February 2020, it was reported that the phase III trial (NCT04269200) in patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer was expected to complete in March 2025 [ <ulink linkID=\"2402913\" linkType=\"Reference\">  2402913 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Feb-2020",
            "endDate": "10-Jun-2025",
            "statusDate": "13-Feb-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "81%",
            "timeToRegistration": "1.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "13-Feb-2020",
                "endDate": "09-May-2024",
                "successPercentage": "85%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-May-2024",
                "endDate": "03-May-2025",
                "successPercentage": "95%",
                "predictedDateL50": "10-Oct-2023",
                "predictedDateU50": "21-Nov-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "03-May-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Jan-2025",
                "predictedDateU50": "10-Jun-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In July 2021, first data from the DUO-E phase III trial (NCT04269200) assessing durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer were expected in 2022 or later [ <ulink linkID=\"2501429\" linkType=\"Reference\">  2501429 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "10-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, data from the phase III trial NCT04269200 (DUO-E) in patients with newly diagnosed advanced or recurrent endometrial cancer were reported. Patients treated with durvalumab plus chemotherapy, with durvalumab alone or in combination with olaparib maintenance therapy had statistically significant improvement of PFS compared with chemotherapy alone [ <ulink linkID=\"2955752\" linkType=\"Reference\"> 2955752 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In July 2022, data readout from phase III trial (NCT04269200; DUO-E) of durvalumab with or without olaparib for first-line treatment of advanced or recurrent endometrial neoplasms were expected in 2H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2025",
                "milestoneExtendedDate": "05-Mar-2025",
                "notes": "In February 2020, it was reported that the phase III trial (NCT04269200) in patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer was expected to complete in March 2025 [ <ulink linkID=\"2402913\" linkType=\"Reference\">  2402913 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Jan-2017",
            "endDate": "23-Mar-2025",
            "statusDate": "13-Feb-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "81%",
            "timeToRegistration": "1.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-Jan-2017",
                "endDate": "13-Feb-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "13-Feb-2020",
                "endDate": "09-May-2024",
                "successPercentage": "85%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-May-2024",
                "endDate": "21-Feb-2025",
                "successPercentage": "95%",
                "predictedDateL50": "23-Sep-2023",
                "predictedDateU50": "02-Dec-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "21-Feb-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Nov-2024",
                "predictedDateU50": "23-Mar-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2020",
                "milestoneExtendedDate": "01-Nov-2020",
                "notes": "In November 2020, it was reported that data were expected after 2021 [ <ulink linkID=\"2354707\" linkType=\"Reference\"> 2354707 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In July 2021, first data from the DUO-E phase III trial (NCT04269200) assessing durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer were expected in 2022 or later [ <ulink linkID=\"2501429\" linkType=\"Reference\">  2501429 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "10-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, data from the phase III trial NCT04269200 (DUO-E) in patients with newly diagnosed advanced or recurrent endometrial cancer were reported. Patients treated with durvalumab plus chemotherapy, with durvalumab alone or in combination with olaparib maintenance therapy had statistically significant improvement of PFS compared with chemotherapy alone [ <ulink linkID=\"2955752\" linkType=\"Reference\"> 2955752 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In July 2022, data readout from phase III trial (NCT04269200; DUO-E) of durvalumab with or without olaparib for first-line treatment of advanced or recurrent endometrial neoplasms were expected in 2H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2025",
                "milestoneExtendedDate": "05-Mar-2025",
                "notes": "In February 2020, it was reported that the phase III trial (NCT04269200) in patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer was expected to complete in March 2025 [ <ulink linkID=\"2402913\" linkType=\"Reference\"> 2402913 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Feb-2020",
            "endDate": "21-Jun-2025",
            "statusDate": "13-Feb-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "81%",
            "timeToRegistration": "1.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "13-Feb-2020",
                "endDate": "09-May-2024",
                "successPercentage": "85%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-May-2024",
                "endDate": "07-May-2025",
                "successPercentage": "95%",
                "predictedDateL50": "04-Oct-2023",
                "predictedDateU50": "23-Nov-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-May-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-Jan-2025",
                "predictedDateU50": "21-Jun-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In July 2021, first data from the DUO-E phase III trial (NCT04269200) assessing durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer were expected in 2022 or later [ <ulink linkID=\"2501429\" linkType=\"Reference\">  2501429 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "10-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, data from the phase III trial NCT04269200 (DUO-E) in patients with newly diagnosed advanced or recurrent endometrial cancer were reported. Patients treated with durvalumab plus chemotherapy, with durvalumab alone or in combination with olaparib maintenance therapy had statistically significant improvement of PFS compared with chemotherapy alone [ <ulink linkID=\"2955752\" linkType=\"Reference\"> 2955752 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In July 2022, data readout from phase III trial (NCT04269200; DUO-E) of durvalumab with or without olaparib for first-line treatment of advanced or recurrent endometrial neoplasms were expected in 2H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2025",
                "milestoneExtendedDate": "05-Mar-2025",
                "notes": "In February 2020, it was reported that the phase III trial (NCT04269200) in patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer was expected to complete in March 2025 [ <ulink linkID=\"2402913\" linkType=\"Reference\">  2402913 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1744",
              "name": "Mantle cell lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "06-Dec-2018",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1745",
              "name": "Follicle center lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "06-Dec-2018",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1749",
              "name": "Diffuse large B-cell lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "19-Jul-2016",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1749",
              "name": "Diffuse large B-cell lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "19-Jul-2016",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1765",
              "name": "Cholangiocarcinoma"
            },
            "country": {
              "id": "EU",
              "name": "EU (DE)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-May-2018",
            "endDate": "05-Aug-2028",
            "statusDate": "02-May-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "02-May-2018",
                "endDate": "01-Dec-2024",
                "successPercentage": "5%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "01-Dec-2024",
                "endDate": "08-Aug-2027",
                "successPercentage": "17%",
                "predictedDateL50": "01-Mar-2024",
                "predictedDateU50": "25-Jun-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "08-Aug-2027",
                "endDate": "27-Jun-2028",
                "successPercentage": "95%",
                "predictedDateL50": "18-Jun-2026",
                "predictedDateU50": "09-Jan-2028",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Jun-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "17-Mar-2028",
                "predictedDateU50": "05-Aug-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "10-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In September 2022, negative data from a phase II trial (NCT03473574) in treatment-naive patients with cholangio and gallbladder carcinoma were presented. Across arms A (tremelimumab + durvalumab + gemcitabine; n = 22), B (tremelimumab 4 x 75 mg, q3w + durvalumab + gemcitabine + cisplatin; n = 22), C (gemcitabine + cisplatin; n = 35), D (tremelimumab 1 X 300 mg, q3w + durvalumab + gemcitabine + cisplatin; n = 30) and E (durvalumab + gemcitabine + cisplatin; n = 29), ORR as per investigator‚Äôs assessment according to RECIST version 1.1 was 4.6, 18.2, 28.6, 26.7 and 20.7%, respectively (primary endpoint not met as there is no improvement in ORR with the addition of durvalumab alone or in combination with tremelimumab compared to chemotherapy alone); best overall response included complete remission (0.0, 4.5, 2.9, 0.0 and 0.0%), partial remission (4.5, 13.6, 25.7, 26.7 and 20.7%, stable disease (31.8, 50.0, 37.1, 43.3 and 44.8%), and progressive disease (40.9, 13.6, 5.7, 10.0 and 20.7%, respectively); median DOR was 2.2, 7.18, 6.07, 6.78 months and not reached; median PFS was 2.75, 5.98, 8.7, 8.13, and 5.97 months; median OS was 7.38, 12.32, 16.93, 22.73 and 12.87 months, respectively [ <ulink linkID=\"2748134\" linkType=\"Reference\"> 2748134 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "10-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In September 2022, negative data from a phase II trial (NCT03473574) in treatment-naive patients with cholangio and gallbladder carcinoma were presented. Across arms A (tremelimumab + durvalumab + gemcitabine; n = 22), B (tremelimumab 4 x 75 mg, q3w + durvalumab + gemcitabine + cisplatin; n = 22), C (gemcitabine + cisplatin; n = 35), D (tremelimumab 1 X 300 mg, q3w + durvalumab + gemcitabine + cisplatin; n = 30) and E (durvalumab + gemcitabine + cisplatin; n = 29), ORR as per investigator‚Äôs assessment according to RECIST version 1.1 was 4.6, 18.2, 28.6, 26.7 and 20.7%, respectively (primary endpoint not met as there is no improvement in ORR with the addition of durvalumab alone or in combination with tremelimumab compared to chemotherapy alone); best overall response included complete remission (0.0, 4.5, 2.9, 0.0 and 0.0%), partial remission (4.5, 13.6, 25.7, 26.7 and 20.7%, stable disease (31.8, 50.0, 37.1, 43.3 and 44.8%), and progressive disease (40.9, 13.6, 5.7, 10.0 and 20.7%, respectively); median DOR was 2.2, 7.18, 6.07, 6.78 months and not reached; median PFS was 2.75, 5.98, 8.7, 8.13, and 5.97 months; median OS was 7.38, 12.32, 16.93, 22.73 and 12.87 months, respectively [ <ulink linkID=\"2748134\" linkType=\"Reference\"> 2748134 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "DE"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1765",
              "name": "Cholangiocarcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "24-Aug-2021",
            "endDate": "13-May-2030",
            "statusDate": "24-Aug-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "6%",
            "timeToRegistration": "6.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "24-Aug-2021",
                "endDate": "15-Nov-2026",
                "successPercentage": "44%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "15-Nov-2026",
                "endDate": "11-Jul-2029",
                "successPercentage": "15%",
                "predictedDateL50": "02-May-2026",
                "predictedDateU50": "12-Apr-2027",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "11-Jul-2029",
                "endDate": "12-Apr-2030",
                "successPercentage": "94%",
                "predictedDateL50": "22-May-2028",
                "predictedDateU50": "06-Dec-2029",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Apr-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Jan-2030",
                "predictedDateU50": "13-May-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In December 2022, a phase II study (NCT05655949) was planned to initiate later that month in the US in locally advanced, unresectable or metastatic intrahepatic cholangiocarcinoma [ <ulink linkID=\"2800428\" linkType=\"Reference\"> 2800428 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, positive topline data from a phase II study (NCT04301778) of durvalumab + SNDX-6352 in five patients were presented. Grade 3 treatment-related adverse events (TRAEs) were reported in three patients including elevated creatinine kinase and AST in two patients, elevated ALT in one patient, femoral pseudoaneurysm and cellulitis in one patient; no grade 4 to 5 AEs were reported. Partial responses (PR) by RECIST 1.1 and stable disease was achieved by one patient each; two patients had PR of target lesions, but overall progression due to appearance of new liver lesions. Overall, the combination treatment of durvalumab and axatilimab was well tolerated in patients with advanced cholangiocarcinoma [ <ulink linkID=\"2982526\" linkType=\"Reference\"> 2982526 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, positive topline data from a phase II study (NCT04301778) of durvalumab + SNDX-6352 in five patients were presented. Grade 3 treatment-related adverse events (TRAEs) were reported in three patients including elevated creatinine kinase and AST in two patients, elevated ALT in one patient, femoral pseudoaneurysm and cellulitis in one patient; no grade 4 to 5 AEs were reported. Partial responses (PR) by RECIST 1.1 and stable disease was achieved by one patient each; two patients had PR of target lesions, but overall progression due to appearance of new liver lesions. Overall, the combination treatment of durvalumab and axatilimab was well tolerated in patients with advanced cholangiocarcinoma [ <ulink linkID=\"2982526\" linkType=\"Reference\"> 2982526 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Nov-2023",
                "milestoneExtendedDate": "30-Nov-2023",
                "notes": "In August 2023, a phase II trial (NCT06017297) was planned to initiate in the US in November 2023 for intrahepatic cholangiocarcinoma [ <ulink linkID=\"3060324\" linkType=\"Reference\"> 3060324 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-May-2024",
                "milestoneExtendedDate": "31-May-2024",
                "notes": "In March 2020, a phase II trial (NCT04301778) in patients with intrahepatic cholangiocarcinoma was expected to complete in May 2024 [ <ulink linkID=\"2254326\" linkType=\"Reference\"> 2254326 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Nov-2026",
                "milestoneExtendedDate": "30-Nov-2026",
                "notes": "In August 2023, a phase II trial (NCT06017297)for intrahepatic cholangiocarcinoma was expected to complete in the US in November 2026 [ <ulink linkID=\"3060324\" linkType=\"Reference\"> 3060324 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-Dec-2027",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, a phase II study (NCT05655949)in locally advanced, unresectable or metastatic intrahepatic cholangiocarcinoma was expected to complete in December 2027 [ <ulink linkID=\"2800428\" linkType=\"Reference\"> 2800428 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1766",
              "name": "Renal cell carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Oct-2021",
            "endDate": "18-May-2025",
            "statusDate": "28-Oct-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "80%",
            "timeToRegistration": "1.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "28-Oct-2021",
                "endDate": "18-Feb-2024",
                "successPercentage": "84%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "18-Feb-2024",
                "endDate": "20-Mar-2025",
                "successPercentage": "95%",
                "predictedDateL50": "27-Jul-2023",
                "predictedDateU50": "12-Jul-2024",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "20-Mar-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "12-Nov-2024",
                "predictedDateU50": "18-May-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "18-Feb-2023",
                "milestoneExtendedDate": "",
                "notes": "In February 2023, interim data from a phase III study (NCT05043090) in patients with renal cancer were presented. In MET-driven/PD-L1-positive, MET-driven/PD-L1-negative, and non-MET-driven/PD-L1-positive cohorts, response rates were 46, 67, and 22%; median progression-free survival was 12.0, 16.7, and 2.7 months; median overall survival was 21.3, 16.9, and 12.3 months, respectively [ <ulink linkID=\"2914448\" linkType=\"Reference\"> 2914448 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1766",
              "name": "Renal cell carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe(FR, GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Jan-2017",
            "endDate": "23-Mar-2025",
            "statusDate": "28-Oct-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "77%",
            "timeToRegistration": "1.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Jan-2017",
                "endDate": "28-Oct-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "28-Oct-2021",
                "endDate": "18-Feb-2024",
                "successPercentage": "81%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "18-Feb-2024",
                "endDate": "12-Feb-2025",
                "successPercentage": "95%",
                "predictedDateL50": "16-Jul-2023",
                "predictedDateU50": "26-Jul-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Feb-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "14-Oct-2024",
                "predictedDateU50": "23-Mar-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "11-Mar-2019",
                "milestoneExtendedDate": "",
                "notes": "In March 2019, positive data were reported for the phase I/II trial (NCT02819596) in patients metastatic renal cancer which showed that the trial met its primary endpoints [ <ulink linkID=\"2249518\" linkType=\"Reference\">  2249518 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "11-Mar-2019",
                "milestoneExtendedDate": "",
                "notes": "In March 2019, interim data from phase II trial (NCT02819596) were reported [ <ulink linkID=\"2249518\" linkType=\"Reference\">  2249518 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "18-Feb-2023",
                "milestoneExtendedDate": "",
                "notes": "In February 2023, interim data from a phase III study (NCT05043090) in patients with renal cancer were presented. In MET-driven/PD-L1-positive, MET-driven/PD-L1-negative, and non-MET-driven/PD-L1-positive cohorts, response rates were 46, 67, and 22%; median progression-free survival was 12.0, 16.7, and 2.7 months; median overall survival was 21.3, 16.9, and 12.3 months, respectively [ <ulink linkID=\"2914448\" linkType=\"Reference\"> 2914448 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "07-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, a phase I trial (NCT04504669) in adult patients with select advanced solid tumors including HNSCC, TNBC, NSCLC, ccRCC, gastric cancer, melanoma, cervical cancer and small-cell lung cancer was expected to complete in September 2023 [ <ulink linkID=\"2308081\" linkType=\"Reference\">  2308081 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "FR",
              " GB",
              " X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1766",
              "name": "Renal cell carcinoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Oct-2021",
            "endDate": "28-Dec-2024",
            "statusDate": "28-Oct-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "79%",
            "timeToRegistration": "1.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "28-Oct-2021",
                "endDate": "18-Feb-2024",
                "successPercentage": "83%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "18-Feb-2024",
                "endDate": "28-Nov-2024",
                "successPercentage": "95%",
                "predictedDateL50": "29-Aug-2023",
                "predictedDateU50": "27-Apr-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "28-Nov-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "21-Aug-2024",
                "predictedDateU50": "28-Dec-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "18-Feb-2023",
                "milestoneExtendedDate": "",
                "notes": "In February 2023, interim data from a phase III study (NCT05043090) in patients with renal cancer were presented. In MET-driven/PD-L1-positive, MET-driven/PD-L1-negative, and non-MET-driven/PD-L1-positive cohorts, response rates were 46, 67, and 22%; median progression-free survival was 12.0, 16.7, and 2.7 months; median overall survival was 21.3, 16.9, and 12.3 months, respectively [ <ulink linkID=\"2914448\" linkType=\"Reference\"> 2914448 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1766",
              "name": "Renal cell carcinoma"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Oct-2021",
            "endDate": "16-Mar-2025",
            "statusDate": "28-Oct-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "79%",
            "timeToRegistration": "1.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "28-Oct-2021",
                "endDate": "18-Feb-2024",
                "successPercentage": "83%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "18-Feb-2024",
                "endDate": "04-Feb-2025",
                "successPercentage": "95%",
                "predictedDateL50": "08-Jul-2023",
                "predictedDateU50": "23-Jul-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Feb-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Oct-2024",
                "predictedDateU50": "16-Mar-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "18-Feb-2023",
                "milestoneExtendedDate": "",
                "notes": "In February 2023, interim data from a phase III study (NCT05043090) in patients with renal cancer were presented. In MET-driven/PD-L1-positive, MET-driven/PD-L1-negative, and non-MET-driven/PD-L1-positive cohorts, response rates were 46, 67, and 22%; median progression-free survival was 12.0, 16.7, and 2.7 months; median overall survival was 21.3, 16.9, and 12.3 months, respectively [ <ulink linkID=\"2914448\" linkType=\"Reference\"> 2914448 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1766",
              "name": "Renal cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Aug-2020",
            "endDate": "24-Dec-2024",
            "statusDate": "28-Oct-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "78%",
            "timeToRegistration": "1.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "25-Aug-2020",
                "endDate": "28-Oct-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "28-Oct-2021",
                "endDate": "18-Feb-2024",
                "successPercentage": "82%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "18-Feb-2024",
                "endDate": "24-Nov-2024",
                "successPercentage": "95%",
                "predictedDateL50": "30-Jun-2023",
                "predictedDateU50": "24-Jul-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "24-Nov-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Aug-2024",
                "predictedDateU50": "24-Dec-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "18-Feb-2023",
                "milestoneExtendedDate": "",
                "notes": "In February 2023, interim data from a phase III study (NCT05043090) in patients with renal cancer were presented. In MET-driven/PD-L1-positive, MET-driven/PD-L1-negative, and non-MET-driven/PD-L1-positive cohorts, response rates were 46, 67, and 22%; median progression-free survival was 12.0, 16.7, and 2.7 months; median overall survival was 21.3, 16.9, and 12.3 months, respectively [ <ulink linkID=\"2914448\" linkType=\"Reference\"> 2914448 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "07-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, a phase I trial (NCT04504669) in adult patients with select advanced solid tumors including HNSCC, TNBC, NSCLC, ccRCC, gastric cancer, melanoma, cervical cancer and small-cell lung cancer was expected to complete in September 2023 [ <ulink linkID=\"2308081\" linkType=\"Reference\"> 2308081 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "19-Oct-2015",
            "endDate": "24-Dec-2025",
            "statusDate": "21-Nov-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "1.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "19-Oct-2015",
                "endDate": "11-Oct-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "11-Oct-2017",
                "endDate": "23-Sep-2024",
                "successPercentage": "90%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "23-Sep-2024",
                "endDate": "27-Oct-2025",
                "successPercentage": "95%",
                "predictedDateL50": "29-Feb-2024",
                "predictedDateU50": "02-Feb-2025",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Oct-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "20-Jun-2025",
                "predictedDateU50": "24-Dec-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "19-Feb-2019",
                "milestoneExtendedDate": "",
                "notes": "In February 2019, AstraZeneca filed an IND for hepatocellular carcinoma in China [ <ulink linkID=\"2115841\" linkType=\"Reference\">  2115841 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "23-Apr-2019",
                "milestoneExtendedDate": "",
                "notes": "In April 2019, AstraZeneca received an implied clinical trial approval for durvalumab monotherapy or in combination with bevacizumab as an adjuvant therapy for hepatocellular carcinoma in China [ <ulink linkID=\"2142223\" linkType=\"Reference\">  2142223 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jun-2019",
                "milestoneExtendedDate": "16-Jun-2019",
                "notes": "In February 2019, the trial was expected to complete in June 16, 2023 [ <ulink linkID=\"2179843\" linkType=\"Reference\">  2179843 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "29-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, interim data were reported from a phase II trial (NCT02519348) in patients (n = 322) with advanced hepatocellular carcinoma. Across tremelimumab 300 mg + durvalumab, durvalumab monotherapy, tremelimumab monotherapy, and tremelimumab 300 mg + durvalumab arms, the proportion of patients that reported grade 3 or 4 AEs was 58.1, 55.4, 66.7 and 61.0%; grade 3 or 4 treatment related AEs was 35.1, 17.8, 43.5 and 23.2%; any serious AE was 41.9, 42.6, 52.2 and 43.9%; treatment related serious AE was 16.2, 10.9, 24.6 and 14.6%, respectively [ <ulink linkID=\"2284323\" linkType=\"Reference\">  2284323 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "29-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, positive data were reported from a phase II trial (NCT02519348) in patients (n = 322) with advanced hepatocellular carcinoma, which showed that the trial met its primary endpoint of safety. Across tremelimumab 300 mg + durvalumab, durvalumab monotherapy, tremelimumab monotherapy, and tremelimumab 300 mg + durvalumab arms, the proportion of patients that reported grade 3 or 4 AEs was 58.1, 55.4, 66.7 and 61.0%; grade 3 or 4 treatment related AEs was 35.1, 17.8, 43.5 and 23.2%; any serious AE was 41.9, 42.6, 52.2 and 43.9%; treatment related serious AE was 16.2, 10.9, 24.6 and 14.6%, respectively [ <ulink linkID=\"2284323\" linkType=\"Reference\">  2284323 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In February 2020, initial data from phase III trial (NCT03847428) were expected in 2021 [ <ulink linkID=\"2245088\" linkType=\"Reference\">  2245088 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In February 2020, key data from phase III trial (NCT03298451; HIMALAYA) assessing first-line treatment of liver cancer were expected in 2H21 [ <ulink linkID=\"2354705\" linkType=\"Reference\">  2354705 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In July 2022, data readout from phase III study (NCT03847428; EMERALD-2) of durvalumab monotherapy or in combination with bevacizumab as adjuvant therapy, in patients with hepatocellular carcinoma, were expected in 1H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "16-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In February 2019, the trial was expected to complete in June 16, 2023 [ <ulink linkID=\"2179843\" linkType=\"Reference\">  2179843 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected sNDA/sBLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In July 2022, regulatory submission in China for the treatment of locoregional liver carcinoma, based on EMERALD-1 study data was expected in 2H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "21-Feb-2027",
            "statusDate": "11-Oct-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "3.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "11-Oct-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "11-Oct-2017",
                "endDate": "13-Apr-2026",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Apr-2026",
                "endDate": "22-Jan-2027",
                "successPercentage": "95%",
                "predictedDateL50": "19-Oct-2025",
                "predictedDateU50": "21-Jun-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Jan-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Oct-2026",
                "predictedDateU50": "21-Feb-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "29-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, interim data were reported from a phase II trial (NCT02519348) in patients (n = 322) with advanced hepatocellular carcinoma. Across tremelimumab 300 mg + durvalumab, durvalumab monotherapy, tremelimumab monotherapy, and tremelimumab 300 mg + durvalumab arms, the proportion of patients that reported grade 3 or 4 AEs was 58.1, 55.4, 66.7 and 61.0%; grade 3 or 4 treatment related AEs was 35.1, 17.8, 43.5 and 23.2%; any serious AE was 41.9, 42.6, 52.2 and 43.9%; treatment related serious AE was 16.2, 10.9, 24.6 and 14.6%, respectively [ <ulink linkID=\"2284323\" linkType=\"Reference\">  2284323 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "29-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, positive data were reported from a phase II trial (NCT02519348) in patients (n = 322) with advanced hepatocellular carcinoma, which showed that the trial met its primary endpoint of safety. Across tremelimumab 300 mg + durvalumab, durvalumab monotherapy, tremelimumab monotherapy, and tremelimumab 300 mg + durvalumab arms, the proportion of patients that reported grade 3 or 4 AEs was 58.1, 55.4, 66.7 and 61.0%; grade 3 or 4 treatment related AEs was 35.1, 17.8, 43.5 and 23.2%; any serious AE was 41.9, 42.6, 52.2 and 43.9%; treatment related serious AE was 16.2, 10.9, 24.6 and 14.6%, respectively [ <ulink linkID=\"2284323\" linkType=\"Reference\">  2284323 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In February 2020, key data from phase III trial (NCT03298451; HIMALAYA) assessing first-line treatment of liver cancer were expected in 2H21 [ <ulink linkID=\"2354705\" linkType=\"Reference\">  2354705 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "15-Oct-2021",
                "milestoneExtendedDate": "",
                "notes": "In October 2021, positive topline data from the HIMALAYA trial were reported. A single, high priming dose of tremelimumab plus durvalumab significantly improved OS versus sorafenib. Durvalumab alone also showed non-inferiority to sorafenib in OS (a non-significant trend in favor of durvalumab was observed). The combination was safe and did not increase severe hepatic toxicity [ <ulink linkID=\"2547259\" linkType=\"Reference\">  2547259 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "15-Oct-2021",
                "milestoneExtendedDate": "",
                "notes": "In October 2021, positive topline data from the HIMALAYA trial were reported. A single, high priming dose of tremelimumab plus durvalumab significantly improved OS versus sorafenib. Durvalumab alone also showed non-inferiority to sorafenib in OS (a non-significant trend in favor of durvalumab was observed). The combination was safe and did not increase severe hepatic toxicity [ <ulink linkID=\"2547259\" linkType=\"Reference\">  2547259 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "31-Mar-2022",
                "milestoneExtendedDate": "",
                "notes": "In March 2022, a phase III trial (NCT05301842) was to begin later that month [ <ulink linkID=\"2646864\" linkType=\"Reference\">  2646864 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In July 2022, data readout from phase III study (NCT03847428; EMERALD-2) of durvalumab monotherapy or in combination with bevacizumab as adjuvant therapy, in patients with hepatocellular carcinoma, were expected in 1H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "13-Apr-2026",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, a phase IIIb trial (NCT05883644; SIERRA)( was expected to complete in April 2026 [2965430].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "29-Jan-2027",
                "milestoneExtendedDate": "",
                "notes": "In March 2022, a phase III trial (NCT05301842) was expected to complete in January 2027 [ <ulink linkID=\"2646864\" linkType=\"Reference\">  2646864 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "19-Oct-2015",
            "endDate": "09-May-2027",
            "statusDate": "27-Jun-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "77%",
            "timeToRegistration": "3.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "19-Oct-2015",
                "endDate": "30-Nov-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "30-Nov-2018",
                "endDate": "13-Apr-2026",
                "successPercentage": "81%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Apr-2026",
                "endDate": "29-Mar-2027",
                "successPercentage": "95%",
                "predictedDateL50": "19-Sep-2025",
                "predictedDateU50": "14-Aug-2026",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "29-Mar-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "03-Dec-2026",
                "predictedDateU50": "09-May-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In July 2022, data readout from phase III study (NCT03847428; EMERALD-2) of durvalumab monotherapy or in combination with bevacizumab as adjuvant therapy, in patients with hepatocellular carcinoma, were expected in 1H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "13-Apr-2026",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, a phase IIIb trial (NCT05883644; SIERRA)( was expected to complete in April 2026 [2965430].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1828",
              "name": "Multiple myeloma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "01-Jan-2017",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1828",
              "name": "Multiple myeloma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "01-Jan-2017",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "2243",
              "name": "Fallopian tube cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Oct-2019",
            "endDate": "24-Mar-2028",
            "statusDate": "11-Oct-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-Oct-2019",
                "endDate": "08-Oct-2024",
                "successPercentage": "27%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "08-Oct-2024",
                "endDate": "20-May-2027",
                "successPercentage": "11%",
                "predictedDateL50": "09-Feb-2024",
                "predictedDateU50": "05-Apr-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-May-2027",
                "endDate": "23-Feb-2028",
                "successPercentage": "94%",
                "predictedDateL50": "02-Apr-2026",
                "predictedDateU50": "10-Oct-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Feb-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Nov-2027",
                "predictedDateU50": "24-Mar-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "31-Oct-2019",
                "milestoneExtendedDate": "",
                "notes": "In July 2019, a phase I/II trial in patients with platinum-resistant, recurrent and refractory epithelial ovarian carcinoma, fallopian tube carcinoma and primary peritoneal carcinoma was expected to begin in October 2019 [ <ulink linkID=\"2175571\" linkType=\"Reference\"> 2175571 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-Sep-2021",
                "milestoneExtendedDate": "",
                "notes": "In July 2019, a phase I/II trial in patients with platinum-resistant, recurrent and refractory epithelial ovarian carcinoma, fallopian tube carcinoma and primary peritoneal carcinoma was expected to complete in September 2021 [ <ulink linkID=\"2175571\" linkType=\"Reference\"> 2175571 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "2380",
              "name": "Bladder cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe(FR)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Oct-2016",
            "endDate": "",
            "statusDate": "06-Dec-2018",
            "phaseHighestStatus": "Failed",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "28-Jun-2022",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "03-Oct-2016",
                "endDate": "16-Nov-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Nov-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "FR",
              " X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "2380",
              "name": "Bladder cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "16-Nov-2018",
            "endDate": "12-Apr-2025",
            "statusDate": "16-Nov-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "48%",
            "timeToRegistration": "1.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "16-Nov-2018",
                "endDate": "28-May-2024",
                "successPercentage": "51%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "28-May-2024",
                "endDate": "13-Mar-2025",
                "successPercentage": "95%",
                "predictedDateL50": "26-Jan-2024",
                "predictedDateU50": "10-Sep-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Mar-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Nov-2024",
                "predictedDateU50": "12-Apr-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected sNDA/sBLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2019",
                "milestoneExtendedDate": "31-Dec-2019",
                "notes": "In February 2019, further regulatory submissions for durvalumab with or without tremelimumab for the first-line treatment of bladder cancer were expected in 2H19 [ <ulink linkID=\"2119607\" linkType=\"Reference\">  2119607 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In October 2020, key data from the phase III study (NCT03732677; NIAGARA) assessing the drug for the adjuvant treatment of bladder cancer were expected in 2H21 [ <ulink linkID=\"2354705\" linkType=\"Reference\">  2354705 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In November 2021, first data from the phase III VOLGA trial (NCT04960709) for perioperative treatment in patients ineligible for cisplatin undergoing radical cystectomy for muscle invasive bladder cancer were expected in 2022+ [ <ulink linkID=\"2565879\" linkType=\"Reference\">  2565879 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In February 2022, data from the phase III NIAGARA trial (NCT03732677) of durvalumab in combination with gemcitabine+cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment of muscle-invasive bladder cancer were expected in 2023 [ <ulink linkID=\"2612948\" linkType=\"Reference\">  2612948 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In July 2022, data from a phase III trial (NCT03732677; NIAGARA) of durvalumab in combination with gemcitabine+cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in patients with muscle-invasive bladder cancer were expected in 1H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected sNDA/sBLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In July 2022, regulatory submission for muscle invasive bladder cancer, based on the NIAGARA trial, was expected in 2H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "2380",
              "name": "Bladder cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "16-Nov-2018",
            "endDate": "03-Mar-2025",
            "statusDate": "16-Nov-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "48%",
            "timeToRegistration": "1.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "16-Nov-2018",
                "endDate": "20-Apr-2024",
                "successPercentage": "51%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-Apr-2024",
                "endDate": "01-Feb-2025",
                "successPercentage": "95%",
                "predictedDateL50": "23-Jan-2024",
                "predictedDateU50": "16-Jun-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Feb-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "22-Oct-2024",
                "predictedDateU50": "03-Mar-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In October 2020, key data from the phase III study (NCT03732677; NIAGARA) assessing the drug for the adjuvant treatment of bladder cancer were expected in 2H21 [ <ulink linkID=\"2354705\" linkType=\"Reference\">  2354705 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In November 2021, first data from the phase III VOLGA trial (NCT04960709) for perioperative treatment in patients ineligible for cisplatin undergoing radical cystectomy for muscle invasive bladder cancer were expected in 2022+ [ <ulink linkID=\"2565879\" linkType=\"Reference\">  2565879 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In July 2022, data from a phase III trial (NCT03732677; NIAGARA) of durvalumab in combination with gemcitabine+cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in patients with muscle-invasive bladder cancer were expected in 1H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In February 2022, data from the phase III NIAGARA trial (NCT03732677) of durvalumab in combination with gemcitabine+cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment of muscle-invasive bladder cancer were expected in 2023 [ <ulink linkID=\"2612948\" linkType=\"Reference\">  2612948 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "2380",
              "name": "Bladder cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Breakthrough Therapy, Accelerated Approval",
            "startDate": "03-Oct-2016",
            "endDate": "11-Feb-2025",
            "statusDate": "16-Nov-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "1.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "03-Oct-2016",
                "endDate": "16-Nov-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Nov-2018",
                "endDate": "09-May-2024",
                "successPercentage": "91%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-May-2024",
                "endDate": "06-Jan-2025",
                "successPercentage": "95%",
                "predictedDateL50": "25-Jan-2024",
                "predictedDateU50": "14-Aug-2024",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "06-Jan-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Oct-2024",
                "predictedDateU50": "11-Feb-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Accelerated Approval",
                "status": "Filed",
                "milestoneDate": "13-Oct-2016",
                "milestoneExtendedDate": "",
                "notes": "Treatment of locally advanced or metastatic urothelial carcinoma</para>",
                "newMilestone": false
              },
              {
                "title": "Accelerated Approval",
                "status": "Granted",
                "milestoneDate": "01-May-2017",
                "milestoneExtendedDate": "",
                "notes": "Treatment of locally advanced or metastatic urothelial carcinoma</para>",
                "newMilestone": false
              },
              {
                "title": "Expected sNDA/sBLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2019",
                "milestoneExtendedDate": "31-Dec-2019",
                "notes": "In February 2019, further regulatory submissions for durvalumab with or without tremelimumab for the first-line treatment of bladder cancer were expected in 2H19 [ <ulink linkID=\"2119607\" linkType=\"Reference\"> 2119607 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected sNDA/sBLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2020",
                "milestoneExtendedDate": "30-Jun-2020",
                "notes": "In July 2019, regulatory submission for bladder cancer was expected in the first half of 2020 [ <ulink linkID=\"2176778\" linkType=\"Reference\"> 2176778 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In October 2020, key data from the phase III study (NCT03732677; NIAGARA) assessing the drug for the adjuvant treatment of bladder cancer were expected in 2H21 [ <ulink linkID=\"2354705\" linkType=\"Reference\"> 2354705 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In November 2021, first data from the phase III VOLGA trial (NCT04960709) for perioperative treatment in patients ineligible for cisplatin undergoing radical cystectomy for muscle invasive bladder cancer were expected in 2022+ [ <ulink linkID=\"2565879\" linkType=\"Reference\">  2565879 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In February 2022, data from the phase III NIAGARA trial (NCT03732677) of durvalumab in combination with gemcitabine+cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment of muscle-invasive bladder cancer were expected in 2023 [ <ulink linkID=\"2612948\" linkType=\"Reference\">  2612948 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In July 2022, data from a phase III trial (NCT03732677; NIAGARA) of durvalumab in combination with gemcitabine+cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in patients with muscle-invasive bladder cancer were expected in 1H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "sNDA/sBLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In February 2022, a filing for the neoadjuvant treatment followed by durvalumab alone for adjuvant treatment of muscle-invasive bladder cancer, based on the NIAGARA trial, was expected in 2023 [ <ulink linkID=\"2612948\" linkType=\"Reference\">  2612948 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial termination",
                "status": "Negative Outcome",
                "milestoneDate": "18-Feb-2023",
                "milestoneExtendedDate": "",
                "notes": "In February 2023, data from a phase II trial (NCT03912818) in 6 patients with bladder cancer were presented. The trial was terminated due to difficulty with enrollment. Incidence of adverse events (AEs) was grade 3 treatment-related AE (n = 3), inclusive of anemia, decreased neutrophil count, and hypomagnesemia. Pathological complete response was achieved by one patient with sarcomatoid and glandular histology and pT20 was experienced by a patient with 10% squamous and papillary at cystectomy [ <ulink linkID=\"2914456\" linkType=\"Reference\"> 2914456 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected sNDA/sBLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In July 2022, regulatory submission for muscle invasive bladder cancer, based on the NIAGARA trial, was expected in 2H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "2454",
              "name": "Glioblastoma"
            },
            "country": {
              "id": "EU",
              "name": "EU (FR)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "",
            "statusDate": "17-Jan-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "FR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "2454",
              "name": "Glioblastoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "",
            "statusDate": "28-Feb-2015",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3083",
              "name": "Peritoneal tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Oct-2019",
            "endDate": "28-Mar-2028",
            "statusDate": "11-Oct-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-Oct-2019",
                "endDate": "14-Oct-2024",
                "successPercentage": "20%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "14-Oct-2024",
                "endDate": "26-May-2027",
                "successPercentage": "13%",
                "predictedDateL50": "10-Feb-2024",
                "predictedDateU50": "24-Apr-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-May-2027",
                "endDate": "25-Feb-2028",
                "successPercentage": "93%",
                "predictedDateL50": "08-Apr-2026",
                "predictedDateU50": "16-Oct-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-Feb-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Nov-2027",
                "predictedDateU50": "28-Mar-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "31-Oct-2019",
                "milestoneExtendedDate": "",
                "notes": "In July 2019, a phase I/II trial in patients with platinum-resistant, recurrent and refractory epithelial ovarian carcinoma, fallopian tube carcinoma and primary peritoneal carcinoma was expected to begin in October 2019 [ <ulink linkID=\"2175571\" linkType=\"Reference\"> 2175571 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-Sep-2021",
                "milestoneExtendedDate": "",
                "notes": "In July 2019, a phase I/II trial in patients with platinum-resistant, recurrent and refractory epithelial ovarian carcinoma, fallopian tube carcinoma and primary peritoneal carcinoma was expected to complete in September 2021 [ <ulink linkID=\"2175571\" linkType=\"Reference\"> 2175571 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3146",
              "name": "Gallbladder tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Jul-2023",
            "endDate": "31-Jan-2027",
            "statusDate": "21-Jul-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "52%",
            "timeToRegistration": "3.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "21-Jul-2023",
                "endDate": "03-Nov-2025",
                "successPercentage": "55%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-Nov-2025",
                "endDate": "04-Dec-2026",
                "successPercentage": "95%",
                "predictedDateL50": "02-Nov-2024",
                "predictedDateU50": "19-Mar-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Dec-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "29-Jul-2026",
                "predictedDateU50": "31-Jan-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-May-2025",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, a phase IIIb trial (NCT05924880; TopDouble) was expected to complete in May 2025 [ <ulink linkID=\"2994956\" linkType=\"Reference\"> 2994956 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3146",
              "name": "Gallbladder tumor"
            },
            "country": {
              "id": "EU",
              "name": "EU (DE)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-May-2018",
            "endDate": "09-Oct-2028",
            "statusDate": "02-May-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "02-May-2018",
                "endDate": "06-Jan-2025",
                "successPercentage": "12%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "06-Jan-2025",
                "endDate": "09-Sep-2027",
                "successPercentage": "29%",
                "predictedDateL50": "17-Mar-2024",
                "predictedDateU50": "11-Sep-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-Sep-2027",
                "endDate": "31-Aug-2028",
                "successPercentage": "95%",
                "predictedDateL50": "23-Jul-2026",
                "predictedDateU50": "09-Feb-2028",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "31-Aug-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "04-May-2028",
                "predictedDateU50": "09-Oct-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "10-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In September 2022, negative data from a phase II trial (NCT03473574) in treatment-naive patients with cholangio and gallbladder carcinoma were presented. Across arms A (tremelimumab + durvalumab + gemcitabine; n = 22), B (tremelimumab 4 x 75 mg, q3w + durvalumab + gemcitabine + cisplatin; n = 22), C (gemcitabine + cisplatin; n = 35), D (tremelimumab 1 X 300 mg, q3w + durvalumab + gemcitabine + cisplatin; n = 30) and E (durvalumab + gemcitabine + cisplatin; n = 29), ORR as per investigator‚Äôs assessment according to RECIST version 1.1 was 4.6, 18.2, 28.6, 26.7 and 20.7%, respectively (primary endpoint not met as there is no improvement in ORR with the addition of durvalumab alone or in combination with tremelimumab compared to chemotherapy alone); best overall response included complete remission (0.0, 4.5, 2.9, 0.0 and 0.0%), partial remission (4.5, 13.6, 25.7, 26.7 and 20.7%, stable disease (31.8, 50.0, 37.1, 43.3 and 44.8%), and progressive disease (40.9, 13.6, 5.7, 10.0 and 20.7%, respectively); median DOR was 2.2, 7.18, 6.07, 6.78 months and not reached; median PFS was 2.75, 5.98, 8.7, 8.13, and 5.97 months; median OS was 7.38, 12.32, 16.93, 22.73 and 12.87 months, respectively [ <ulink linkID=\"2748134\" linkType=\"Reference\"> 2748134 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "10-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In September 2022, negative data from a phase II trial (NCT03473574) in treatment-naive patients with cholangio and gallbladder carcinoma were presented. Across arms A (tremelimumab + durvalumab + gemcitabine; n = 22), B (tremelimumab 4 x 75 mg, q3w + durvalumab + gemcitabine + cisplatin; n = 22), C (gemcitabine + cisplatin; n = 35), D (tremelimumab 1 X 300 mg, q3w + durvalumab + gemcitabine + cisplatin; n = 30) and E (durvalumab + gemcitabine + cisplatin; n = 29), ORR as per investigator‚Äôs assessment according to RECIST version 1.1 was 4.6, 18.2, 28.6, 26.7 and 20.7%, respectively (primary endpoint not met as there is no improvement in ORR with the addition of durvalumab alone or in combination with tremelimumab compared to chemotherapy alone); best overall response included complete remission (0.0, 4.5, 2.9, 0.0 and 0.0%), partial remission (4.5, 13.6, 25.7, 26.7 and 20.7%, stable disease (31.8, 50.0, 37.1, 43.3 and 44.8%), and progressive disease (40.9, 13.6, 5.7, 10.0 and 20.7%, respectively); median DOR was 2.2, 7.18, 6.07, 6.78 months and not reached; median PFS was 2.75, 5.98, 8.7, 8.13, and 5.97 months; median OS was 7.38, 12.32, 16.93, 22.73 and 12.87 months, respectively [ <ulink linkID=\"2748134\" linkType=\"Reference\"> 2748134 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "DE"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3246",
              "name": "Hormone refractory prostate cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Aug-2019",
            "endDate": "10-Jan-2028",
            "statusDate": "29-Aug-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "29-Aug-2019",
                "endDate": "05-Sep-2024",
                "successPercentage": "27%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Sep-2024",
                "endDate": "29-Mar-2027",
                "successPercentage": "16%",
                "predictedDateL50": "06-Feb-2024",
                "predictedDateU50": "11-Feb-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Mar-2027",
                "endDate": "02-Dec-2027",
                "successPercentage": "91%",
                "predictedDateL50": "17-Feb-2026",
                "predictedDateU50": "12-Aug-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Dec-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Sep-2027",
                "predictedDateU50": "10-Jan-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "18-Mar-2021",
                "milestoneExtendedDate": "",
                "notes": "In August 2019, a phase II trial (NCT04089553) for metastatic castration-resistant prostate cancer was expected to complete in March 2021 [ <ulink linkID=\"2193920\" linkType=\"Reference\"> 2193920 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3257",
              "name": "Stage IV melanoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "",
            "statusDate": "30-Nov-2015",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3257",
              "name": "Stage IV melanoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "",
            "statusDate": "30-Nov-2015",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3293",
              "name": "Vaginal tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Mar-2018",
            "endDate": "",
            "statusDate": "31-Mar-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "31-Mar-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3378",
              "name": "Soft tissue sarcoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "",
            "statusDate": "31-Aug-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3378",
              "name": "Soft tissue sarcoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "",
            "statusDate": "31-Dec-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3462",
              "name": "Metastatic liver cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Jun-2023",
            "endDate": "24-Feb-2027",
            "statusDate": "27-Jun-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "44%",
            "timeToRegistration": "3.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "27-Jun-2023",
                "endDate": "13-Apr-2026",
                "successPercentage": "46%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Apr-2026",
                "endDate": "25-Jan-2027",
                "successPercentage": "95%",
                "predictedDateL50": "01-Apr-2025",
                "predictedDateU50": "30-Aug-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-Jan-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Oct-2026",
                "predictedDateU50": "24-Feb-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "13-Apr-2026",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, a phase IIIb trial (NCT05883644; SIERRA)( was expected to complete in April 2026 [2965430].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3462",
              "name": "Metastatic liver cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Jun-2023",
            "endDate": "21-Feb-2027",
            "statusDate": "27-Jun-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "44%",
            "timeToRegistration": "3.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "27-Jun-2023",
                "endDate": "13-Apr-2026",
                "successPercentage": "46%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Apr-2026",
                "endDate": "22-Jan-2027",
                "successPercentage": "95%",
                "predictedDateL50": "04-May-2025",
                "predictedDateU50": "17-Aug-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Jan-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Oct-2026",
                "predictedDateU50": "21-Feb-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "13-Apr-2026",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, a phase IIIb trial (NCT05883644; SIERRA)( was expected to complete in April 2026 [2965430].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3462",
              "name": "Metastatic liver cancer"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Jun-2023",
            "endDate": "13-Apr-2027",
            "statusDate": "27-Jun-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "39%",
            "timeToRegistration": "3.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "27-Jun-2023",
                "endDate": "13-Apr-2026",
                "successPercentage": "41%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Apr-2026",
                "endDate": "08-Mar-2027",
                "successPercentage": "95%",
                "predictedDateL50": "21-Mar-2025",
                "predictedDateU50": "30-Aug-2026",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "08-Mar-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "24-Nov-2026",
                "predictedDateU50": "13-Apr-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "13-Apr-2026",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, a phase IIIb trial (NCT05883644; SIERRA)( was expected to complete in April 2026 [2965430].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3462",
              "name": "Metastatic liver cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Jun-2023",
            "endDate": "18-Feb-2027",
            "statusDate": "27-Jun-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "41%",
            "timeToRegistration": "3.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "27-Jun-2023",
                "endDate": "13-Apr-2026",
                "successPercentage": "43%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Apr-2026",
                "endDate": "19-Jan-2027",
                "successPercentage": "95%",
                "predictedDateL50": "04-Mar-2025",
                "predictedDateU50": "26-Aug-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-Jan-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Oct-2026",
                "predictedDateU50": "18-Feb-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "13-Apr-2026",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, a phase IIIb trial (NCT05883644; SIERRA)( was expected to complete in April 2026 [2965430].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3462",
              "name": "Metastatic liver cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Jun-2023",
            "endDate": "15-Apr-2027",
            "statusDate": "27-Jun-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "43%",
            "timeToRegistration": "3.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "27-Jun-2023",
                "endDate": "13-Apr-2026",
                "successPercentage": "45%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Apr-2026",
                "endDate": "11-Mar-2027",
                "successPercentage": "95%",
                "predictedDateL50": "04-Mar-2025",
                "predictedDateU50": "26-Aug-2026",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Mar-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "26-Nov-2026",
                "predictedDateU50": "15-Apr-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "13-Apr-2026",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, a phase IIIb trial (NCT05883644; SIERRA)( was expected to complete in April 2026 [2965430].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3466",
              "name": "Metastatic bladder cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Nov-2015",
            "endDate": "03-Jan-2030",
            "statusDate": "02-Nov-2015",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "5.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "02-Nov-2015",
                "endDate": "06-Oct-2028",
                "successPercentage": "5%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "12.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "06-Oct-2028",
                "endDate": "06-Nov-2029",
                "successPercentage": "95%",
                "predictedDateL50": "30-Sep-2027",
                "predictedDateU50": "13-Dec-2029",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "06-Nov-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Jun-2029",
                "predictedDateU50": "03-Jan-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "06-Mar-2020",
                "milestoneExtendedDate": "",
                "notes": "In March 2020, negative data were presented from the phase III DANUBE trial in first-line metastatic bladder cancer; the trial missed its primary endpoint of OS versus chemotherapy [ <ulink linkID=\"2252339\" linkType=\"Reference\">  2252339 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "06-Mar-2020",
                "milestoneExtendedDate": "",
                "notes": "In March 2020, negative data were presented from the phase III DANUBE trial in first-line metastatic bladder cancer; the trial missed its primary endpoint of OS versus chemotherapy [ <ulink linkID=\"2252339\" linkType=\"Reference\">  2252339 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "19-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, negative data were presented from the phase III DANUBE trial in first-line metastatic bladder cancer; the trial missed its primary endpoint of OS versus chemotherapy. In durvalumab versus chemotherapy in the PD-L1 high population, the median overall survival (OS; co-primary endpoint) was 14.4 versus 12.1 months (hazard ratio (HR), 0.89; p = 0.3039). In durvalumab versus chemotherapy in the intent-to-treat (ITT) population, the median OS (co-primary endpoint) was 15.1 versus 12.1 months (HR, 0.85; p = 0.0751) [ <ulink linkID=\"2324626\" linkType=\"Reference\">  2324626 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In July 2022, data from a phase III trial (NCT03682068; NILE) of first-line durvalumab with or without tremelimumab with SoC chemotherapy followed by durvalumab monotherapy versus SoC alone, in patients with unresectable locally advanced or metastatic urothelial bladder cancer, were expected in 1H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3466",
              "name": "Metastatic bladder cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Nov-2015",
            "endDate": "23-Jul-2029",
            "statusDate": "02-Nov-2015",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "5.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "02-Nov-2015",
                "endDate": "11-Sep-2028",
                "successPercentage": "5%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "12.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "11-Sep-2028",
                "endDate": "23-Jun-2029",
                "successPercentage": "95%",
                "predictedDateL50": "25-Sep-2027",
                "predictedDateU50": "06-Jun-2029",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Jun-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Mar-2029",
                "predictedDateU50": "23-Jul-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Oct-2018",
                "milestoneExtendedDate": "05-Oct-2018",
                "notes": "In September 2018, the phase III trial was expected to begin in October 2018 [ <ulink linkID=\"2076729\" linkType=\"Reference\">  2076729 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "06-Mar-2020",
                "milestoneExtendedDate": "",
                "notes": "In March 2020, negative data were presented from the phase III DANUBE trial in first-line metastatic bladder cancer; the trial missed its primary endpoint of OS versus chemotherapy [ <ulink linkID=\"2252339\" linkType=\"Reference\">  2252339 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "06-Mar-2020",
                "milestoneExtendedDate": "",
                "notes": "In March 2020, negative data were presented from the phase III DANUBE trial in first-line metastatic bladder cancer; the trial missed its primary endpoint of OS versus chemotherapy [ <ulink linkID=\"2252339\" linkType=\"Reference\">  2252339 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "19-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, negative data were presented from the phase III DANUBE trial in first-line metastatic bladder cancer; the trial missed its primary endpoint of OS versus chemotherapy. In durvalumab versus chemotherapy in the PD-L1 high population, the median overall survival (OS; co-primary endpoint) was 14.4 versus 12.1 months (hazard ratio (HR), 0.89; p = 0.3039). In durvalumab versus chemotherapy in the intent-to-treat (ITT) population, the median OS (co-primary endpoint) was 15.1 versus 12.1 months (HR, 0.85; p = 0.0751) [ <ulink linkID=\"2324626\" linkType=\"Reference\">  2324626 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In February 2020, initial data from phase III trial (NCT03682068) were expected in 2021 [ <ulink linkID=\"2245088\" linkType=\"Reference\">  2245088 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-May-2022",
                "milestoneExtendedDate": "05-May-2022",
                "notes": "In September 2018, the phase III trial was expected to complete in May 2022 [ <ulink linkID=\"2076729\" linkType=\"Reference\">  2076729 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In July 2022, data from a phase III trial (NCT03682068; NILE) of first-line durvalumab with or without tremelimumab with SoC chemotherapy followed by durvalumab monotherapy versus SoC alone, in patients with unresectable locally advanced or metastatic urothelial bladder cancer, were expected in 1H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected sNDA/sBLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In July 2022, regulatory submission for durvalumab for the first-line treatment of bladder cancer, based on the NILE study, was expected in 2H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3466",
              "name": "Metastatic bladder cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "19-Mar-2029",
            "statusDate": "02-Nov-2015",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "5.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "02-Nov-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "02-Nov-2015",
                "endDate": "09-May-2028",
                "successPercentage": "5%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "12.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-May-2028",
                "endDate": "17-Feb-2029",
                "successPercentage": "95%",
                "predictedDateL50": "21-Aug-2027",
                "predictedDateU50": "28-Aug-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Feb-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Nov-2028",
                "predictedDateU50": "19-Mar-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Oct-2018",
                "milestoneExtendedDate": "05-Oct-2018",
                "notes": "In September 2018, the phase III trial was expected to begin in October 2018 [ <ulink linkID=\"2076729\" linkType=\"Reference\">  2076729 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "06-Mar-2020",
                "milestoneExtendedDate": "",
                "notes": "In March 2020, negative data were presented from the phase III DANUBE trial in first-line metastatic bladder cancer; the trial missed its primary endpoint of OS versus chemotherapy [ <ulink linkID=\"2252339\" linkType=\"Reference\">  2252339 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "06-Mar-2020",
                "milestoneExtendedDate": "",
                "notes": "In March 2020, negative data were presented from the phase III DANUBE trial in first-line metastatic bladder cancer; the trial missed its primary endpoint of OS versus chemotherapy [ <ulink linkID=\"2252339\" linkType=\"Reference\">  2252339 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "19-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, negative data were presented from the phase III DANUBE trial in first-line metastatic bladder cancer; the trial missed its primary endpoint of OS versus chemotherapy. In durvalumab versus chemotherapy in the PD-L1 high population, the median overall survival (OS; co-primary endpoint) was 14.4 versus 12.1 months (hazard ratio (HR), 0.89; p = 0.3039). In durvalumab versus chemotherapy in the intent-to-treat (ITT) population, the median OS (co-primary endpoint) was 15.1 versus 12.1 months (HR, 0.85; p = 0.0751) [ <ulink linkID=\"2324626\" linkType=\"Reference\">  2324626 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In February 2020, initial data from phase III trial (NCT03682068) were expected in 2021 [ <ulink linkID=\"2245088\" linkType=\"Reference\">  2245088 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "27-Apr-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2018, the phase III NILE trial in combination with chemotherapy for first-line advanced bladder cancer was expected to complete in April 2022 [ <ulink linkID=\"2076729\" linkType=\"Reference\">  2076729 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-May-2022",
                "milestoneExtendedDate": "05-May-2022",
                "notes": "In September 2018, the phase III trial was expected to complete in May 2022 [ <ulink linkID=\"2076729\" linkType=\"Reference\">  2076729 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In July 2022, data from a phase III trial (NCT03682068; NILE) of first-line durvalumab with or without tremelimumab with SoC chemotherapy followed by durvalumab monotherapy versus SoC alone, in patients with unresectable locally advanced or metastatic urothelial bladder cancer, were expected in 1H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3466",
              "name": "Metastatic bladder cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "25-Nov-2029",
            "statusDate": "02-Nov-2015",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "5.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "02-Nov-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "02-Nov-2015",
                "endDate": "23-Oct-2028",
                "successPercentage": "5%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "13.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "23-Oct-2028",
                "endDate": "17-Oct-2029",
                "successPercentage": "95%",
                "predictedDateL50": "10-Oct-2027",
                "predictedDateU50": "17-Mar-2030",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Oct-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "18-Jun-2029",
                "predictedDateU50": "25-Nov-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Oct-2018",
                "milestoneExtendedDate": "31-Oct-2018",
                "notes": "In October 2018, an investigator-led, phase II trial was to be initiated later that month in Spain. At that time, the trial was expected to complete in December 2022 [ <ulink linkID=\"2083225\" linkType=\"Reference\">  2083225 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Oct-2018",
                "milestoneExtendedDate": "05-Oct-2018",
                "notes": "In September 2018, the phase III trial was expected to begin in October 2018 [ <ulink linkID=\"2076729\" linkType=\"Reference\">  2076729 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "06-Mar-2020",
                "milestoneExtendedDate": "",
                "notes": "In March 2020, negative data were presented from the phase III DANUBE trial in first-line metastatic bladder cancer; the trial missed its primary endpoint of OS versus chemotherapy [ <ulink linkID=\"2252339\" linkType=\"Reference\">  2252339 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "06-Mar-2020",
                "milestoneExtendedDate": "",
                "notes": "In March 2020, negative data were presented from the phase III DANUBE trial in first-line metastatic bladder cancer; the trial missed its primary endpoint of OS versus chemotherapy [ <ulink linkID=\"2252339\" linkType=\"Reference\">  2252339 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "19-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, negative data were presented from the phase III DANUBE trial in first-line metastatic bladder cancer; the trial missed its primary endpoint of OS versus chemotherapy. In durvalumab versus chemotherapy in the PD-L1 high population, the median overall survival (OS; co-primary endpoint) was 14.4 versus 12.1 months (hazard ratio (HR), 0.89; p = 0.3039). In durvalumab versus chemotherapy in the intent-to-treat (ITT) population, the median OS (co-primary endpoint) was 15.1 versus 12.1 months (HR, 0.85; p = 0.0751) [ <ulink linkID=\"2324626\" linkType=\"Reference\">  2324626 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In February 2020, initial data from phase III trial (NCT03682068) were expected in 2021 [ <ulink linkID=\"2245088\" linkType=\"Reference\">  2245088 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "27-Apr-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2018, the phase III NILE trial in combination with chemotherapy for first-line advanced bladder cancer was expected to complete in April 2022 [ <ulink linkID=\"2076729\" linkType=\"Reference\">  2076729 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-May-2022",
                "milestoneExtendedDate": "05-May-2022",
                "notes": "In September 2018, the phase III trial was expected to complete in May 2022 [ <ulink linkID=\"2076729\" linkType=\"Reference\">  2076729 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2018, an investigator-led, phase II trial was to be initiated later that month in Spain. At that time, the trial was expected to complete in December 2022 [ <ulink linkID=\"2083225\" linkType=\"Reference\">  2083225 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In July 2022, data from a phase III trial (NCT03682068; NILE) of first-line durvalumab with or without tremelimumab with SoC chemotherapy followed by durvalumab monotherapy versus SoC alone, in patients with unresectable locally advanced or metastatic urothelial bladder cancer, were expected in 1H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected sNDA/sBLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In July 2022, regulatory submission for durvalumab for the first-line treatment of bladder cancer, based on the NILE study, was expected in 2H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Nov-2022",
            "endDate": "28-Jul-2030",
            "statusDate": "28-Nov-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "58%",
            "timeToRegistration": "6.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "28-Nov-2022",
                "endDate": "13-Apr-2029",
                "successPercentage": "61%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Apr-2029",
                "endDate": "27-May-2030",
                "successPercentage": "95%",
                "predictedDateL50": "29-May-2028",
                "predictedDateU50": "21-Aug-2029",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-May-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "12-Jan-2030",
                "predictedDateU50": "28-Jul-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "15-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, a phase III study (NCT06103864) in patients with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer (tropion-breast05) was planned to initiate in November 2023 in the US,Australia, Canada,China,India,Japan,Korea,Mexico,Singapore,Taiwan and Europe [ <ulink linkID=\"3482585\" linkType=\"Reference\"> 3482585 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "13-Apr-2029",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, a phase III study (NCT06103864) in patients with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer (tropion-breast05) was expected to complete in April 2029 [ <ulink linkID=\"3482585\" linkType=\"Reference\"> 3482585 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "27-Mar-2030",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, phase III trial (TROPION-Breast03) for Dato-DXd with or without durvalumab in patients with stage I to III triple negative breast cancer with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy was expected to complete in March 2030 [ <ulink linkID=\"2787089\" linkType=\"Reference\"> 2787089 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Jan-2017",
            "endDate": "03-Mar-2030",
            "statusDate": "28-Nov-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "58%",
            "timeToRegistration": "6.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "04-Jan-2017",
                "endDate": "28-Nov-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "28-Nov-2022",
                "endDate": "13-Apr-2029",
                "successPercentage": "61%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Apr-2029",
                "endDate": "01-Feb-2030",
                "successPercentage": "95%",
                "predictedDateL50": "31-May-2028",
                "predictedDateU50": "20-Aug-2029",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Feb-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "17-Oct-2029",
                "predictedDateU50": "03-Mar-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "15-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, a phase III study (NCT06103864) in patients with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer (tropion-breast05) was planned to initiate in November 2023 in the US,Australia, Canada,China,India,Japan,Korea,Mexico,Singapore,Taiwan and Europe [ <ulink linkID=\"3482585\" linkType=\"Reference\"> 3482585 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "13-Apr-2029",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, a phase III study (NCT06103864) in patients with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer (tropion-breast05) was expected to complete in April 2029 [ <ulink linkID=\"3482585\" linkType=\"Reference\"> 3482585 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "01-Mar-2030",
            "statusDate": "28-Nov-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "58%",
            "timeToRegistration": "6.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "28-Nov-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "10.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "28-Nov-2022",
                "endDate": "13-Apr-2029",
                "successPercentage": "61%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Apr-2029",
                "endDate": "30-Jan-2030",
                "successPercentage": "95%",
                "predictedDateL50": "03-Jul-2028",
                "predictedDateU50": "03-Aug-2029",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "30-Jan-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "17-Oct-2029",
                "predictedDateU50": "01-Mar-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "08-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, positive results of a phase Ib/II trial (NCT03742102) of datopotamab deruxtecan in combination with durvalumab in 47 patients were presented. In treatment arm, the median follow up duration was 7.5 months, confirmed overall response rate (ORR) was 79%, complete response (CR) was 6%, and partial response (PR) was 73%. Combination treatment reported manageable and consistent adverse events (AEs) with treatment-related AEs (87%), any grade 3 to 4 AEs (36%), and serious AEs (15%). Most commonly reported all grade AEs were nausea (55%) and stomatitis (51%), grade 1 to 2 were diarrhea (13%), anemia and neutropenia in (n = 4 and 1) patients; dose reduction was 19%, delayed treatment was 23%, and treatment discontinuation due to AEs was 6%. Datopotamab deruxtecan with durvalumab exhibited manageable safety profile and clinical benefits in patients with a/mTNBC [ <ulink linkID=\"2796364\" linkType=\"Reference\"> 2796364 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "15-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, a phase III study (NCT06103864) in patients with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer (tropion-breast05) was planned to initiate in November 2023 in the US,Australia, Canada,China,India,Japan,Korea,Mexico,Singapore,Taiwan and Europe [ <ulink linkID=\"3482585\" linkType=\"Reference\"> 3482585 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "13-Apr-2029",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, a phase III study (NCT06103864) in patients with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer (tropion-breast05) was expected to complete in April 2029 [ <ulink linkID=\"3482585\" linkType=\"Reference\"> 3482585 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "US",
              "name": "US, US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "27-Feb-2030",
            "statusDate": "28-Nov-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "56%",
            "timeToRegistration": "6.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "28-Nov-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "10.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "28-Nov-2022",
                "endDate": "13-Apr-2029",
                "successPercentage": "59%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Apr-2029",
                "endDate": "28-Jan-2030",
                "successPercentage": "95%",
                "predictedDateL50": "28-Apr-2028",
                "predictedDateU50": "18-Aug-2029",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "28-Jan-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Oct-2029",
                "predictedDateU50": "27-Feb-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US",
              " US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe(X5)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "27-May-2030",
            "statusDate": "28-Nov-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "57%",
            "timeToRegistration": "6.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "28-Nov-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "10.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "28-Nov-2022",
                "endDate": "13-Apr-2029",
                "successPercentage": "60%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Apr-2029",
                "endDate": "11-Apr-2030",
                "successPercentage": "95%",
                "predictedDateL50": "27-Apr-2028",
                "predictedDateU50": "16-Aug-2029",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Apr-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Dec-2029",
                "predictedDateU50": "27-May-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "09-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In September 2022, negative topline data from a phase II trial (NCT03616886) in 127 patients with advanced or metastatic triple-negative breast cancer were presented. At a median follow-up of 13.2 months, clinical benefit rate (CBR, primary endpoint) was 42.9% in arm A (durvalumab + paclitaxel or carboplatin + oleclumab) and 43.3% in arm B (durvalumab + paclitaxel or carboplatin), with one-sided Fisher‚Äôs exact p = 0.61, and no significant difference observed in CBR by PD-L-1 and CD73 status. The safety profile was similar in both arms. Overall, at week 24, durvalumab in combination with oleclumab did not increase the CBR in patients with advanced or metastatic TNBC [ <ulink linkID=\"2748295\" linkType=\"Reference\"> 2748295 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "09-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In September 2022, negative primary endpoint data from a phase II trial (NCT03616886) in 127 patients with advanced or metastatic triple-negative breast cancer were presented. At a median follow-up of 13.2 months, clinical benefit rate (CBR, primary endpoint) was 42.9% in arm A (durvalumab + paclitaxel or carboplatin + oleclumab) and 43.3% in arm B (durvalumab + paclitaxel or carboplatin), with one-sided Fisher‚Äôs exact p = 0.61, and no significant difference observed in CBR by PD-L-1 and CD73 status. The safety profile was similar in both arms. Overall, at week 24, durvalumab in combination with oleclumab did not increase the CBR in patients with advanced or metastatic TNBC [ <ulink linkID=\"2748295\" linkType=\"Reference\"> 2748295 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "08-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, positive results of a phase Ib/II trial (NCT03742102) of datopotamab deruxtecan in combination with durvalumab in 47 patients were presented. In treatment arm, the median follow up duration was 7.5 months, confirmed overall response rate (ORR) was 79%, complete response (CR) was 6%, and partial response (PR) was 73%. Combination treatment reported manageable and consistent adverse events (AEs) with treatment-related AEs (87%), any grade 3 to 4 AEs (36%), and serious AEs (15%). Most commonly reported all grade AEs were nausea (55%) and stomatitis (51%), grade 1 to 2 were diarrhea (13%), anemia and neutropenia in (n = 4 and 1) patients; dose reduction was 19%, delayed treatment was 23%, and treatment discontinuation due to AEs was 6%. Datopotamab deruxtecan with durvalumab exhibited manageable safety profile and clinical benefits in patients with a/mTNBC [ <ulink linkID=\"2796364\" linkType=\"Reference\"> 2796364 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "07-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, a phase I trial (NCT04504669) in adult patients with select advanced solid tumors including HNSCC, TNBC, NSCLC, ccRCC, gastric cancer, melanoma, cervical cancer and small-cell lung cancer was expected to complete in September 2023 [ <ulink linkID=\"2308081\" linkType=\"Reference\">  2308081 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "15-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, a phase III study (NCT06103864) in patients with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer (tropion-breast05) was planned to initiate in November 2023 in the US,Australia, Canada,China,India,Japan,Korea,Mexico,Singapore,Taiwan and Europe [ <ulink linkID=\"3482585\" linkType=\"Reference\"> 3482585 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "13-Apr-2029",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, a phase III study (NCT06103864) in patients with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer (tropion-breast05) was expected to complete in April 2029 [ <ulink linkID=\"3482585\" linkType=\"Reference\"> 3482585 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "27-Mar-2030",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, phase III trial (TROPION-Breast03) for Dato-DXd with or without durvalumab in patients with stage I to III triple negative breast cancer with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy was expected to complete in March 2030 [ <ulink linkID=\"2787089\" linkType=\"Reference\"> 2787089 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5",
              " X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3658",
              "name": "Metastatic colorectal cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU (FR)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "",
            "statusDate": "26-Aug-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "FR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3658",
              "name": "Metastatic colorectal cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "",
            "statusDate": "02-Dec-2014",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Jan-2017",
            "endDate": "25-Jul-2028",
            "statusDate": "29-Dec-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "79%",
            "timeToRegistration": "4.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "02-Jan-2017",
                "endDate": "20-May-2027",
                "successPercentage": "83%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "10.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-May-2027",
                "endDate": "04-Jun-2028",
                "successPercentage": "95%",
                "predictedDateL50": "15-Dec-2026",
                "predictedDateU50": "31-Jul-2027",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Jun-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Jan-2028",
                "predictedDateU50": "25-Jul-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "28-Oct-2019",
                "milestoneExtendedDate": "",
                "notes": "In October 2019, positive data from the phase III POSEIDON trial (NCT03164616) for first-line treatment of metastatic non-small-cell lung cancer were reported showing that the primary and secondary PFS endpoints were met. A significant and clinically meaningful improvement in the final PFS was achieved for durvalumab in combination with five standard-of-care platinum-based chemotherapy options versus chemotherapy alone, and for durvalumab+tremelimumab in combination with platinum-based chemotherapy options versus chemotherapy alone [ <ulink linkID=\"2210087\" linkType=\"Reference\">  2210087 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "28-Oct-2019",
                "milestoneExtendedDate": "",
                "notes": "In October 2019, positive data from the phase III POSEIDON trial (NCT03164616) for first-line treatment of metastatic non-small-cell lung cancer were reported showing that the primary and secondary PFS endpoints were met. A significant and clinically meaningful improvement in the final PFS was achieved for durvalumab in combination with five standard-of-care platinum-based chemotherapy options versus chemotherapy alone, and for durvalumab+tremelimumab in combination with platinum-based chemotherapy options versus chemotherapy alone [ <ulink linkID=\"2210087\" linkType=\"Reference\">  2210087 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In February 2020, marketing application submission in China was expected in 2H20 for the treatment of SCLC [ <ulink linkID=\"2245088\" linkType=\"Reference\">  2245088 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In October 2020, key data from the phase III study (NCT03003962; PEARL) assessing the drug for the first-line treatment of non-small cell lung cancer were expected in 1H21 [ <ulink linkID=\"2354705\" linkType=\"Reference\">  2354705 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In July 2021, data readout from the phase III study (NCT03003962; PEARL) assessing the drug for the first-line treatment of non-small cell lung cancer was expected in 1H22 [ <ulink linkID=\"2501429\" linkType=\"Reference\">  2501429 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "30-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In May 2022, a phase II (NCT05374603) study to evaluate the efficacy and safety of savolitinib combine with durvalumab was planned to be initiated in June 2022 [ <ulink linkID=\"2674115\" linkType=\"Reference\">  2674115 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In April 2022, data readout from the phase III study (NCT03003962; PEARL) assessing the drug for the first-line treatment of non-small cell lung cancer was expected in 2H22 [ <ulink linkID=\"2659964\" linkType=\"Reference\">  2659964 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "19-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, negative data were reported from the phase III study (NCT03003962; PEARL) [ <ulink linkID=\"2794020\" linkType=\"Reference\"> 2794020 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected sNDA/sBLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In April 2022, a regulatory submission for the monotherapy treatment of durvalumab for first-line metastatic NSCLC, based on the PEARL trial, was expected in 2023 [ <ulink linkID=\"2659964\" linkType=\"Reference\">  2659964 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected sNDA/sBLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In July 2022, regulatory submission for the monotherapy treatment of durvalumab for first-line metastatic NSCLC, based on the PEARL trial, was expected in 1H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-May-2024",
                "milestoneExtendedDate": "",
                "notes": "In May 2022, a phase II (NCT05374603) study to evaluate the efficacy and safety of savolitinib combine with durvalumab was planned to be completed in May 2024 [ <ulink linkID=\"2674115\" linkType=\"Reference\">  2674115 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-May-2027",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, a phase III trial (NCT05687266) was expected to complete in May 2027 [ <ulink linkID=\"2811470\" linkType=\"Reference\"> 2811470 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "",
            "statusDate": "10-Feb-2022",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "13-Jan-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "13-Jan-2015",
                "endDate": "10-Feb-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Feb-2022",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Feb-2014",
            "endDate": "02-Jul-2018",
            "statusDate": "10-Feb-2022",
            "phaseHighestStatus": "Reg",
            "probabilityOfSuccess": null,
            "timeToRegistration": "-5.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "25-Feb-2014",
                "endDate": "13-Jan-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "13-Jan-2015",
                "endDate": "02-Jul-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Jul-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "JP",
              " JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "09-Oct-2024",
            "statusDate": "13-Jan-2015",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "52%",
            "timeToRegistration": "0.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "13-Jan-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "13-Jan-2015",
                "endDate": "10-Dec-2023",
                "successPercentage": "55%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "06-Sep-2024",
                "successPercentage": "95%",
                "predictedDateL50": "12-Jun-2023",
                "predictedDateU50": "29-Feb-2024",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "06-Sep-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "06-Jun-2024",
                "predictedDateU50": "09-Oct-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "24-Apr-2018",
                "milestoneExtendedDate": "",
                "notes": "In April 2018, data from the phase III ARCTIC trial (NCT02352948) were reported. In sub-study B, the combination of durvalumab plus tremelimumab in patients with PD-L1 low/negative non-small-cell lung cancer did not meet the primary endpoints of a significant and clinically meaningful improvement in progression-free survival and overall survival compared with standard of care. Sub-study A was not powered for statistical significance; however, durvalumab monotherapy showed a clinically meaningful reduction in the risk of death compared with chemotherapy [ <ulink linkID=\"2026801\" linkType=\"Reference\">  2026801 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "24-Apr-2018",
                "milestoneExtendedDate": "",
                "notes": "In April 2018, data from the phase III ARCTIC trial (NCT02352948) were reported. In sub-study B, the combination of durvalumab plus tremelimumab in patients with PD-L1 low/negative non-small-cell lung cancer did not meet the primary endpoints of a significant and clinically meaningful improvement in progression-free survival and overall survival compared with standard of care. Sub-study A was not powered for statistical significance; however, durvalumab monotherapy showed a clinically meaningful reduction in the risk of death compared with chemotherapy [ <ulink linkID=\"2026801\" linkType=\"Reference\">  2026801 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "25-Sep-2018",
                "milestoneExtendedDate": "",
                "notes": "In September 2018, data from the phase III trial (NCT02125461) were presented. Also at that time, two-year follow-up data were published [ <ulink linkID=\"2075968\" linkType=\"Reference\">  2075968 </ulink>], [ <ulink linkID=\"2076542\" linkType=\"Reference\">  2076542 </ulink>], [ <ulink linkID=\"2075871\" linkType=\"Reference\">  2075871 </ulink>], [ <ulink linkID=\"2077205\" linkType=\"Reference\">  2077205 </ulink>], [ <ulink linkID=\"2077275\" linkType=\"Reference\">  2077275 </ulink>], [ <ulink linkID=\"2080844\" linkType=\"Reference\">  2080844 </ulink>], [ <ulink linkID=\"2080784\" linkType=\"Reference\">  2080784 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "16-Nov-2018",
                "milestoneExtendedDate": "",
                "notes": "In November 2018, final overall survival data were reported from the phase III MYSTIC trial (NCT02453282) of first line durvalumab in combination with tremelimumab or durvalumab monotherapy versus standard of care platinum-based chemotherapy in locally advanced or metastatic non-small cell lung cancer showing that both the monotherapy and the combination failed to meet the primary endpoint compared with standard of care. A hazard ratio (HR) of 0.76 (p = 0.036) was observed with monotherapy and 0.85 (p = 0.202) with combination therapy; further analysis in exploratory subgroups was planned [ <ulink linkID=\"2095708\" linkType=\"Reference\">  2095708 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "16-Nov-2018",
                "milestoneExtendedDate": "",
                "notes": "In November 2018, final overall survival data were reported from the phase III MYSTIC trial (NCT02453282) of first line durvalumab in combination with tremelimumab or durvalumab monotherapy versus standard of care platinum-based chemotherapy in locally advanced or metastatic non-small cell lung cancer showing that both the monotherapy and the combination failed to meet the primary endpoint compared with standard of care. A hazard ratio (HR) of 0.76 (p = 0.036) was observed with monotherapy and 0.85 (p = 0.202) with combination therapy; further analysis in exploratory subgroups was planned [ <ulink linkID=\"2095708\" linkType=\"Reference\">  2095708 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "02-Jun-2019",
                "milestoneExtendedDate": "",
                "notes": "In June 2019 n June 2019, 3-year data were consistent with other years, with improvement in median OS (not reached) and OS rates (57 versus 43.5% for placebo) [ <ulink linkID=\"2156346\" linkType=\"Reference\">  2156346 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "21-Aug-2019",
                "milestoneExtendedDate": "",
                "notes": "In August 2019, overall survival data from the phase III NEPTUNE trial (NCT02542293) for first-line treatment of metastatic non-small-cell lung cancer were reported showing that the combination of durvalumab+tremelimumab failed to meet the primary endpoint of improved OS versus chemotherapy [ <ulink linkID=\"2183386\" linkType=\"Reference\">  2183386 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "21-Aug-2019",
                "milestoneExtendedDate": "",
                "notes": "In August 2019, overall survival data from the phase III NEPTUNE trial (NCT02542293) for first-line treatment of metastatic non-small-cell lung cancer were reported showing that the combination of durvalumab+tremelimumab failed to meet the primary endpoint of improved OS versus chemotherapy [ <ulink linkID=\"2183386\" linkType=\"Reference\">  2183386 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "28-Oct-2019",
                "milestoneExtendedDate": "",
                "notes": "In October 2019, positive data from the phase III POSEIDON trial (NCT03164616) for first-line treatment of metastatic non-small-cell lung cancer were reported showing that the primary and secondary PFS endpoints were met. A significant and clinically meaningful improvement in the final PFS was achieved for durvalumab in combination with five standard-of-care platinum-based chemotherapy options versus chemotherapy alone, and for durvalumab+tremelimumab in combination with platinum-based chemotherapy options versus chemotherapy alone [ <ulink linkID=\"2210087\" linkType=\"Reference\">  2210087 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "28-Oct-2019",
                "milestoneExtendedDate": "",
                "notes": "In October 2019, positive data from the phase III POSEIDON trial (NCT03164616) for first-line treatment of metastatic non-small-cell lung cancer were reported showing that the primary and secondary PFS endpoints were met. A significant and clinically meaningful improvement in the final PFS was achieved for durvalumab in combination with five standard-of-care platinum-based chemotherapy options versus chemotherapy alone, and for durvalumab+tremelimumab in combination with platinum-based chemotherapy options versus chemotherapy alone [ <ulink linkID=\"2210087\" linkType=\"Reference\">  2210087 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In April 2020, data from phase III (NCT03800134) trial were expected in 2021 [ <ulink linkID=\"2272877\" linkType=\"Reference\">  2272877 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In October 2020, key data from the phase III study (NCT03003962; PEARL) assessing the drug for the first-line treatment of non-small cell lung cancer were expected in 1H21 [ <ulink linkID=\"2354705\" linkType=\"Reference\">  2354705 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In July 2021, data readout from the phase III study (NCT03003962; PEARL) assessing the drug for the first-line treatment of non-small cell lung cancer was expected in 1H22 [ <ulink linkID=\"2501429\" linkType=\"Reference\">  2501429 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In April 2022, data readout from the phase III study (NCT03003962; PEARL) assessing the drug for the first-line treatment of non-small cell lung cancer was expected in 2H22 [ <ulink linkID=\"2659964\" linkType=\"Reference\">  2659964 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "19-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, negative data were reported from the phase III study (NCT03003962; PEARL) [ <ulink linkID=\"2794020\" linkType=\"Reference\"> 2794020 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "",
            "statusDate": "10-Feb-2022",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "13-Jan-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "13-Jan-2015",
                "endDate": "10-Feb-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Feb-2022",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Nov-2020",
            "endDate": "25-Jul-2028",
            "statusDate": "02-Nov-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "19%",
            "timeToRegistration": "4.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "02-Nov-2020",
                "endDate": "31-Aug-2024",
                "successPercentage": "74%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "31-Aug-2024",
                "endDate": "21-Apr-2027",
                "successPercentage": "27%",
                "predictedDateL50": "29-Jan-2024",
                "predictedDateU50": "17-Feb-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "21-Apr-2027",
                "endDate": "25-May-2028",
                "successPercentage": "95%",
                "predictedDateL50": "04-Mar-2026",
                "predictedDateU50": "15-Sep-2027",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-May-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Jan-2028",
                "predictedDateU50": "25-Jul-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In February 2022, data from the phase II DESTINY-Gastric03 study (NCT04379596) to evaluate trastuzumab deruxtecan monotherapy and in combination with chemotherapy and/or durvalumab in adult patients with HER2-overexpressing advanced/metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma were expected in 2023 [ <ulink linkID=\"2612948\" linkType=\"Reference\">  2612948 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "14-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "By April 2022, the phase II DESTINY-Gastric03 study (NCT04379596) to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and antitumor activity of trastuzumab deruxtecan monotherapy and in combination with chemotherapy and/or durvalumab in adult patients with HER2-overexpressing advanced/metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma was expected to complete in July 2023 [ <ulink linkID=\"2350917\" linkType=\"Reference\">  2350917 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "21-Feb-2027",
            "statusDate": "31-Mar-2015",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "23%",
            "timeToRegistration": "3.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "10-Dec-2023",
                "successPercentage": "88%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "11.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "12-Apr-2026",
                "successPercentage": "28%",
                "predictedDateL50": "12-Jul-2022",
                "predictedDateU50": "08-Jun-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "12-Apr-2026",
                "endDate": "22-Jan-2027",
                "successPercentage": "95%",
                "predictedDateL50": "14-Apr-2025",
                "predictedDateU50": "31-Aug-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Jan-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "14-Oct-2026",
                "predictedDateU50": "21-Feb-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "03-Jun-2018",
                "milestoneExtendedDate": "",
                "notes": "In June 2018, positive data were reported from a phase I/II trial (NCT02340975) in metastatic or recurrent gastric or gastroesophogeal junction adenocarcinoma. In arms A, B, C and D, confirmed overall response rate (ORR) was 7.4, 0, 10 and 4%, respectively; confirmed+ unconfirmed ORR was 11.1, 8.3, 8.3 and 12%, respectively; median PFS was 1.8, 1.6, 1.7 and 1.8 months, respectively; PFS at 6 months was 6.1, 0, 20 and 15%, respectively; median overall survival (OS) was 9.2, 3.2, 7.7 and 10.6 months, respectively; and OS rate at 12 months was 40, 4.5, 22.9 and 38.8%, respectively [ <ulink linkID=\"2039449\" linkType=\"Reference\">  2039449 </ulink>], [ <ulink linkID=\"2039941\" linkType=\"Reference\">  2039941 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "29-Apr-2019",
                "milestoneExtendedDate": "",
                "notes": "In April 2019, a phase I/II trial (NCT02340975) in metastatic or recurrent gastric or gastroesophogeal junction adenocarcinoma completed [ <ulink linkID=\"1628334\" linkType=\"Reference\">  1628334 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "22-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, the phase II DESTINY-Gastric03 study (NCT04379596) to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and antitumor activity of trastuzumab deruxtecan monotherapy and in combination with chemotherapy and/or durvalumab in adult patients with HER2-overexpressing advanced/metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma was expected to complete in December 2022 [ <ulink linkID=\"2350917\" linkType=\"Reference\">  2350917 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In February 2022, data from the phase II DESTINY-Gastric03 study (NCT04379596) to evaluate trastuzumab deruxtecan monotherapy and in combination with chemotherapy and/or durvalumab in adult patients with HER2-overexpressing advanced/metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma were expected in 2023 [ <ulink linkID=\"2612948\" linkType=\"Reference\">  2612948 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "14-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "By April 2022, the phase II DESTINY-Gastric03 study (NCT04379596) to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and antitumor activity of trastuzumab deruxtecan monotherapy and in combination with chemotherapy and/or durvalumab in adult patients with HER2-overexpressing advanced/metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma was expected to complete in July 2023 [ <ulink linkID=\"2350917\" linkType=\"Reference\">  2350917 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "",
            "statusDate": "31-Mar-2015",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "",
            "statusDate": "03-Jun-2020",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "19-Oct-2020",
            "endDate": "10-Nov-2025",
            "statusDate": "19-Oct-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "52%",
            "timeToRegistration": "1.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "19-Oct-2020",
                "endDate": "11-Aug-2024",
                "successPercentage": "55%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "11-Aug-2024",
                "endDate": "12-Sep-2025",
                "successPercentage": "95%",
                "predictedDateL50": "01-Feb-2024",
                "predictedDateU50": "09-Dec-2024",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Sep-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-May-2025",
                "predictedDateU50": "10-Nov-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In November 2021, first data from the phase III KUNLUN trial (NCT04550260) for locally advanced esophageal squamous cell carcinoma were expected in 2022+ [ <ulink linkID=\"2565879\" linkType=\"Reference\">  2565879 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In February 2022, data from the phase II DESTINY-Gastric03 study (NCT04379596) to evaluate trastuzumab deruxtecan monotherapy and in combination with chemotherapy and/or durvalumab in adult patients with HER2-overexpressing advanced/metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma were expected in 2023 [ <ulink linkID=\"2612948\" linkType=\"Reference\">  2612948 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "14-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "By April 2022, the phase II DESTINY-Gastric03 study (NCT04379596) to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and antitumor activity of trastuzumab deruxtecan monotherapy and in combination with chemotherapy and/or durvalumab in adult patients with HER2-overexpressing advanced/metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma was expected to complete in July 2023 [ <ulink linkID=\"2350917\" linkType=\"Reference\">  2350917 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Sep-2013",
            "endDate": "05-Jul-2025",
            "statusDate": "19-Oct-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "57%",
            "timeToRegistration": "1.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "12-Sep-2013",
                "endDate": "31-Mar-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "31-Mar-2015",
                "endDate": "19-Oct-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "19-Oct-2020",
                "endDate": "25-Aug-2024",
                "successPercentage": "60%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-Aug-2024",
                "endDate": "05-Jun-2025",
                "successPercentage": "95%",
                "predictedDateL50": "08-Feb-2024",
                "predictedDateU50": "03-Jan-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Jun-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "26-Feb-2025",
                "predictedDateU50": "05-Jul-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "03-Jun-2018",
                "milestoneExtendedDate": "",
                "notes": "In June 2018, positive data were reported from a phase I/II trial (NCT02340975) in metastatic or recurrent gastric or gastroesophogeal junction adenocarcinoma. In arms A, B, C and D, confirmed overall response rate (ORR) was 7.4, 0, 10 and 4%, respectively; confirmed+ unconfirmed ORR was 11.1, 8.3, 8.3 and 12%, respectively; median PFS was 1.8, 1.6, 1.7 and 1.8 months, respectively; PFS at 6 months was 6.1, 0, 20 and 15%, respectively; median overall survival (OS) was 9.2, 3.2, 7.7 and 10.6 months, respectively; and OS rate at 12 months was 40, 4.5, 22.9 and 38.8%, respectively [ <ulink linkID=\"2039449\" linkType=\"Reference\">  2039449 </ulink>], [ <ulink linkID=\"2039941\" linkType=\"Reference\">  2039941 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "29-Apr-2019",
                "milestoneExtendedDate": "",
                "notes": "In April 2019, a phase I/II trial (NCT02340975) in metastatic or recurrent gastric or gastroesophogeal junction adenocarcinoma completed [ <ulink linkID=\"1628334\" linkType=\"Reference\">  1628334 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In November 2021, first data from the phase III KUNLUN trial (NCT04550260) for locally advanced esophageal squamous cell carcinoma were expected in 2022+ [ <ulink linkID=\"2565879\" linkType=\"Reference\">  2565879 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "18-Apr-2025",
            "statusDate": "19-Oct-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "55%",
            "timeToRegistration": "1.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "19-Oct-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "19-Oct-2020",
                "endDate": "09-Jun-2024",
                "successPercentage": "58%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-Jun-2024",
                "endDate": "19-Mar-2025",
                "successPercentage": "95%",
                "predictedDateL50": "17-Jan-2024",
                "predictedDateU50": "07-Sep-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-Mar-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Dec-2024",
                "predictedDateU50": "18-Apr-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "03-Jun-2018",
                "milestoneExtendedDate": "",
                "notes": "In June 2018, positive data were reported from a phase I/II trial (NCT02340975) in metastatic or recurrent gastric or gastroesophogeal junction adenocarcinoma. In arms A, B, C and D, confirmed overall response rate (ORR) was 7.4, 0, 10 and 4%, respectively; confirmed+ unconfirmed ORR was 11.1, 8.3, 8.3 and 12%, respectively; median PFS was 1.8, 1.6, 1.7 and 1.8 months, respectively; PFS at 6 months was 6.1, 0, 20 and 15%, respectively; median overall survival (OS) was 9.2, 3.2, 7.7 and 10.6 months, respectively; and OS rate at 12 months was 40, 4.5, 22.9 and 38.8%, respectively [ <ulink linkID=\"2039449\" linkType=\"Reference\">  2039449 </ulink>], [ <ulink linkID=\"2039941\" linkType=\"Reference\">  2039941 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "29-Apr-2019",
                "milestoneExtendedDate": "",
                "notes": "In April 2019, a phase I/II trial (NCT02340975) in metastatic or recurrent gastric or gastroesophogeal junction adenocarcinoma completed [ <ulink linkID=\"1628334\" linkType=\"Reference\">  1628334 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In November 2021, first data from the phase III KUNLUN trial (NCT04550260) for locally advanced esophageal squamous cell carcinoma were expected in 2022+ [ <ulink linkID=\"2565879\" linkType=\"Reference\">  2565879 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "22-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, the phase II DESTINY-Gastric03 study (NCT04379596) to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and antitumor activity of trastuzumab deruxtecan monotherapy and in combination with chemotherapy and/or durvalumab in adult patients with HER2-overexpressing advanced/metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma was expected to complete in December 2022 [ <ulink linkID=\"2350917\" linkType=\"Reference\">  2350917 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In February 2022, data from the phase II DESTINY-Gastric03 study (NCT04379596) to evaluate trastuzumab deruxtecan monotherapy and in combination with chemotherapy and/or durvalumab in adult patients with HER2-overexpressing advanced/metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma were expected in 2023 [ <ulink linkID=\"2612948\" linkType=\"Reference\">  2612948 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "14-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "By April 2022, the phase II DESTINY-Gastric03 study (NCT04379596) to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and antitumor activity of trastuzumab deruxtecan monotherapy and in combination with chemotherapy and/or durvalumab in adult patients with HER2-overexpressing advanced/metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma was expected to complete in July 2023 [ <ulink linkID=\"2350917\" linkType=\"Reference\">  2350917 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "16-Aug-2025",
            "statusDate": "19-Oct-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "54%",
            "timeToRegistration": "1.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "19-Oct-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "19-Oct-2020",
                "endDate": "12-Oct-2024",
                "successPercentage": "57%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "12-Oct-2024",
                "endDate": "17-Jul-2025",
                "successPercentage": "95%",
                "predictedDateL50": "19-Feb-2024",
                "predictedDateU50": "11-Mar-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Jul-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Apr-2025",
                "predictedDateU50": "16-Aug-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "03-Jun-2018",
                "milestoneExtendedDate": "",
                "notes": "In June 2018, positive data were reported from a phase I/II trial (NCT02340975) in metastatic or recurrent gastric or gastroesophogeal junction adenocarcinoma. In arms A, B, C and D, confirmed overall response rate (ORR) was 7.4, 0, 10 and 4%, respectively; confirmed+ unconfirmed ORR was 11.1, 8.3, 8.3 and 12%, respectively; median PFS was 1.8, 1.6, 1.7 and 1.8 months, respectively; PFS at 6 months was 6.1, 0, 20 and 15%, respectively; median overall survival (OS) was 9.2, 3.2, 7.7 and 10.6 months, respectively; and OS rate at 12 months was 40, 4.5, 22.9 and 38.8%, respectively [ <ulink linkID=\"2039449\" linkType=\"Reference\">  2039449 </ulink>], [ <ulink linkID=\"2039941\" linkType=\"Reference\">  2039941 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "17-Jan-2019",
                "milestoneExtendedDate": "",
                "notes": "In January 2019, primary endpoint result was presented at the at the 2019 ASCO Gastrointestinal Cancers Symposium in San Francisco, CA [ <ulink linkID=\"2113135\" linkType=\"Reference\"> 2113135 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "29-Apr-2019",
                "milestoneExtendedDate": "",
                "notes": "In April 2019, a phase I/II trial (NCT02340975) in metastatic or recurrent gastric or gastroesophogeal junction adenocarcinoma completed [ <ulink linkID=\"1628334\" linkType=\"Reference\">  1628334 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In November 2021, first data from the phase III KUNLUN trial (NCT04550260) for locally advanced esophageal squamous cell carcinoma were expected in 2022+ [ <ulink linkID=\"2565879\" linkType=\"Reference\">  2565879 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "22-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, the phase II DESTINY-Gastric03 study (NCT04379596) to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and antitumor activity of trastuzumab deruxtecan monotherapy and in combination with chemotherapy and/or durvalumab in adult patients with HER2-overexpressing advanced/metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma was expected to complete in December 2022 [ <ulink linkID=\"2350917\" linkType=\"Reference\">  2350917 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In February 2022, data from the phase II DESTINY-Gastric03 study (NCT04379596) to evaluate trastuzumab deruxtecan monotherapy and in combination with chemotherapy and/or durvalumab in adult patients with HER2-overexpressing advanced/metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma were expected in 2023 [ <ulink linkID=\"2612948\" linkType=\"Reference\">  2612948 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "14-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "By April 2022, the phase II DESTINY-Gastric03 study (NCT04379596) to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and antitumor activity of trastuzumab deruxtecan monotherapy and in combination with chemotherapy and/or durvalumab in adult patients with HER2-overexpressing advanced/metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma was expected to complete in July 2023 [ <ulink linkID=\"2350917\" linkType=\"Reference\">  2350917 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": "18008",
              "name": "MedImmune LLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "19-Oct-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3669",
              "name": "Metastatic pancreas cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "",
            "statusDate": "16-Nov-2015",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3669",
              "name": "Metastatic pancreas cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "",
            "statusDate": "16-Nov-2015",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3669",
              "name": "Metastatic pancreas cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "24-Jul-2030",
            "statusDate": "16-Nov-2015",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "8%",
            "timeToRegistration": "6.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "16-Oct-2026",
                "successPercentage": "25%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "14.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Oct-2026",
                "endDate": "08-Jul-2029",
                "successPercentage": "32%",
                "predictedDateL50": "21-Mar-2026",
                "predictedDateU50": "24-Jun-2027",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "08-Jul-2029",
                "endDate": "13-Jun-2030",
                "successPercentage": "95%",
                "predictedDateL50": "16-May-2028",
                "predictedDateU50": "15-Dec-2029",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Jun-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Feb-2030",
                "predictedDateU50": "24-Jul-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Jul-2023",
                "notes": "In July 2023, a phase I/II trial (NCT05927142) was planned to initiate later that month [ <ulink linkID=\"3000460\" linkType=\"Reference\"> 3000460 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Oct-2026",
                "milestoneExtendedDate": "31-Oct-2026",
                "notes": "In July 2023, a phase I/II trial (NCT05927142) was expected to complete in October 2026 [ <ulink linkID=\"3000460\" linkType=\"Reference\"> 3000460 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3672",
              "name": "Metastatic colon cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Mar-2018",
            "endDate": "20-Jun-2028",
            "statusDate": "21-Mar-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "21-Mar-2018",
                "endDate": "21-Nov-2024",
                "successPercentage": "20%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-Nov-2024",
                "endDate": "21-Aug-2027",
                "successPercentage": "18%",
                "predictedDateL50": "17-Mar-2024",
                "predictedDateU50": "29-Jun-2025",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "21-Aug-2027",
                "endDate": "20-May-2028",
                "successPercentage": "95%",
                "predictedDateL50": "25-Jun-2026",
                "predictedDateU50": "03-Feb-2028",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "20-May-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Feb-2028",
                "predictedDateU50": "20-Jun-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "EU",
              "name": "EU (FR)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "21-Jan-2029",
            "statusDate": "02-Dec-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "30%",
            "timeToRegistration": "5.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "01-Mar-2025",
                "successPercentage": "76%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "12.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "01-Mar-2025",
                "endDate": "08-Jan-2028",
                "successPercentage": "41%",
                "predictedDateL50": "10-Mar-2024",
                "predictedDateU50": "10-Sep-2025",
                "phaseDuration": "2.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "08-Jan-2028",
                "endDate": "13-Dec-2028",
                "successPercentage": "95%",
                "predictedDateL50": "30-Oct-2026",
                "predictedDateU50": "04-Aug-2028",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Dec-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "24-Aug-2028",
                "predictedDateU50": "21-Jan-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "07-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, interim data from a phase I study (NCT04613492) in patients with advanced/metastatic solid tumors were reported. Combination treatment of MEDI-9253 + durvalumab elicited modest clinical efficacy. In total of 13 patients, grade 3 to 4 toxicities were observed. In the SD2 cohort (20 patients at 10(10) with sequential durvalumab) following infusion, Cmax was 6.3 log10 copies/ml [ <ulink linkID=\"3015540\" linkType=\"Reference\"> 3015540 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-Nov-2024",
                "milestoneExtendedDate": "",
                "notes": "In November 2020, a phase I trial (NCT04613492) of MEDI-9253 in combination with durvalumab in adult patients with select advanced/metastatic solid tumors was to complete in November 2024 [ <ulink linkID=\"2357653\" linkType=\"Reference\"> 2357653 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "FR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2012",
            "endDate": "13-Oct-2028",
            "statusDate": "02-Dec-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "24%",
            "timeToRegistration": "4.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2012",
                "endDate": "01-Mar-2025",
                "successPercentage": "74%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "12.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "01-Mar-2025",
                "endDate": "16-Dec-2027",
                "successPercentage": "34%",
                "predictedDateL50": "10-Mar-2024",
                "predictedDateU50": "10-Sep-2025",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "16-Dec-2027",
                "endDate": "11-Sep-2028",
                "successPercentage": "95%",
                "predictedDateL50": "14-Oct-2026",
                "predictedDateU50": "23-Jun-2028",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Sep-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "09-Jun-2028",
                "predictedDateU50": "13-Oct-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "07-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, interim data from a phase I study (NCT04613492) in patients with advanced/metastatic solid tumors were reported. Combination treatment of MEDI-9253 + durvalumab elicited modest clinical efficacy. In total of 13 patients, grade 3 to 4 toxicities were observed. In the SD2 cohort (20 patients at 10(10) with sequential durvalumab) following infusion, Cmax was 6.3 log10 copies/ml [ <ulink linkID=\"3015540\" linkType=\"Reference\"> 3015540 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-Nov-2024",
                "milestoneExtendedDate": "",
                "notes": "In November 2020, a phase I trial (NCT04613492) of MEDI-9253 in combination with durvalumab in adult patients with select advanced/metastatic solid tumors was to complete in November 2024 [ <ulink linkID=\"2357653\" linkType=\"Reference\"> 2357653 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3737",
              "name": "Germ cell and embryonic cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU (IT)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Feb-2017",
            "endDate": "",
            "statusDate": "28-Feb-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "28-Feb-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "IT"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3769",
              "name": "Anaplastic thyroid cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Apr-2017",
            "endDate": "",
            "statusDate": "18-Apr-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "18-Apr-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Nov-2018",
            "endDate": "13-Sep-2025",
            "statusDate": "09-Nov-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Nov-2018",
                "endDate": "02-Jun-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "02-Jun-2024",
                "endDate": "13-Jul-2025",
                "successPercentage": "95%",
                "predictedDateL50": "29-Dec-2023",
                "predictedDateU50": "16-Oct-2024",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Jul-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Mar-2025",
                "predictedDateU50": "13-Sep-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "20-Sep-2019",
                "milestoneExtendedDate": "",
                "notes": "In September 2019, an IND was filed in China [ <ulink linkID=\"2188569\" linkType=\"Reference\">  2188569 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "27-Nov-2019",
                "milestoneExtendedDate": "",
                "notes": "In November 2019, an implied trial approval was granted for the trial NCT03737643 [ <ulink linkID=\"2212112\" linkType=\"Reference\">  2212112 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In July 2021, initial data from phase III trial (NCT03737643; DuO-O) assessing first-line treatment of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer were expected in 2022 or later [ <ulink linkID=\"2501429\" linkType=\"Reference\">  2501429 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In April 2022, data readout from phase III trial (NCT03737643; DUO-O) of durvalumab in combination with olaparib as first-line treatment in patients with advanced ovarian cancer were expected in 2023 [ <ulink linkID=\"2659964\" linkType=\"Reference\">  2659964 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In July 2022, data readout from phase III trial (NCT03737643; DUO-O) of durvalumab in combination with olaparib as first-line treatment in patients with advanced ovarian cancer were expected in 1H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "03-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, positive results from a phase III trial (NCT03737643) in 1130 patients with newly diagnosed advanced ovarian cancer without a tumor BRCA1/2 mutation were presented. The primary endpoint of PFS was met in homologous recombination deficiency (HRD)-positive and ITT subgroups. Across treatment arms 1 (chemotherapy plus bevacizumab, with bevacizumab as maintenance; n = 378), 2 (chemotherapy plus bevacizumab and durvalumab, with bevacizumab and durvalumab as maintenance; n = 374), and 3 (chemotherapy plus bevacizumab and durvalumab, with bevacizumab, durvalumab olaparib as maintenance; n = 378), median PFS was 19.3, 20.6 and 24.2 months in the ITT population; 23.0, 24.4 and 37.3 months in HRD-positive subgroup; 17.4, 15.4 and 20.9 months in HRD-negative subgroup, respectively. Across treatment arms 1, 2 and 3, grade &gt;/= 3 AEs were reported in 61, 66 and 71% of patients; AEs leading to death were reported in 1, 2 and 2% of patients; AEs leading to discontinuation were reported in 20, 26 and 35% of patients, respectively [ <ulink linkID=\"3020598\" linkType=\"Reference\"> 3020598 </ulink>], [ <ulink linkID=\"2953924\" linkType=\"Reference\"> 2953924 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "03-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, the primary endpoint (PFS) of a phase III trial (NCT03737643) in patients with newly diagnosed advanced ovarian cancer without a tumor BRCA1/2 mutation was met. Across treatment arms 1 (chemotherapy plus bevacizumab, with bevacizumab as maintenance; n = 378), 2 (chemotherapy plus bevacizumab and durvalumab, with bevacizumab and durvalumab as maintenance; n = 374), and 3 (chemotherapy plus bevacizumab and durvalumab, with bevacizumab, durvalumab olaparib as maintenance; n = 378), median PFS was 19.3, 20.6 and 24.2 months in the ITT population; 23.0, 24.4 and 37.3 months in HRD-positive subgroup; 17.4, 15.4 and 20.9 months in HRD-negative subgroup, respectively [ <ulink linkID=\"3020598\" linkType=\"Reference\"> 3020598 </ulink>], [ <ulink linkID=\"2953924\" linkType=\"Reference\"> 2953924 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Jan-2019",
            "endDate": "20-Apr-2025",
            "statusDate": "04-Jan-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "04-Jan-2019",
                "endDate": "02-Jun-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "02-Jun-2024",
                "endDate": "21-Mar-2025",
                "successPercentage": "95%",
                "predictedDateL50": "30-Dec-2023",
                "predictedDateU50": "03-Oct-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "21-Mar-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "06-Dec-2024",
                "predictedDateU50": "20-Apr-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In February 2020, initial data from phase III trial (NCT03737643) were expected in 2021 [ <ulink linkID=\"2245088\" linkType=\"Reference\">  2245088 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In July 2021, initial data from phase III trial (NCT03737643; DuO-O) assessing first-line treatment of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer were expected in 2022 or later [ <ulink linkID=\"2501429\" linkType=\"Reference\">  2501429 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In July 2022, data readout from phase III trial (NCT03737643; DUO-O) of durvalumab in combination with olaparib as first-line treatment in patients with advanced ovarian cancer were expected in 1H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In April 2022, data readout from phase III trial (NCT03737643; DUO-O) of durvalumab in combination with olaparib as first-line treatment in patients with advanced ovarian cancer were expected in 2023 [ <ulink linkID=\"2659964\" linkType=\"Reference\">  2659964 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "03-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, the primary endpoint (PFS) of a phase III trial (NCT03737643) in patients with newly diagnosed advanced ovarian cancer without a tumor BRCA1/2 mutation was met. Across treatment arms 1 (chemotherapy plus bevacizumab, with bevacizumab as maintenance; n = 378), 2 (chemotherapy plus bevacizumab and durvalumab, with bevacizumab and durvalumab as maintenance; n = 374), and 3 (chemotherapy plus bevacizumab and durvalumab, with bevacizumab, durvalumab olaparib as maintenance; n = 378), median PFS was 19.3, 20.6 and 24.2 months in the ITT population; 23.0, 24.4 and 37.3 months in HRD-positive subgroup; 17.4, 15.4 and 20.9 months in HRD-negative subgroup, respectively [ <ulink linkID=\"3020598\" linkType=\"Reference\"> 3020598 </ulink>], [ <ulink linkID=\"2953924\" linkType=\"Reference\"> 2953924 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "03-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, positive results from a phase III trial (NCT03737643) in 1130 patients with newly diagnosed advanced ovarian cancer without a tumor BRCA1/2 mutation were presented. The primary endpoint of PFS was met in homologous recombination deficiency (HRD)-positive and ITT subgroups. Across treatment arms 1 (chemotherapy plus bevacizumab, with bevacizumab as maintenance; n = 378), 2 (chemotherapy plus bevacizumab and durvalumab, with bevacizumab and durvalumab as maintenance; n = 374), and 3 (chemotherapy plus bevacizumab and durvalumab, with bevacizumab, durvalumab olaparib as maintenance; n = 378), median PFS was 19.3, 20.6 and 24.2 months in the ITT population; 23.0, 24.4 and 37.3 months in HRD-positive subgroup; 17.4, 15.4 and 20.9 months in HRD-negative subgroup, respectively. Across treatment arms 1, 2 and 3, grade &gt;/= 3 AEs were reported in 61, 66 and 71% of patients; AEs leading to death were reported in 1, 2 and 2% of patients; AEs leading to discontinuation were reported in 20, 26 and 35% of patients, respectively [ <ulink linkID=\"3020598\" linkType=\"Reference\"> 3020598 </ulink>], [ <ulink linkID=\"2953924\" linkType=\"Reference\"> 2953924 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Jan-2019",
            "endDate": "18-Apr-2025",
            "statusDate": "04-Jan-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "04-Jan-2019",
                "endDate": "02-Jun-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "02-Jun-2024",
                "endDate": "19-Mar-2025",
                "successPercentage": "95%",
                "predictedDateL50": "26-Jan-2024",
                "predictedDateU50": "04-Aug-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-Mar-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-Dec-2024",
                "predictedDateU50": "18-Apr-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In February 2020, initial data from phase III trial (NCT03737643) were expected in 2021 [ <ulink linkID=\"2245088\" linkType=\"Reference\">  2245088 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In July 2021, initial data from phase III trial (NCT03737643; DuO-O) assessing first-line treatment of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer were expected in 2022 or later [ <ulink linkID=\"2501429\" linkType=\"Reference\">  2501429 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In July 2022, data readout from phase III trial (NCT03737643; DUO-O) of durvalumab in combination with olaparib as first-line treatment in patients with advanced ovarian cancer were expected in 1H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In April 2022, data readout from phase III trial (NCT03737643; DUO-O) of durvalumab in combination with olaparib as first-line treatment in patients with advanced ovarian cancer were expected in 2023 [ <ulink linkID=\"2659964\" linkType=\"Reference\">  2659964 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "03-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, positive results from a phase III trial (NCT03737643) in 1130 patients with newly diagnosed advanced ovarian cancer without a tumor BRCA1/2 mutation were presented. The primary endpoint of PFS was met in homologous recombination deficiency (HRD)-positive and ITT subgroups. Across treatment arms 1 (chemotherapy plus bevacizumab, with bevacizumab as maintenance; n = 378), 2 (chemotherapy plus bevacizumab and durvalumab, with bevacizumab and durvalumab as maintenance; n = 374), and 3 (chemotherapy plus bevacizumab and durvalumab, with bevacizumab, durvalumab olaparib as maintenance; n = 378), median PFS was 19.3, 20.6 and 24.2 months in the ITT population; 23.0, 24.4 and 37.3 months in HRD-positive subgroup; 17.4, 15.4 and 20.9 months in HRD-negative subgroup, respectively. Across treatment arms 1, 2 and 3, grade &gt;/= 3 AEs were reported in 61, 66 and 71% of patients; AEs leading to death were reported in 1, 2 and 2% of patients; AEs leading to discontinuation were reported in 20, 26 and 35% of patients, respectively [ <ulink linkID=\"3020598\" linkType=\"Reference\"> 3020598 </ulink>], [ <ulink linkID=\"2953924\" linkType=\"Reference\"> 2953924 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "03-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, the primary endpoint (PFS) of a phase III trial (NCT03737643) in patients with newly diagnosed advanced ovarian cancer without a tumor BRCA1/2 mutation was met. Across treatment arms 1 (chemotherapy plus bevacizumab, with bevacizumab as maintenance; n = 378), 2 (chemotherapy plus bevacizumab and durvalumab, with bevacizumab and durvalumab as maintenance; n = 374), and 3 (chemotherapy plus bevacizumab and durvalumab, with bevacizumab, durvalumab olaparib as maintenance; n = 378), median PFS was 19.3, 20.6 and 24.2 months in the ITT population; 23.0, 24.4 and 37.3 months in HRD-positive subgroup; 17.4, 15.4 and 20.9 months in HRD-negative subgroup, respectively [ <ulink linkID=\"3020598\" linkType=\"Reference\"> 3020598 </ulink>], [ <ulink linkID=\"2953924\" linkType=\"Reference\"> 2953924 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Jan-2019",
            "endDate": "16-Apr-2025",
            "statusDate": "04-Jan-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "04-Jan-2019",
                "endDate": "02-Jun-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "02-Jun-2024",
                "endDate": "17-Mar-2025",
                "successPercentage": "95%",
                "predictedDateL50": "18-Dec-2023",
                "predictedDateU50": "22-Nov-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Mar-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-Dec-2024",
                "predictedDateU50": "16-Apr-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In February 2020, initial data from phase III trial (NCT03737643) were expected in 2021 [ <ulink linkID=\"2245088\" linkType=\"Reference\"> 2245088 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In July 2021, initial data from phase III trial (NCT03737643; DuO-O) assessing first-line treatment of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer were expected in 2022 or later [ <ulink linkID=\"2501429\" linkType=\"Reference\">  2501429 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In April 2022, data readout from phase III trial (NCT03737643; DUO-O) of durvalumab in combination with olaparib as first-line treatment in patients with advanced ovarian cancer were expected in 2023 [ <ulink linkID=\"2659964\" linkType=\"Reference\">  2659964 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In July 2022, data readout from phase III trial (NCT03737643; DUO-O) of durvalumab in combination with olaparib as first-line treatment in patients with advanced ovarian cancer were expected in 1H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "03-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, the primary endpoint (PFS) of a phase III trial (NCT03737643) in patients with newly diagnosed advanced ovarian cancer without a tumor BRCA1/2 mutation was met. Across treatment arms 1 (chemotherapy plus bevacizumab, with bevacizumab as maintenance; n = 378), 2 (chemotherapy plus bevacizumab and durvalumab, with bevacizumab and durvalumab as maintenance; n = 374), and 3 (chemotherapy plus bevacizumab and durvalumab, with bevacizumab, durvalumab olaparib as maintenance; n = 378), median PFS was 19.3, 20.6 and 24.2 months in the ITT population; 23.0, 24.4 and 37.3 months in HRD-positive subgroup; 17.4, 15.4 and 20.9 months in HRD-negative subgroup, respectively [ <ulink linkID=\"3020598\" linkType=\"Reference\"> 3020598 </ulink>], [ <ulink linkID=\"2953924\" linkType=\"Reference\"> 2953924 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "03-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, positive results from a phase III trial (NCT03737643) in 1130 patients with newly diagnosed advanced ovarian cancer without a tumor BRCA1/2 mutation were presented. The primary endpoint of PFS was met in homologous recombination deficiency (HRD)-positive and ITT subgroups. Across treatment arms 1 (chemotherapy plus bevacizumab, with bevacizumab as maintenance; n = 378), 2 (chemotherapy plus bevacizumab and durvalumab, with bevacizumab and durvalumab as maintenance; n = 374), and 3 (chemotherapy plus bevacizumab and durvalumab, with bevacizumab, durvalumab olaparib as maintenance; n = 378), median PFS was 19.3, 20.6 and 24.2 months in the ITT population; 23.0, 24.4 and 37.3 months in HRD-positive subgroup; 17.4, 15.4 and 20.9 months in HRD-negative subgroup, respectively. Across treatment arms 1, 2 and 3, grade &gt;/= 3 AEs were reported in 61, 66 and 71% of patients; AEs leading to death were reported in 1, 2 and 2% of patients; AEs leading to discontinuation were reported in 20, 26 and 35% of patients, respectively [ <ulink linkID=\"3020598\" linkType=\"Reference\"> 3020598 </ulink>], [ <ulink linkID=\"2953924\" linkType=\"Reference\"> 2953924 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-May-2017",
            "endDate": "15-Jul-2025",
            "statusDate": "04-Jan-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "05-May-2017",
                "endDate": "04-Jan-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "04-Jan-2019",
                "endDate": "02-Jun-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "02-Jun-2024",
                "endDate": "31-May-2025",
                "successPercentage": "95%",
                "predictedDateL50": "18-Dec-2023",
                "predictedDateU50": "19-Nov-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "31-May-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "29-Jan-2025",
                "predictedDateU50": "15-Jul-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "20-Dec-2018",
                "milestoneExtendedDate": "",
                "notes": "In November 2018, Phase 3 study was to be initiated in December 2018 [ <ulink linkID=\"2094445\" linkType=\"Reference\">  2094445 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In February 2020, initial data from phase III trial (NCT03737643) were expected in 2021 [ <ulink linkID=\"2245088\" linkType=\"Reference\">  2245088 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "23-Jun-2021",
                "notes": "In January 2021, a phase II collaboration trial (DOVACC) was planned to commence in 1H21 of Ultimovacs' UV-1 cancer vaccine in combination with durvalumab and olaparib in patients with high-grade BRCA-negative ovarian cancer. At that time, topline data were expected in 2023 [ <ulink linkID=\"2390292\" linkType=\"Reference\">  2390292 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In July 2021, initial data from phase III trial (NCT03737643; DuO-O) assessing first-line treatment of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer were expected in 2022 or later [ <ulink linkID=\"2501429\" linkType=\"Reference\">  2501429 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In April 2022, data readout from phase III trial (NCT03737643; DUO-O) of durvalumab in combination with olaparib as first-line treatment in patients with advanced ovarian cancer were expected in 2023 [ <ulink linkID=\"2659964\" linkType=\"Reference\">  2659964 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In July 2022, data readout from phase III trial (NCT03737643; DUO-O) of durvalumab in combination with olaparib as first-line treatment in patients with advanced ovarian cancer were expected in 1H23 [ <ulink linkID=\"2710957\" linkType=\"Reference\"> 2710957 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "03-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, positive results from a phase III trial (NCT03737643) in 1130 patients with newly diagnosed advanced ovarian cancer without a tumor BRCA1/2 mutation were presented. The primary endpoint of PFS was met in homologous recombination deficiency (HRD)-positive and ITT subgroups. Across treatment arms 1 (chemotherapy plus bevacizumab, with bevacizumab as maintenance; n = 378), 2 (chemotherapy plus bevacizumab and durvalumab, with bevacizumab and durvalumab as maintenance; n = 374), and 3 (chemotherapy plus bevacizumab and durvalumab, with bevacizumab, durvalumab olaparib as maintenance; n = 378), median PFS was 19.3, 20.6 and 24.2 months in the ITT population; 23.0, 24.4 and 37.3 months in HRD-positive subgroup; 17.4, 15.4 and 20.9 months in HRD-negative subgroup, respectively. Across treatment arms 1, 2 and 3, grade &gt;/= 3 AEs were reported in 61, 66 and 71% of patients; AEs leading to death were reported in 1, 2 and 2% of patients; AEs leading to discontinuation were reported in 20, 26 and 35% of patients, respectively [ <ulink linkID=\"3020598\" linkType=\"Reference\"> 3020598 </ulink>], [ <ulink linkID=\"2953924\" linkType=\"Reference\"> 2953924 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "03-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, the primary endpoint (PFS) of a phase III trial (NCT03737643) in patients with newly diagnosed advanced ovarian cancer without a tumor BRCA1/2 mutation was met. Across treatment arms 1 (chemotherapy plus bevacizumab, with bevacizumab as maintenance; n = 378), 2 (chemotherapy plus bevacizumab and durvalumab, with bevacizumab and durvalumab as maintenance; n = 374), and 3 (chemotherapy plus bevacizumab and durvalumab, with bevacizumab, durvalumab olaparib as maintenance; n = 378), median PFS was 19.3, 20.6 and 24.2 months in the ITT population; 23.0, 24.4 and 37.3 months in HRD-positive subgroup; 17.4, 15.4 and 20.9 months in HRD-negative subgroup, respectively [ <ulink linkID=\"3020598\" linkType=\"Reference\"> 3020598 </ulink>], [ <ulink linkID=\"2953924\" linkType=\"Reference\"> 2953924 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2021, a phase II collaboration trial (DOVACC) was planned to commence in 1H21 of Ultimovacs' UV-1 cancer vaccine in combination with durvalumab and olaparib in patients with high-grade BRCA-negative ovarian cancer. At that time, topline data were expected in 2023 [ <ulink linkID=\"2390292\" linkType=\"Reference\">  2390292 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "12819",
              "name": "Metastatic cholangiocarcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Jul-2023",
            "endDate": "09-Nov-2026",
            "statusDate": "21-Jul-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "2.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "21-Jul-2023",
                "endDate": "09-Oct-2025",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-Oct-2025",
                "endDate": "29-Sep-2026",
                "successPercentage": "95%",
                "predictedDateL50": "17-Oct-2024",
                "predictedDateU50": "22-Feb-2026",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "29-Sep-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "03-Jun-2026",
                "predictedDateU50": "09-Nov-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-May-2025",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, a phase IIIb trial (NCT05924880; TopDouble) was expected to complete in May 2025 [ <ulink linkID=\"2994956\" linkType=\"Reference\"> 2994956 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "12824",
              "name": "Metastatic biliary cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Jul-2023",
            "endDate": "06-Jan-2027",
            "statusDate": "21-Jul-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "60%",
            "timeToRegistration": "3.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "21-Jul-2023",
                "endDate": "03-Nov-2025",
                "successPercentage": "63%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-Nov-2025",
                "endDate": "15-Nov-2026",
                "successPercentage": "95%",
                "predictedDateL50": "02-Nov-2024",
                "predictedDateU50": "19-Mar-2026",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "15-Nov-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "14-Jul-2026",
                "predictedDateU50": "06-Jan-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-May-2025",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, a phase IIIb trial (NCT05924880; TopDouble) was expected to complete in May 2025 [ <ulink linkID=\"2994956\" linkType=\"Reference\"> 2994956 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "203",
              "name": "Lymphoma"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-May-2016",
            "endDate": "09-Mar-2028",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "11%",
            "timeToRegistration": "4.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-May-2016",
                "endDate": "02-Nov-2024",
                "successPercentage": "43%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "02-Nov-2024",
                "endDate": "20-Apr-2027",
                "successPercentage": "28%",
                "predictedDateL50": "09-Apr-2024",
                "predictedDateU50": "24-Apr-2025",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-Apr-2027",
                "endDate": "08-Feb-2028",
                "successPercentage": "95%",
                "predictedDateL50": "25-Mar-2026",
                "predictedDateU50": "06-Sep-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "08-Feb-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "24-Oct-2027",
                "predictedDateU50": "09-Mar-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "203",
              "name": "Lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "203",
              "name": "Lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-May-2016",
            "endDate": "18-Oct-2028",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "16%",
            "timeToRegistration": "4.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-May-2016",
                "endDate": "27-Dec-2024",
                "successPercentage": "43%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "27-Dec-2024",
                "endDate": "13-Oct-2027",
                "successPercentage": "38%",
                "predictedDateL50": "09-Mar-2024",
                "predictedDateU50": "16-Jul-2025",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Oct-2027",
                "endDate": "11-Sep-2028",
                "successPercentage": "95%",
                "predictedDateL50": "08-Aug-2026",
                "predictedDateU50": "20-Apr-2028",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Sep-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "27-May-2028",
                "predictedDateU50": "18-Oct-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1272",
              "name": "Myelodysplastic syndrome"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-May-2014",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "20-May-2014",
                "endDate": "06-Jul-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "06-Jul-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1272",
              "name": "Myelodysplastic syndrome"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-May-2014",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "20-May-2014",
                "endDate": "06-Jul-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "06-Jul-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1731",
              "name": "Acute myelogenous leukemia"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Dec-2015",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Dec-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1731",
              "name": "Acute myelogenous leukemia"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Dec-2015",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Dec-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1734",
              "name": "Chronic lymphocytic leukemia"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-May-2016",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-May-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1734",
              "name": "Chronic lymphocytic leukemia"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-May-2016",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-May-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1734",
              "name": "Chronic lymphocytic leukemia"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-May-2016",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-May-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1749",
              "name": "Diffuse large B-cell lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-May-2016",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-May-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1749",
              "name": "Diffuse large B-cell lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Jul-2016",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "13-Jul-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1753",
              "name": "Peripheral T-cell lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "EU (IT)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Jun-2018",
            "endDate": "12-Oct-2028",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "16%",
            "timeToRegistration": "4.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-Jun-2018",
                "endDate": "21-Dec-2024",
                "successPercentage": "43%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-Dec-2024",
                "endDate": "07-Oct-2027",
                "successPercentage": "38%",
                "predictedDateL50": "06-Mar-2024",
                "predictedDateU50": "22-Jul-2025",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-Oct-2027",
                "endDate": "05-Sep-2028",
                "successPercentage": "95%",
                "predictedDateL50": "02-Aug-2026",
                "predictedDateU50": "14-Apr-2028",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Sep-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "21-May-2028",
                "predictedDateU50": "12-Oct-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "IT"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1753",
              "name": "Peripheral T-cell lymphoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Jun-2018",
            "endDate": "11-Mar-2028",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "15%",
            "timeToRegistration": "4.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-Jun-2018",
                "endDate": "21-Dec-2024",
                "successPercentage": "43%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-Dec-2024",
                "endDate": "28-Apr-2027",
                "successPercentage": "37%",
                "predictedDateL50": "06-Mar-2024",
                "predictedDateU50": "22-Jul-2025",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "28-Apr-2027",
                "endDate": "10-Feb-2028",
                "successPercentage": "95%",
                "predictedDateL50": "28-Apr-2026",
                "predictedDateU50": "19-Sep-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Feb-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "31-Oct-2027",
                "predictedDateU50": "11-Mar-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1753",
              "name": "Peripheral T-cell lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Jun-2018",
            "endDate": "31-Jul-2028",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "12%",
            "timeToRegistration": "4.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-Jun-2018",
                "endDate": "21-Dec-2024",
                "successPercentage": "41%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-Dec-2024",
                "endDate": "19-Sep-2027",
                "successPercentage": "31%",
                "predictedDateL50": "06-Mar-2024",
                "predictedDateU50": "22-Jul-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "19-Sep-2027",
                "endDate": "01-Jul-2028",
                "successPercentage": "95%",
                "predictedDateL50": "24-Jul-2026",
                "predictedDateU50": "01-Mar-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Jul-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "22-Mar-2028",
                "predictedDateU50": "31-Jul-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1828",
              "name": "Multiple myeloma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Apr-2016",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "25-Apr-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1828",
              "name": "Multiple myeloma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Jan-2016",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "11-Jan-2016",
                "endDate": "25-Apr-2016",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "25-Apr-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "90272",
        "displayName": "immunoglobulin + hyaluronidase (immune deficiency/demyelinating polyneuropathy/multifocal motor neuropathy/chronic fatigue syndrome, Enhanze), Shire/Halozyme",
        "drugPrograms": [
          {
            "company": {
              "id": "20300",
              "name": "Takeda Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "678",
              "name": "Neuropathy"
            },
            "country": {
              "id": "EU",
              "name": "EU (DK)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Oct-2016",
            "endDate": "",
            "statusDate": "08-Jan-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "25-Oct-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "DK"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "20300",
              "name": "Takeda Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "678",
              "name": "Neuropathy"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "07-Dec-2021",
            "endDate": "07-Dec-2025",
            "statusDate": "07-Dec-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "1.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "07-Dec-2021",
                "endDate": "31-Dec-2024",
                "successPercentage": "91%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Dec-2024",
                "endDate": "30-Oct-2025",
                "successPercentage": "95%",
                "predictedDateL50": "12-Jul-2024",
                "predictedDateU50": "16-Mar-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "30-Oct-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "20-Jul-2025",
                "predictedDateU50": "07-Dec-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In July 2023, regulatory filing in Japan for the treatment of MMN was expected in 2024 [ <ulink linkID=\"3026403\" linkType=\"Reference\"> 3026403 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-Jun-2025",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, a phase III trial (NCT05084053) in chronic inflammatory demyelinating polyradiculoneuropathy ( and multifocal motor neuropathy was expected to complete in June 2025 [ <ulink linkID=\"2584692\" linkType=\"Reference\">  2584692 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "20300",
              "name": "Takeda Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "746",
              "name": "Infectious disease"
            },
            "country": {
              "id": "EU",
              "name": "EU (DE)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Jul-2016",
            "endDate": "",
            "statusDate": "08-Jan-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "21-Jul-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "DE"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "20300",
              "name": "Takeda Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "1058",
              "name": "Chronic fatigue syndrome"
            },
            "country": {
              "id": "EU",
              "name": "EU (DE)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Jul-2016",
            "endDate": "",
            "statusDate": "08-Jan-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "21-Jul-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "DE"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "20300",
              "name": "Takeda Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "2381",
              "name": "Chronic inflammatory demyelinating polyneuropathy"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Oct-2015",
            "endDate": "28-Apr-2024",
            "statusDate": "31-Mar-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "15-Oct-2015",
                "endDate": "31-Mar-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Mar-2023",
                "endDate": "26-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-Mar-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Jan-2024",
                "predictedDateU50": "28-Apr-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "23-Feb-2022",
                "milestoneExtendedDate": "",
                "notes": "In February 2022, the pivotal phase III trial (NCT02549170) in CIPD was completed [  <ulink linkID=\"1748262\" linkType=\"Reference\">   1748262  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "31-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, regulatory submissions were filed for Hyqvia in the EU for the treatment of CIPD [ <ulink linkID=\"2932355\" linkType=\"Reference\"> 2932355 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "20-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, full data from phase III study (NCT02955355) in CIDP were presented [ <ulink linkID=\"2983133\" linkType=\"Reference\"> 2983133 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "04-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, a phase III study (NCT02955355) was completed [ <ulink linkID=\"2280944\" linkType=\"Reference\"> 2280944 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Sep-2023",
                "milestoneExtendedDate": "29-Sep-2023",
                "notes": "In May 2020, a phase III trial (NCT02955355) was expected to complete in September 2023 [<ulink linkType=\"Reference\" linkID=\"2280944\">2280944</ulink>], [<ulink linkType=\"Reference\" linkID=\"2271917\">2271917</ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Mar-2024",
                "notes": "In May 2021, the approval for CIDP in the US was expected in fiscal year 2023 [  <ulink linkID=\"2451427\" linkType=\"Reference\">  2451427 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "20300",
              "name": "Takeda Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "2381",
              "name": "Chronic inflammatory demyelinating polyneuropathy"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "07-Dec-2021",
            "endDate": "29-Nov-2025",
            "statusDate": "07-Dec-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "74%",
            "timeToRegistration": "1.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "07-Dec-2021",
                "endDate": "31-Dec-2024",
                "successPercentage": "78%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Dec-2024",
                "endDate": "27-Oct-2025",
                "successPercentage": "95%",
                "predictedDateL50": "23-Jul-2024",
                "predictedDateU50": "19-Mar-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Oct-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "12-Jul-2025",
                "predictedDateU50": "29-Nov-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In July 2023, regulatory filing in Japan for the treatment of CIDP was expected in 2024 [ <ulink linkID=\"3026403\" linkType=\"Reference\"> 3026403 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-Jun-2025",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, a phase III trial (NCT05084053) in chronic inflammatory demyelinating polyradiculoneuropathy ( and multifocal motor neuropathy was expected to complete in June 2025 [ <ulink linkID=\"2584692\" linkType=\"Reference\">  2584692 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "20300",
              "name": "Takeda Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "2381",
              "name": "Chronic inflammatory demyelinating polyneuropathy"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Oct-2015",
            "endDate": "23-Feb-2024",
            "statusDate": "28-Feb-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "15-Oct-2015",
                "endDate": "28-Feb-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "28-Feb-2023",
                "endDate": "24-Jan-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "24-Jan-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Dec-2023",
                "predictedDateU50": "23-Feb-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "23-Feb-2022",
                "milestoneExtendedDate": "",
                "notes": "In February 2022, the pivotal phase III trial (NCT02549170) in CIPD was completed [  <ulink linkID=\"1748262\" linkType=\"Reference\">   1748262  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "28-Feb-2023",
                "milestoneExtendedDate": "",
                "notes": "In February 2023, regulatory submissions were filed for Hyqvia in the US for the treatment of CIPD [ <ulink linkID=\"2932355\" linkType=\"Reference\"> 2932355 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "20-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, full data from phase III study (NCT02955355) in CIDP were presented [ <ulink linkID=\"2983133\" linkType=\"Reference\"> 2983133 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "04-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, a phase III study (NCT02955355) was completed [ <ulink linkID=\"2280944\" linkType=\"Reference\"> 2280944 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Mar-2024",
                "notes": "In May 2021, the approval for CIDP in the US was expected in fiscal year 2023 [  <ulink linkID=\"2451427\" linkType=\"Reference\">  2451427 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "96470",
        "displayName": "belzutifan",
        "drugPrograms": [
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "249",
              "name": "Pancreas tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Aug-2021",
            "endDate": "02-Sep-2028",
            "statusDate": "12-Aug-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "45%",
            "timeToRegistration": "4.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Aug-2021",
                "endDate": "15-Dec-2024",
                "successPercentage": "83%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "15-Dec-2024",
                "endDate": "03-Jul-2027",
                "successPercentage": "57%",
                "predictedDateL50": "20-Aug-2024",
                "predictedDateU50": "23-Mar-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-Jul-2027",
                "endDate": "13-Jul-2028",
                "successPercentage": "95%",
                "predictedDateL50": "29-May-2026",
                "predictedDateU50": "18-Nov-2027",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Jul-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Mar-2028",
                "predictedDateU50": "02-Sep-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "262",
              "name": "Pheochromocytoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Aug-2021",
            "endDate": "09-Apr-2028",
            "statusDate": "12-Aug-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "62%",
            "timeToRegistration": "4.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Aug-2021",
                "endDate": "14-Oct-2024",
                "successPercentage": "85%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "14-Oct-2024",
                "endDate": "05-May-2027",
                "successPercentage": "77%",
                "predictedDateL50": "29-Jun-2024",
                "predictedDateU50": "31-Dec-2024",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-May-2027",
                "endDate": "03-Mar-2028",
                "successPercentage": "95%",
                "predictedDateL50": "25-Mar-2026",
                "predictedDateU50": "18-Sep-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "03-Mar-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "20-Nov-2027",
                "predictedDateU50": "09-Apr-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "262",
              "name": "Pheochromocytoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Aug-2021",
            "endDate": "27-Jul-2028",
            "statusDate": "12-Aug-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "66%",
            "timeToRegistration": "4.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Aug-2021",
                "endDate": "14-Oct-2024",
                "successPercentage": "86%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "14-Oct-2024",
                "endDate": "22-May-2027",
                "successPercentage": "81%",
                "predictedDateL50": "29-Jun-2024",
                "predictedDateU50": "31-Dec-2024",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-May-2027",
                "endDate": "07-Jun-2028",
                "successPercentage": "95%",
                "predictedDateL50": "11-Apr-2026",
                "predictedDateU50": "14-Oct-2027",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-Jun-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Jan-2028",
                "predictedDateU50": "27-Jul-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "989",
              "name": "Colorectal tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Jul-2022",
            "endDate": "14-Jan-2028",
            "statusDate": "28-Jul-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "10%",
            "timeToRegistration": "4.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "28-Jul-2022",
                "endDate": "24-Oct-2024",
                "successPercentage": "35%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "24-Oct-2024",
                "endDate": "21-Feb-2027",
                "successPercentage": "32%",
                "predictedDateL50": "21-Mar-2024",
                "predictedDateU50": "09-Feb-2025",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "21-Feb-2027",
                "endDate": "14-Dec-2027",
                "successPercentage": "93%",
                "predictedDateL50": "23-Feb-2026",
                "predictedDateU50": "13-Jul-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Dec-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Aug-2027",
                "predictedDateU50": "14-Jan-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1011",
              "name": "Esophagus tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "26-Oct-2023",
            "endDate": "08-Dec-2028",
            "statusDate": "26-Oct-2023",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "9%",
            "timeToRegistration": "4.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "26-Oct-2023",
                "endDate": "01-Sep-2025",
                "successPercentage": "29%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "01-Sep-2025",
                "endDate": "14-Jan-2028",
                "successPercentage": "34%",
                "predictedDateL50": "22-Sep-2024",
                "predictedDateU50": "21-Jan-2026",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "14-Jan-2028",
                "endDate": "05-Nov-2028",
                "successPercentage": "94%",
                "predictedDateL50": "05-Jan-2027",
                "predictedDateU50": "02-Jun-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Nov-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "20-Jul-2028",
                "predictedDateU50": "08-Dec-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1128",
              "name": "Neuroendocrine tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Aug-2021",
            "endDate": "24-Feb-2028",
            "statusDate": "12-Aug-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "62%",
            "timeToRegistration": "4.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Aug-2021",
                "endDate": "15-Jul-2024",
                "successPercentage": "85%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "15-Jul-2024",
                "endDate": "17-Dec-2026",
                "successPercentage": "77%",
                "predictedDateL50": "19-Apr-2024",
                "predictedDateU50": "05-Sep-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "17-Dec-2026",
                "endDate": "05-Jan-2028",
                "successPercentage": "95%",
                "predictedDateL50": "28-Nov-2025",
                "predictedDateU50": "04-May-2027",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Jan-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Aug-2027",
                "predictedDateU50": "24-Feb-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1516",
              "name": "Biliary cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Jul-2022",
            "endDate": "03-Feb-2028",
            "statusDate": "28-Jul-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "12%",
            "timeToRegistration": "4.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "28-Jul-2022",
                "endDate": "24-Oct-2024",
                "successPercentage": "35%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "24-Oct-2024",
                "endDate": "16-Mar-2027",
                "successPercentage": "36%",
                "predictedDateL50": "21-Mar-2024",
                "predictedDateU50": "09-Feb-2025",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "16-Mar-2027",
                "endDate": "04-Jan-2028",
                "successPercentage": "95%",
                "predictedDateL50": "04-Mar-2026",
                "predictedDateU50": "03-Aug-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Jan-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Sep-2027",
                "predictedDateU50": "03-Feb-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1612",
              "name": "Hippel Lindau syndrome"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "06-Jun-2018",
            "endDate": "28-Dec-2029",
            "statusDate": "30-Jul-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "65%",
            "timeToRegistration": "5.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "06-Jun-2018",
                "endDate": "29-Mar-2026",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "29-Mar-2026",
                "endDate": "03-Nov-2028",
                "successPercentage": "72%",
                "predictedDateL50": "18-Sep-2025",
                "predictedDateU50": "22-Aug-2026",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-Nov-2028",
                "endDate": "07-Nov-2029",
                "successPercentage": "95%",
                "predictedDateL50": "24-Sep-2027",
                "predictedDateU50": "28-Mar-2029",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-Nov-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "06-Jul-2029",
                "predictedDateU50": "28-Dec-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "13-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, first-time results from phase II trial (NCT03401788) for the treatment of renal cell carcinoma were reported [<ulink linkType=\"Reference\" linkID=\"2277875\">2277875</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Positive Opinion",
                "milestoneDate": "20-Jul-2020",
                "milestoneExtendedDate": "",
                "notes": "In July 2020, the EMA's COMP adopted positive opinion recommending for Orphan Drug designation to belzutifan for the treatment of von Hippel-Lindau disease [<ulink linkType=\"Reference\" linkID=\"2312190\">2312190</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "21-Aug-2020",
                "milestoneExtendedDate": "",
                "notes": "In August 2020, the drug was granted Orphan Drug designation for the treatment of Von-Hippel-Lindau disease [<ulink linkType=\"Reference\" linkID=\"2325811\">2325811</ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "20-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, additional data from phase II trial (NCT03401788) for the treatment of VHL disease-associated renal cell carcinoma were presented at the ESMO Virtual Congress 2020 [<ulink linkType=\"Reference\" linkID=\"2324439\">2324439</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "29-Mar-2026",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, a phase II trial (NCT03401788) of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma was expected to complete in March 2026 [ <ulink linkID=\"2009654\" linkType=\"Reference\"> 2009654 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "26-Oct-2023",
            "endDate": "07-Nov-2028",
            "statusDate": "26-Oct-2023",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "15%",
            "timeToRegistration": "4.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "26-Oct-2023",
                "endDate": "26-Jul-2025",
                "successPercentage": "36%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "26-Jul-2025",
                "endDate": "08-Dec-2027",
                "successPercentage": "44%",
                "predictedDateL50": "02-Sep-2024",
                "predictedDateU50": "28-Nov-2025",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "08-Dec-2027",
                "endDate": "04-Oct-2028",
                "successPercentage": "95%",
                "predictedDateL50": "29-Nov-2026",
                "predictedDateU50": "26-Apr-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Oct-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "21-Jun-2028",
                "predictedDateU50": "07-Nov-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1766",
              "name": "Renal cell carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-May-2018",
            "endDate": "24-Apr-2027",
            "statusDate": "26-Oct-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "58%",
            "timeToRegistration": "3.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "02-May-2018",
                "endDate": "26-Oct-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "26-Oct-2023",
                "endDate": "29-Mar-2026",
                "successPercentage": "64%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Mar-2026",
                "endDate": "14-Mar-2027",
                "successPercentage": "90%",
                "predictedDateL50": "01-May-2025",
                "predictedDateU50": "02-Aug-2026",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Mar-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "18-Nov-2026",
                "predictedDateU50": "24-Apr-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Jul-2022",
            "endDate": "19-Nov-2027",
            "statusDate": "28-Jul-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "7%",
            "timeToRegistration": "3.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "28-Jul-2022",
                "endDate": "29-Sep-2024",
                "successPercentage": "38%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "29-Sep-2024",
                "endDate": "26-Dec-2026",
                "successPercentage": "21%",
                "predictedDateL50": "14-Mar-2024",
                "predictedDateU50": "22-Jan-2025",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-Dec-2026",
                "endDate": "19-Oct-2027",
                "successPercentage": "89%",
                "predictedDateL50": "02-Jan-2026",
                "predictedDateU50": "16-May-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-Oct-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "03-Jul-2027",
                "predictedDateU50": "19-Nov-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "2876",
              "name": "Paraganglioma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Aug-2021",
            "endDate": "22-Feb-2028",
            "statusDate": "12-Aug-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "67%",
            "timeToRegistration": "4.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Aug-2021",
                "endDate": "24-Aug-2024",
                "successPercentage": "84%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "24-Aug-2024",
                "endDate": "27-Mar-2027",
                "successPercentage": "84%",
                "predictedDateL50": "22-May-2024",
                "predictedDateU50": "28-Oct-2024",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Mar-2027",
                "endDate": "20-Jan-2028",
                "successPercentage": "95%",
                "predictedDateL50": "13-Feb-2026",
                "predictedDateU50": "12-Aug-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "20-Jan-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-Oct-2027",
                "predictedDateU50": "22-Feb-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "2876",
              "name": "Paraganglioma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Aug-2021",
            "endDate": "28-May-2028",
            "statusDate": "12-Aug-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "69%",
            "timeToRegistration": "4.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Aug-2021",
                "endDate": "24-Aug-2024",
                "successPercentage": "85%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "24-Aug-2024",
                "endDate": "01-Apr-2027",
                "successPercentage": "85%",
                "predictedDateL50": "22-May-2024",
                "predictedDateU50": "28-Oct-2024",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "01-Apr-2027",
                "endDate": "08-Apr-2028",
                "successPercentage": "95%",
                "predictedDateL50": "19-Feb-2026",
                "predictedDateU50": "24-Aug-2027",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "08-Apr-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-Dec-2027",
                "predictedDateU50": "28-May-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "4250",
              "name": "Metastatic renal cell carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Jul-2022",
            "endDate": "03-Nov-2028",
            "statusDate": "27-Jul-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "77%",
            "timeToRegistration": "4.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "27-Jul-2022",
                "endDate": "11-Jun-2027",
                "successPercentage": "81%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "11-Jun-2027",
                "endDate": "14-Aug-2028",
                "successPercentage": "95%",
                "predictedDateL50": "04-Oct-2026",
                "predictedDateU50": "01-Oct-2027",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Aug-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "27-Mar-2028",
                "predictedDateU50": "03-Nov-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "11-Jun-2027",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, a phase III trial (NCT05899049) was expected to complete in June 2027 [ <ulink linkID=\"2973987\" linkType=\"Reference\"> 2973987 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "4250",
              "name": "Metastatic renal cell carcinoma"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Feb-2020",
            "endDate": "15-Jul-2025",
            "statusDate": "27-Feb-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "27-Feb-2020",
                "endDate": "29-Jul-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Jul-2024",
                "endDate": "02-Jun-2025",
                "successPercentage": "95%",
                "predictedDateL50": "16-Jan-2024",
                "predictedDateU50": "04-Jan-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Jun-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "22-Feb-2025",
                "predictedDateU50": "15-Jul-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "18-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, endpoints from the phase III trial (NCT04195750) in metastatic renal cell carcinoma were met [ <ulink linkID=\"3044394\" linkType=\"Reference\"> 3044394 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "18-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, positive topline data from the phase III trial (NCT04195750) in metastatic renal cell carcinoma demonstrating significant improvement in PFS compared to everolimus, and objective response rate (ORR) were reported [ <ulink linkID=\"3044394\" linkType=\"Reference\"> 3044394 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "4250",
              "name": "Metastatic renal cell carcinoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Feb-2020",
            "endDate": "05-Aug-2025",
            "statusDate": "27-Feb-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "27-Feb-2020",
                "endDate": "17-Aug-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "17-Aug-2024",
                "endDate": "20-Jun-2025",
                "successPercentage": "95%",
                "predictedDateL50": "29-Mar-2024",
                "predictedDateU50": "12-Nov-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "20-Jun-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Mar-2025",
                "predictedDateU50": "05-Aug-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "18-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, positive topline data from the phase III trial (NCT04195750) in metastatic renal cell carcinoma demonstrating significant improvement in PFS compared to everolimus, and objective response rate (ORR) were reported [ <ulink linkID=\"3044394\" linkType=\"Reference\"> 3044394 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "18-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, endpoints from the phase III trial (NCT04195750) in metastatic renal cell carcinoma were met [ <ulink linkID=\"3044394\" linkType=\"Reference\"> 3044394 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "4250",
              "name": "Metastatic renal cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Priority Review, Breakthrough Therapy",
            "startDate": "07-Dec-2016",
            "endDate": "13-Jun-2024",
            "statusDate": "19-Sep-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "07-Dec-2016",
                "endDate": "21-Sep-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "21-Sep-2018",
                "endDate": "27-Feb-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "27-Feb-2020",
                "endDate": "19-Sep-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "19-Sep-2023",
                "endDate": "14-May-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-May-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Feb-2024",
                "predictedDateU50": "13-Jun-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Priority Review",
                "status": "Granted",
                "milestoneDate": "16-Mar-2020",
                "milestoneExtendedDate": "",
                "notes": "By March 2021, Merck had filed an NDA for belzutifan in the US seeking approval  in VHL disease-associated RCC patients not requiring immediate surgery, based on data from the phase II Study-004 trial. At that time, the FDA accepted the filing, granted priority review and set a PDUFA target action date of September 15, 2021 [2422036].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "13-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, first-time results from phase II trial (NCT03401788) for the treatment of renal cell carcinoma were reported [<ulink linkType=\"Reference\" linkID=\"2277875\">2277875</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Breakthrough Therapy",
                "status": "Granted",
                "milestoneDate": "29-Jul-2020",
                "milestoneExtendedDate": "",
                "notes": "By July 2020, the US FDA granted Breakthrough Therapy designation to MK-6482, for the treatment of patients with von Hippel-Lindau disease-associated renal cell carcinoma with nonmetastatic RCC tumors less than three centimeters in size, unless immediate surgery is required [<ulink linkType=\"Reference\" linkID=\"2305061\">2305061</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "20-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, additional data from phase II trial (NCT03401788) for the treatment of VHL disease-associated renal cell carcinoma were presented at the ESMO Virtual Congress 2020 [<ulink linkType=\"Reference\" linkID=\"2324439\">2324439</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "18-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, endpoints from the phase III trial (NCT04195750) in metastatic renal cell carcinoma were met [ <ulink linkID=\"3044394\" linkType=\"Reference\"> 3044394 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "18-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, positive topline data from the phase III trial (NCT04195750) in metastatic renal cell carcinoma demonstrating significant improvement in PFS compared to everolimus, and objective response rate (ORR) were reported [ <ulink linkID=\"3044394\" linkType=\"Reference\"> 3044394 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Priority Review",
                "status": "Granted",
                "milestoneDate": "19-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, the US FDA accepted the sNDA of belzutifan for the treatment of adult patients with advanced renal cell carcinoma (RCC) following immune checkpoint and anti-angiogenic therapies, based on the positive data from the LITESPARK-005 trial and granted priority review [ <ulink linkID=\"3202703\" linkType=\"Reference\"> 3202703 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "sNDA/sBLA Filing",
                "status": "Filed",
                "milestoneDate": "19-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, the US FDA accepted the sNDA of belzutifan for the treatment of adult patients with advanced renal cell carcinoma (RCC) following immune checkpoint and anti-angiogenic therapies, based on the positive data from the LITESPARK-005 trial [ <ulink linkID=\"3202703\" linkType=\"Reference\"> 3202703 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (sNDA/sBLA)",
                "status": "Planned",
                "milestoneDate": "17-Jan-2024",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, the US FDA accepted the sNDA of belzutifan for the treatment of adult patients with advanced renal cell carcinoma (RCC) following immune checkpoint and anti-angiogenic therapies, based on the positive data from the LITESPARK-005 trial and set a PDUFA target action date of January 17, 2024 [ <ulink linkID=\"3202703\" linkType=\"Reference\"> 3202703 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "18077",
              "name": "Merck & Co Inc"
            },
            "indication": {
              "id": "4250",
              "name": "Metastatic renal cell carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Feb-2020",
            "endDate": "08-Nov-2025",
            "statusDate": "27-Feb-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "27-Feb-2020",
                "endDate": "17-Aug-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "17-Aug-2024",
                "endDate": "13-Sep-2025",
                "successPercentage": "95%",
                "predictedDateL50": "06-Jan-2024",
                "predictedDateU50": "15-Mar-2025",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Sep-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "08-May-2025",
                "predictedDateU50": "08-Nov-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "13-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, first-time results from phase II trial (NCT03401788) for the treatment of renal cell carcinoma were reported [<ulink linkType=\"Reference\" linkID=\"2277875\">2277875</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "20-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, additional data from phase II trial (NCT03401788) for the treatment of VHL disease-associated renal cell carcinoma were presented at the ESMO Virtual Congress 2020 [<ulink linkType=\"Reference\" linkID=\"2324439\">2324439</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "18-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, endpoints from the phase III trial (NCT04195750) in metastatic renal cell carcinoma were met [ <ulink linkID=\"3044394\" linkType=\"Reference\"> 3044394 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "18-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, positive topline data from the phase III trial (NCT04195750) in metastatic renal cell carcinoma demonstrating significant improvement in PFS compared to everolimus, and objective response rate (ORR) were reported [ <ulink linkID=\"3044394\" linkType=\"Reference\"> 3044394 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Oct-2025",
                "milestoneExtendedDate": "04-Oct-2025",
                "notes": "In February 2021, phase II study (NCT04489771) in patients with advanced RCC following progression on prior first-line systemic therapy was expected to complete in October 2025 [<ulink linkType=\"Reference\" linkID=\"2421805\">2421805</ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      }
    ]
  }